Author: "Bouteloup V" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Bouteloup V"' showing total 116 results

Start Over Author "Bouteloup V"

116 results on '"Bouteloup V"'

1. The pattern of cortical thickness associated with executive dysfunction in MCI and SCC: The MEMENTO cohort

Author: Andriuta, D., Roussel, M., Chene, G., Fischer, C., Mangin, J.-F., Dubois, B., Vellas, B., Pasquier, F., Tison, F., Blanc, F., Hanon, O., Paquet, C., Gabelle, A., Ceccaldi, M., Annweiler, C., Krolak-Salmon, P., David, R., Rouch-Leroyer, I., Benetos, A., Moreaud, O., Sellal, F., Jalenques, I., Vandel, P., Bouteloup, V., and Godefroy, O.
Published: 2024
Full Text: View/download PDF

2. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL

Author: Atkinson, A, Miro, J, Mocroft, A, Reiss, P, Kirk, O, Morlat, P, Ghosn, J, Stephan, C, Mussini, C, Antoniadou, A, Doerholt, K, Girardi, E, De Wit, S, Kraus, D, Zwahlen, M, Furrer, H, Castagna, A, Fatkenheuer, G, Raben, D, Teira, R, Zangerle, R, Judd, A, Touloumi, G, Warszawski, J, Meyer, L, Dabis, F, Krause, M, Leport, C, Wittkop, L, Wit, F, Prins, M, Bucher, H, Gibb, D, Del Amo, J, Obel, N, Thorne, C, Perez-Hoyos, S, Hamouda, O, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Antinori, A, d'Arminio Monforte, A, Brockmeyer, N, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Casabona, J, Goetghebuer, T, Sonnerborg, A, Torti, C, Sabin, C, Garrido, M, Haerry, D, Costagliola, D, d'Arminio-Monforte, A, del Amo, J, Chene, G, Barger, D, Schwimmer, C, Termote, M, Frederiksen, C, Brandt, R, Berenguer, J, Bohlius, J, Bouteloup, V, Cozzi-Lepri, A, Davies, M, Dorrucci, M, Dunn, D, Egger, M, Guiguet, M, Grabar, S, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Rohner, E, Schomaker, M, Smit, C, Sterne, J, Thiebaut, R, Wqetu, C, van der Valk, M, Atkinson A., Miro J. M., Mocroft A., Reiss P., Kirk O., Morlat P., Ghosn J., Stephan C., Mussini C., Antoniadou A., Doerholt K., Girardi E., De Wit S., Kraus D., Zwahlen M., Furrer H., Castagna A., Fatkenheuer G., Raben D., Teira R., Zangerle R., Judd A., Touloumi G., Warszawski J., Meyer L., Dabis F., Krause M. M., Leport C., Wittkop L., Wit F., Prins M., Bucher H., Gibb D., Del Amo J., Obel N., Thorne C., Perez-Hoyos S., Hamouda O., Bartmeyer B., Chkhartishvili N., Noguera-Julian A., Antinori A., d'Arminio Monforte A., Brockmeyer N., Prieto L., Conejo P. R., Soriano-Arandes A., Battegay M., Kouyos R., Casabona J., Goetghebuer T., Sonnerborg A., Torti C., Sabin C., Garrido M., Haerry D., Costagliola D., d'Arminio-Monforte A., del Amo J., Chene G., Barger D., Schwimmer C., Termote M., Frederiksen C. M., Brandt R. S., Berenguer J., Bohlius J., Bouteloup V., Cozzi-Lepri A., Davies M. -A., Dorrucci M., Dunn D., Egger M., Guiguet M., Grabar S., Lambotte O., Leroy V., Lodi S., Matheron S., Monge S., Nakagawa F., Paredes R., Phillips A., Puoti M., Rohner E., Schomaker M., Smit C., Sterne J., Thiebaut R., Wqetu C., van der Valk M., Atkinson, A, Miro, J, Mocroft, A, Reiss, P, Kirk, O, Morlat, P, Ghosn, J, Stephan, C, Mussini, C, Antoniadou, A, Doerholt, K, Girardi, E, De Wit, S, Kraus, D, Zwahlen, M, Furrer, H, Castagna, A, Fatkenheuer, G, Raben, D, Teira, R, Zangerle, R, Judd, A, Touloumi, G, Warszawski, J, Meyer, L, Dabis, F, Krause, M, Leport, C, Wittkop, L, Wit, F, Prins, M, Bucher, H, Gibb, D, Del Amo, J, Obel, N, Thorne, C, Perez-Hoyos, S, Hamouda, O, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Antinori, A, d'Arminio Monforte, A, Brockmeyer, N, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Casabona, J, Goetghebuer, T, Sonnerborg, A, Torti, C, Sabin, C, Garrido, M, Haerry, D, Costagliola, D, d'Arminio-Monforte, A, del Amo, J, Chene, G, Barger, D, Schwimmer, C, Termote, M, Frederiksen, C, Brandt, R, Berenguer, J, Bohlius, J, Bouteloup, V, Cozzi-Lepri, A, Davies, M, Dorrucci, M, Dunn, D, Egger, M, Guiguet, M, Grabar, S, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Rohner, E, Schomaker, M, Smit, C, Sterne, J, Thiebaut, R, Wqetu, C, van der Valk, M, Atkinson A., Miro J. M., Mocroft A., Reiss P., Kirk O., Morlat P., Ghosn J., Stephan C., Mussini C., Antoniadou A., Doerholt K., Girardi E., De Wit S., Kraus D., Zwahlen M., Furrer H., Castagna A., Fatkenheuer G., Raben D., Teira R., Zangerle R., Judd A., Touloumi G., Warszawski J., Meyer L., Dabis F., Krause M. M., Leport C., Wittkop L., Wit F., Prins M., Bucher H., Gibb D., Del Amo J., Obel N., Thorne C., Perez-Hoyos S., Hamouda O., Bartmeyer B., Chkhartishvili N., Noguera-Julian A., Antinori A., d'Arminio Monforte A., Brockmeyer N., Prieto L., Conejo P. R., Soriano-Arandes A., Battegay M., Kouyos R., Casabona J., Goetghebuer T., Sonnerborg A., Torti C., Sabin C., Garrido M., Haerry D., Costagliola D., d'Arminio-Monforte A., del Amo J., Chene G., Barger D., Schwimmer C., Termote M., Frederiksen C. M., Brandt R. S., Berenguer J., Bohlius J., Bouteloup V., Cozzi-Lepri A., Davies M. -A., Dorrucci M., Dunn D., Egger M., Guiguet M., Grabar S., Lambotte O., Leroy V., Lodi S., Matheron S., Monge S., Nakagawa F., Paredes R., Phillips A., Puoti M., Rohner E., Schomaker M., Smit C., Sterne J., Thiebaut R., Wqetu C., and van der Valk M.
Abstract: Introduction: Since the beginning of the HIV epidemic in resource-rich countries, Pneumocystis jirovecii pneumonia (PjP) is one of the most frequent opportunistic AIDS-defining infections. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) has shown that primary Pneumocystis jirovecii Pneumonia (PjP) prophylaxis can be safely withdrawn in patients with CD4 counts of 100 to 200 cells/µL if plasma HIV-RNA is suppressed on combination antiretroviral therapy. Whether this holds true for secondary prophylaxis is not known, and this has proved difficult to determine due to the much lower population at risk. Methods: We estimated the incidence of secondary PjP by including patient data collected from 1998 to 2015 from the COHERE cohort collaboration according to time-updated CD4 counts, HIV-RNA and use of PjP prophylaxis in persons >16 years of age. We fitted a Poisson generalized additive model in which the smoothed effect of CD4 was modelled by a restricted cubic spline, and HIV-RNA was stratified as low (<400), medium (400 to 10,000) or high (>10,000copies/mL). Results: There were 373 recurrences of PjP during 74,295 person-years (py) in 10,476 patients. The PjP incidence in the different plasma HIV-RNA strata differed significantly and was lowest in the low stratum. For patients off prophylaxis with CD4 counts between 100 and 200 cells/µL and HIV-RNA below 400 copies/mL, the incidence of recurrent PjP was 3.9 (95% CI: 2.0 to 5.8) per 1000 py, not significantly different from patients on prophylaxis in the same stratum (1.9, 95% CI: 0.1 to 3.7). Conclusions: HIV viraemia importantly affects the risk of recurrent PjP. In virologically suppressed patients on ART with CD4 counts of 100 to 200/µL, the incidence of PjP off prophylaxis is below 10/1000 py. Secondary PjP prophylaxis may be safely withheld in such patients. While European guidelines recommend discontinuing secondary PjP prophylaxis only if CD4 counts ris
Published: 2021

3. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL

Author: Atkinson, A., Miro, J. M., Mocroft, A., Reiss, P., Kirk, O., Morlat, P., Ghosn, J., Stephan, C., Mussini, C., Antoniadou, A., Doerholt, K., Girardi, E., De Wit, S., Kraus, D., Zwahlen, M., Furrer, H., Castagna, A., Fatkenheuer, G., Raben, D., Teira, R., Zangerle, R., Judd, A., Touloumi, G., Warszawski, J., Meyer, L., Dabis, F., Krause, M. M., Leport, C., Wittkop, L., Wit, F., Prins, M., Bucher, H., Gibb, D., Del Amo, J., Obel, N., Thorne, C., Perez-Hoyos, S., Hamouda, O., Bartmeyer, B., Chkhartishvili, N., Noguera-Julian, A., Antinori, A., d'Arminio Monforte, A., Brockmeyer, N., Prieto, L., Conejo, P. R., Soriano-Arandes, A., Battegay, M., Kouyos, R., Casabona, J., Goetghebuer, T., Sonnerborg, A., Torti, C., Sabin, C., Garrido, M., Haerry, D., Costagliola, D., d'Arminio-Monforte, A., del Amo, J., Chene, G., Barger, D., Schwimmer, C., Termote, M., Frederiksen, C. M., Brandt, R. S., Berenguer, J., Bohlius, J., Bouteloup, V., Cozzi-Lepri, A., Davies, M. -A., Dorrucci, M., Dunn, D., Egger, M., Guiguet, M., Grabar, S., Lambotte, O., Leroy, V., Lodi, S., Matheron, S., Monge, S., Nakagawa, F., Paredes, R., Phillips, A., Puoti, M., Rohner, E., Schomaker, M., Smit, C., Sterne, J., Thiebaut, R., Wqetu, C., van der Valk, M., Global Health, Infectious diseases, AII - Infectious diseases, APH - Aging & Later Life, Atkinson, A, Miro, J, Mocroft, A, Reiss, P, Kirk, O, Morlat, P, Ghosn, J, Stephan, C, Mussini, C, Antoniadou, A, Doerholt, K, Girardi, E, De Wit, S, Kraus, D, Zwahlen, M, Furrer, H, Castagna, A, Fatkenheuer, G, Raben, D, Teira, R, Zangerle, R, Judd, A, Touloumi, G, Warszawski, J, Meyer, L, Dabis, F, Krause, M, Leport, C, Wittkop, L, Wit, F, Prins, M, Bucher, H, Gibb, D, Del Amo, J, Obel, N, Thorne, C, Perez-Hoyos, S, Hamouda, O, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Antinori, A, d'Arminio Monforte, A, Brockmeyer, N, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Casabona, J, Goetghebuer, T, Sonnerborg, A, Torti, C, Sabin, C, Garrido, M, Haerry, D, Costagliola, D, d'Arminio-Monforte, A, del Amo, J, Chene, G, Barger, D, Schwimmer, C, Termote, M, Frederiksen, C, Brandt, R, Berenguer, J, Bohlius, J, Bouteloup, V, Cozzi-Lepri, A, Davies, M, Dorrucci, M, Dunn, D, Egger, M, Guiguet, M, Grabar, S, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Rohner, E, Schomaker, M, Smit, C, Sterne, J, Thiebaut, R, Wqetu, C, and van der Valk, M
Subjects: Adult, medicine.medical_specialty, Adolescent, opportunistic infection, Population, Human immunodeficiency virus (HIV), HIV Infections, 610 Medicine & health, Pneumocystis carinii, medicine.disease_cause, Young Adult, 03 medical and health sciences, 0302 clinical medicine, 360 Social problems & social services, Internal medicine, Epidemiology, medicine, Humans, Opportunistic infections, Viremia, 030212 general & internal medicine, education, Research Articles, education.field_of_study, 030505 public health, business.industry, Pneumonia, Pneumocystis, Incidence (epidemiology), prophylaxi, Pneumocystis jirovecii Pneumonia, Public Health, Environmental and Occupational Health, opportunistic infections, Pneumocystis jirovecii pneumonia, CD4 Lymphocyte Count, 3. Good health, Discontinuation, Europe, Infectious Diseases, Cohort, Infeccions per VIH, prophylaxis, 0305 other medical science, business, Viral load, Infeccions oportunistes, Research Article, HIV infections
Abstract: Introduction: Since the beginning of the HIV epidemic in resource-rich countries, Pneumocystis jirovecii pneumonia (PjP) is one of the most frequent opportunistic AIDS-defining infections. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) has shown that primary Pneumocystis jirovecii Pneumonia (PjP) prophylaxis can be safely withdrawn in patients with CD4 counts of 100 to 200 cells/µL if plasma HIV-RNA is suppressed on combination antiretroviral therapy. Whether this holds true for secondary prophylaxis is not known, and this has proved difficult to determine due to the much lower population at risk. Methods: We estimated the incidence of secondary PjP by including patient data collected from 1998 to 2015 from the COHERE cohort collaboration according to time-updated CD4 counts, HIV-RNA and use of PjP prophylaxis in persons >16 years of age. We fitted a Poisson generalized additive model in which the smoothed effect of CD4 was modelled by a restricted cubic spline, and HIV-RNA was stratified as low (10,000copies/mL). Results: There were 373 recurrences of PjP during 74,295 person-years (py) in 10,476 patients. The PjP incidence in the different plasma HIV-RNA strata differed significantly and was lowest in the low stratum. For patients off prophylaxis with CD4 counts between 100 and 200 cells/µL and HIV-RNA below 400 copies/mL, the incidence of recurrent PjP was 3.9 (95% CI: 2.0 to 5.8) per 1000 py, not significantly different from patients on prophylaxis in the same stratum (1.9, 95% CI: 0.1 to 3.7). Conclusions: HIV viraemia importantly affects the risk of recurrent PjP. In virologically suppressed patients on ART with CD4 counts of 100 to 200/µL, the incidence of PjP off prophylaxis is below 10/1000 py. Secondary PjP prophylaxis may be safely withheld in such patients. While European guidelines recommend discontinuing secondary PjP prophylaxis only if CD4 counts rise above 200 cells/mL, the latest US Guidelines consider secondary prophylaxis discontinuation even in patients with a CD4 count above 100 cells/µL and suppressed viral load. Our results strengthen and support this US recommendation. Keywords: opportunistic infections; Pneumocystis jirovecii pneumonia; prophylaxis
Published: 2021
Full Text: View/download PDF

4. Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity

Author: Bastard, Jean-Philippe, Fellahi, Soraya, Couffignal, Camille, Raffi, François, Gras, Guillaume, Hardel, Lucile, Sobel, Alain, Leport, Catherine, Fardet, Laurence, Capeau, Jacqueline, Leport, C., Raffi, F., Chêne, G., Salamon, R., Moatti, J. P., Pierret, J., Spire, B., Brun-Vézinet, F., Fleury, H., Masquelier, B., Peytavin, G., Garraffo, R., Costagliola, D., Dellamonica, P., Katlama, C., Meyer, L., Salmon, D., Sobel, A., Cuzin, L., Dupon, M., Duval, X., Le Moing, V., Marchou, B., May, T., Morlat, P., Rabaud, C., Waldner-Combernoux, A., Reboud, P., Couffin-Cadiergues, S., Marchand, L., Bouteloup, V., Bouhnik, A. D., Brunet-François, C., Caron, V., Carrieri, M. P., Courcoul, M., Couturier, F., Hardel, L., Iordache, L., Kurkdji, P., Martiren, S., Préau, M., Protopopescu, C., Surzyn, J., Taieb, A., Villes, V., Schmit, J. L., Chennebault, J. M., Faller, J. P., Magy-Bertrand, N., Chirouze, C., Humbert, P., Bouchaud, O., Dupon, M., Morlat, P., Ragnaud, J. M., Granier, P., Ansart, S., Verdon, R., Merrien, D., Chevojon, P., Sobel, A., Piroth, L., Perronne, C., Froguel, E., Ceccaldi, J., Peyramond, D., Allard, C., Le Moing, V., May, T., Raffi, F., Fuzibet, J. G., Dellamonica, P., Arsac, P., Bouvet, E., Bricaire, F., Monsonego, J., Girard, P. M., Guillevin, L., Herson, S., Leport, C., Meyohas, M. C., Molina, J. M., Pialoux, G., Sain, O., Salmon, D., Sellier, P., Roblot, F., Jaussaud, R., Michelet, C., Lucht, F., Rapp, C., Chesneau, C., De Jaureguiberry, J. P., Marchou, B., and Bernard, L.
Published: 2015
Full Text: View/download PDF

5. Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis

Author: Willemse, S., Smit, C., Sogni, P., Sarcletti, M., Uberti-Foppa, C., Wittkop, L., Raben, D., D'Arminio Monforte, A., Dabis, F., Van Der Valk, M., Judd, A., Zangerle, R., Touloumi, G., Warszawski, J., Meyer, L., Murielle, M., Ghosn, J., Leport, C., Reiss, P., Wit, F., Prins, M., Bucher, H., Gibb, D., Fatkenheuer, G., Obel, N., Thorne, C., Mocroft, A., Kirk, O., Stephan, C., Perez-Hoyos, S., Hamouda, O., Clinsurv, G., Bartmeyer, B., Chkhartishvili, N., Noguera-Julian, A., Antinori, A., Brockmeyer, N., Prieto, L., Pablo, R., Soriano-Arandes, A., Battegay, M., Kouyos, R., Mussini, C., Tookey, P., Casabona, J., Miro, J. M., Castagna, A., Konopnick, D., Goetghebuer, T., Sonnerborg, A., Torti, C., Sabin, C., Teira, R., Garrido, M., Haerry, D., Stephane, D., Jose, M., Costagliola, D., Raffaele, S., Julia, D., Chene, G., Barger, D., Schwimmer, C., Termote, M., Campbell, M., Frederiksen, C. M., Friis-Moller, N., Kjaer, J., Bohlius, J., Bouteloup, V., Cozzi-Lepri, A., Davies, M. -A., Dorrucci, M., Dunn, D., Egger, M., Furrer, H., Guiguet, M., Grabar, S., Lambotte, O., Leroy, V., Lodi, S., Matheron, S., Monge, S., Nakagawa, F., Paredes, R., Phillips, A., Puoti, M., Rohner, E., Schomaker, M., Sterne, J., Thiebaut, R., Willemse, S., Smit, C., Sogni, P., Sarcletti, M., Uberti-Foppa, C., Wittkop, L., Raben, D., D'Arminio Monforte, A., Dabis, F., Van Der Valk, M., Judd, A., Zangerle, R., Touloumi, G., Warszawski, J., Meyer, L., Murielle, M., Ghosn, J., Leport, C., Reiss, P., Wit, F., Prins, M., Bucher, H., Gibb, D., Fatkenheuer, G., Obel, N., Thorne, C., Mocroft, A., Kirk, O., Stephan, C., Perez-Hoyos, S., Hamouda, O., Clinsurv, G., Bartmeyer, B., Chkhartishvili, N., Noguera-Julian, A., Antinori, A., Brockmeyer, N., Prieto, L., Pablo, R., Soriano-Arandes, A., Battegay, M., Kouyos, R., Mussini, C., Tookey, P., Casabona, J., Miro, J. M., Castagna, A., Konopnick, D., Goetghebuer, T., Sonnerborg, A., Torti, C., Sabin, C., Teira, R., Garrido, M., Haerry, D., Stephane, D., Jose, M., Costagliola, D., Raffaele, S., Julia, D., Chene, G., Barger, D., Schwimmer, C., Termote, M., Campbell, M., Frederiksen, C. M., Friis-Moller, N., Kjaer, J., Bohlius, J., Bouteloup, V., Cozzi-Lepri, A., Davies, M. -A., Dorrucci, M., Dunn, D., Egger, M., Furrer, H., Guiguet, M., Grabar, S., Lambotte, O., Leroy, V., Lodi, S., Matheron, S., Monge, S., Nakagawa, F., Paredes, R., Phillips, A., Puoti, M., Rohner, E., Schomaker, M., Sterne, J., Thiebaut, R., Willemse, S, Smit, C, Sogni, P, Sarcletti, M, Uberti-Foppa, C, Wittkop, L, Raben, D, D'Arminio Monforte, A, Dabis, F, Van Der Valk, M, Judd, A, Zangerle, R, Touloumi, G, Warszawski, J, Meyer, L, Murielle, M, Ghosn, J, Leport, C, Reiss, P, Wit, F, Prins, M, Bucher, H, Gibb, D, Fatkenheuer, G, Obel, N, Thorne, C, Mocroft, A, Kirk, O, Stephan, C, Perez-Hoyos, S, Hamouda, O, Clinsurv, G, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Antinori, A, Brockmeyer, N, Prieto, L, Pablo, R, Soriano-Arandes, A, Battegay, M, Kouyos, R, Mussini, C, Tookey, P, Casabona, J, Miro, J, Castagna, A, Konopnick, D, Goetghebuer, T, Sonnerborg, A, Torti, C, Sabin, C, Teira, R, Garrido, M, Haerry, D, Stephane, D, Jose, M, Costagliola, D, Raffaele, S, Julia, D, Chene, G, Barger, D, Schwimmer, C, Termote, M, Campbell, M, Frederiksen, C, Friis-Moller, N, Kjaer, J, Bohlius, J, Bouteloup, V, Cozzi-Lepri, A, Davies, M, Dorrucci, M, Dunn, D, Egger, M, Furrer, H, Guiguet, M, Grabar, S, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Rohner, E, Schomaker, M, Sterne, J, Thiebaut, R, Infectious diseases, AII - Infectious diseases, Global Health, APH - Aging & Later Life, APH - Global Health, APH - Digital Health, and APH - Personalized Medicine
Subjects: Liver Cirrhosis, Male, Cirrhosis, co‐infection, medicine.disease_cause, 0302 clinical medicine, 80 and over, Mass Screening, 030212 general & internal medicine, Chronic, guideline adherence, Aged, 80 and over, cancer screening, chronic viral hepatitis, co-infection, hepatocellular carcinoma, hepatocellular carcinoma screening, human immunodeficiency virus, liver cirrhosis, Adolescent, Adult, Aged, Carcinoma, Hepatocellular, Coinfection, Female, Guideline Adherence, Hepatitis B, Chronic, Hepatitis C, Chronic, Humans, Liver Neoplasms, Middle Aged, Young Adult, medicine.diagnostic_test, chronic viral hepatiti, virus diseases, Hepatitis C, Hepatitis B, 3. Good health, Infectious Diseases, Hepatocellular carcinoma, Liver biopsy, 030211 gastroenterology & hepatology, medicine.medical_specialty, Hepatitis C virus, Short Communication, Short Communications, 03 medical and health sciences, Virology, Internal medicine, medicine, Mass screening, Hepatitis B virus, Hepatology, business.industry, human immunodeficiency viru, Carcinoma, Hepatocellular, medicine.disease, digestive system diseases, business
Abstract: The incidence of hepatocellular carcinoma (HCC) in patients co-infected with HIV and hepatitis B virus (HBV) or hepatitis C virus (HCV) is increasing. In patients with cirrhosis, guidelines recommend HCC screening every 6 months. We assessed compliance with HCC screening guidelines in cirrhotic HBV/HCV-HIV-co-infected patients. HBV/HCV-HIV-co-infected patients with cirrhosis were enrolled from 4 European prospective cohorts participating in the COHERE collaboration, followed from 1 January 2005-1 January 2015. Assessment of liver cirrhosis was based on clinical diagnosis and liver biopsy or Fibroscan. Compliance with HCC screening guidelines was defined as one ultrasound every 6 months. Generalized estimating equation models adjusted for repeated measurements were fitted to determine predictors of low compliance. Different sensitivity analyses were performed and validation of the data was carried out by randomly checking 10% of each cohort's data. 646 HIV-patients with the diagnosis of cirrhosis were included: 518 (80%) HCV-, 85 (13%) HBV- and 43 (7%) HBV/HCV-co-infected. Median age at cirrhosis diagnosis was 44 years, median follow-up time since diagnosis was 5.3 years. Screening
Published: 2019

6. Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis

Author: Willemse, S, Smit, C, Sogni, P, Sarcletti, M, Uberti-Foppa, C, Wittkop, L, Raben, D, D'Arminio Monforte, A, Dabis, F, Van Der Valk, M, Judd, A, Zangerle, R, Touloumi, G, Warszawski, J, Meyer, L, Murielle, M, Ghosn, J, Leport, C, Reiss, P, Wit, F, Prins, M, Bucher, H, Gibb, D, Fatkenheuer, G, Obel, N, Thorne, C, Mocroft, A, Kirk, O, Stephan, C, Perez-Hoyos, S, Hamouda, O, Clinsurv, G, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Antinori, A, Brockmeyer, N, Prieto, L, Pablo, R, Soriano-Arandes, A, Battegay, M, Kouyos, R, Mussini, C, Tookey, P, Casabona, J, Miro, J, Castagna, A, Konopnick, D, Goetghebuer, T, Sonnerborg, A, Torti, C, Sabin, C, Teira, R, Garrido, M, Haerry, D, Stephane, D, Jose, M, Costagliola, D, Raffaele, S, Julia, D, Chene, G, Barger, D, Schwimmer, C, Termote, M, Campbell, M, Frederiksen, C, Friis-Moller, N, Kjaer, J, Bohlius, J, Bouteloup, V, Cozzi-Lepri, A, Davies, M, Dorrucci, M, Dunn, D, Egger, M, Furrer, H, Guiguet, M, Grabar, S, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Rohner, E, Schomaker, M, Sterne, J, Thiebaut, R, Willemse S., Smit C., Sogni P., Sarcletti M., Uberti-Foppa C., Wittkop L., Raben D., D'Arminio Monforte A., Dabis F., Van Der Valk M., Judd A., Zangerle R., Touloumi G., Warszawski J., Meyer L., Murielle M., Ghosn J., Leport C., Reiss P., Wit F., Prins M., Bucher H., Gibb D., Fatkenheuer G., Obel N., Thorne C., Mocroft A., Kirk O., Stephan C., Perez-Hoyos S., Hamouda O., ClinSurv G., Bartmeyer B., Chkhartishvili N., Noguera-Julian A., Antinori A., Brockmeyer N., Prieto L., Pablo R., Soriano-Arandes A., Battegay M., Kouyos R., Mussini C., Tookey P., Casabona J., Miro J. M., Castagna A., Konopnick D., Goetghebuer T., Sonnerborg A., Torti C., Sabin C., Teira R., Garrido M., Haerry D., Stephane D., Jose M., Costagliola D., Raffaele S., Julia D., Chene G., Barger D., Schwimmer C., Termote M., Campbell M., Frederiksen C. M., Friis-Moller N., Kjaer J., Bohlius J., Bouteloup V., Cozzi-Lepri A., Davies M. -A., Dorrucci M., Dunn D., Egger M., Furrer H., Guiguet M., Grabar S., Lambotte O., Leroy V., Lodi S., Matheron S., Monge S., Nakagawa F., Paredes R., Phillips A., Puoti M., Rohner E., Schomaker M., Sterne J., Thiebaut R., Willemse, S, Smit, C, Sogni, P, Sarcletti, M, Uberti-Foppa, C, Wittkop, L, Raben, D, D'Arminio Monforte, A, Dabis, F, Van Der Valk, M, Judd, A, Zangerle, R, Touloumi, G, Warszawski, J, Meyer, L, Murielle, M, Ghosn, J, Leport, C, Reiss, P, Wit, F, Prins, M, Bucher, H, Gibb, D, Fatkenheuer, G, Obel, N, Thorne, C, Mocroft, A, Kirk, O, Stephan, C, Perez-Hoyos, S, Hamouda, O, Clinsurv, G, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Antinori, A, Brockmeyer, N, Prieto, L, Pablo, R, Soriano-Arandes, A, Battegay, M, Kouyos, R, Mussini, C, Tookey, P, Casabona, J, Miro, J, Castagna, A, Konopnick, D, Goetghebuer, T, Sonnerborg, A, Torti, C, Sabin, C, Teira, R, Garrido, M, Haerry, D, Stephane, D, Jose, M, Costagliola, D, Raffaele, S, Julia, D, Chene, G, Barger, D, Schwimmer, C, Termote, M, Campbell, M, Frederiksen, C, Friis-Moller, N, Kjaer, J, Bohlius, J, Bouteloup, V, Cozzi-Lepri, A, Davies, M, Dorrucci, M, Dunn, D, Egger, M, Furrer, H, Guiguet, M, Grabar, S, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Rohner, E, Schomaker, M, Sterne, J, Thiebaut, R, Willemse S., Smit C., Sogni P., Sarcletti M., Uberti-Foppa C., Wittkop L., Raben D., D'Arminio Monforte A., Dabis F., Van Der Valk M., Judd A., Zangerle R., Touloumi G., Warszawski J., Meyer L., Murielle M., Ghosn J., Leport C., Reiss P., Wit F., Prins M., Bucher H., Gibb D., Fatkenheuer G., Obel N., Thorne C., Mocroft A., Kirk O., Stephan C., Perez-Hoyos S., Hamouda O., ClinSurv G., Bartmeyer B., Chkhartishvili N., Noguera-Julian A., Antinori A., Brockmeyer N., Prieto L., Pablo R., Soriano-Arandes A., Battegay M., Kouyos R., Mussini C., Tookey P., Casabona J., Miro J. M., Castagna A., Konopnick D., Goetghebuer T., Sonnerborg A., Torti C., Sabin C., Teira R., Garrido M., Haerry D., Stephane D., Jose M., Costagliola D., Raffaele S., Julia D., Chene G., Barger D., Schwimmer C., Termote M., Campbell M., Frederiksen C. M., Friis-Moller N., Kjaer J., Bohlius J., Bouteloup V., Cozzi-Lepri A., Davies M. -A., Dorrucci M., Dunn D., Egger M., Furrer H., Guiguet M., Grabar S., Lambotte O., Leroy V., Lodi S., Matheron S., Monge S., Nakagawa F., Paredes R., Phillips A., Puoti M., Rohner E., Schomaker M., Sterne J., and Thiebaut R.
Published: 2019

7. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL

Author: Atkinson, A. Miro, J.M. Mocroft, A. Reiss, P. Kirk, O. Morlat, P. Ghosn, J. Stephan, C. Mussini, C. Antoniadou, A. Doerholt, K. Girardi, E. De Wit, S. Kraus, D. Zwahlen, M. Furrer, H. De Wit, S. Antoniadou, A. Castagna, A. Doerholt, K. Fätkenheuer, G. Raben, D. Teira, R. Zangerle, R. Judd, A. Zangerle, R. Touloumi, G. Warszawski, J. Meyer, L. Dabis, F. Krause, M.M. Leport, C. Wittkop, L. Wit, F. Prins, M. Bucher, H. Gibb, D. Fätkenheuer, G. Del Amo, J. Obel, N. Thorne, C. Pérez-Hoyos, S. Hamouda, O. Bartmeyer, B. Chkhartishvili, N. Noguera-Julian, A. Antinori, A. d’Arminio Monforte, A. Brockmeyer, N. Prieto, L. Conejo, P.R. Soriano-Arandes, A. Battegay, M. Kouyos, R. Casabona, J. Goetghebuer, T. Sönnerborg, A. Torti, C. Sabin, C. Teira, R. Garrido, M. Haerry, D. Costagliola, D. d’Arminio-Monforte, A. del Amo, J. Raben, D. Chêne, G. Judd, A. Conejo, P.R. Barger, D. Schwimmer, C. Termote, M. Wittkop, L. Frederiksen, C.M. Raben, D. Brandt, R.S. Berenguer, J. Bohlius, J. Bouteloup, V. Bucher, H. Cozzi-Lepri, A. Dabis, F. d’Arminio Monforte, A. Davies, M.-A. del Amo, J. Dorrucci, M. Dunn, D. Egger, M. Guiguet, M. Grabar, S. Judd, A. Lambotte, O. Leroy, V. Lodi, S. Matheron, S. Meyer, L. Monge, S. Nakagawa, F. Paredes, R. Phillips, A. Puoti, M. Rohner, E. Schomaker, M. Smit, C. Sterne, J. Thiebaut, R. Thorne, C. Wqetu, C. van der Valk, M. Wittkop, L. the Opportunistic Infections Working Group of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCOORD
Abstract: Introduction: Since the beginning of the HIV epidemic in resource-rich countries, Pneumocystis jirovecii pneumonia (PjP) is one of the most frequent opportunistic AIDS-defining infections. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) has shown that primary Pneumocystis jirovecii Pneumonia (PjP) prophylaxis can be safely withdrawn in patients with CD4 counts of 100 to 200 cells/µL if plasma HIV-RNA is suppressed on combination antiretroviral therapy. Whether this holds true for secondary prophylaxis is not known, and this has proved difficult to determine due to the much lower population at risk. Methods: We estimated the incidence of secondary PjP by including patient data collected from 1998 to 2015 from the COHERE cohort collaboration according to time-updated CD4 counts, HIV-RNA and use of PjP prophylaxis in persons >16 years of age. We fitted a Poisson generalized additive model in which the smoothed effect of CD4 was modelled by a restricted cubic spline, and HIV-RNA was stratified as low (10,000copies/mL). Results: There were 373 recurrences of PjP during 74,295 person-years (py) in 10,476 patients. The PjP incidence in the different plasma HIV-RNA strata differed significantly and was lowest in the low stratum. For patients off prophylaxis with CD4 counts between 100 and 200 cells/µL and HIV-RNA below 400 copies/mL, the incidence of recurrent PjP was 3.9 (95% CI: 2.0 to 5.8) per 1000 py, not significantly different from patients on prophylaxis in the same stratum (1.9, 95% CI: 0.1 to 3.7). Conclusions: HIV viraemia importantly affects the risk of recurrent PjP. In virologically suppressed patients on ART with CD4 counts of 100 to 200/µL, the incidence of PjP off prophylaxis is below 10/1000 py. Secondary PjP prophylaxis may be safely withheld in such patients. While European guidelines recommend discontinuing secondary PjP prophylaxis only if CD4 counts rise above 200 cells/mL, the latest US Guidelines consider secondary prophylaxis discontinuation even in patients with a CD4 count above 100 cells/µL and suppressed viral load. Our results strengthen and support this US recommendation. © 2021 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Published: 2021

8. Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy

Author: Masquelier, Bernard, Taieb, Audrey, Reigadas, Sandrine, Marchou, Bruno, Cheneau, Christine, Spire, Bruno, Charpentier, Charlotte, Leport, Catherine, Raffi, François, Chêne, Geneviève, Descamps, Diane, Leport, C., Raffi, F., Chêne, G., Salamon, R., Moatti, J.-P., Pierret, J., Spire, B., Brun-Vézinet, F., Fleury, H., Masquelier, B., Peytavin, G., Garraffo, R., Costagliola, D., Dellamonica, P., Katlama, C., Meyer, L., Salmon, D., Sobel, A., Cuzin, L., Dupon, M., Duval, X., Le Moing, V., Marchou, B., May, T., Morlat, P., Rabaud, C., Waldner-Combernoux, A., Reboud, P., Couffin-Cadiergues, Sandrine, Marchand, Lucie, Bouteloup, V., Bouhnik, A. D., Brunet-François, C., Caron, V., Carrieri, M. P., Courcoul, M., Couturier, F., Hardel, L., Iordache, L., Kurkdji, P., Martiren, S., Préau, M., Protopopescu, C., Surzyn, J., Taieb, A., Villes, V., Schmit, J. L., Chennebault, J. M., Faller, J. P., Mgy-Bertrand, N., Hoen, B., Drobachef, Bouchaud, O., Dupon, M., Longy-Boursier, Morlat, P., Ragnaud, J. M., Granier, P., Garré, M., Verdon, R., Merrien, D., Devidas, A., Sobel, A., Piroth, L., Perronne, C., Froguel, E., Ceccaldi, J., Peyramond, D., Allard, C., Reynes, J., May, T., Raffi, F., Fuzibet, J. G., Dellamonica, P., Arsac, P., Bouvet, E., Bricaire, F., Bergmann, P., Cabane, J., Monsonego, J., Girard, P. M., Guillevin, L., Herson, S., Leport, C., Meyohas, M. C., Molina, J. M., Pialoux, G., Salmon, D., Roblot, P., Jaussaud, R., Michelet, C., Lucht, F., Debord, T., Rey, D., De Jaureguiberry, J. P., Marchou, B., and Bernard, L.
Published: 2011
Full Text: View/download PDF

9. Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation

Author: Panayidou, K, Davies, M, Anderegg, N, Egger, M, Fatti, G, Vinikoor, M, Sawry, S, Ehmer, J, Eley, B, Phiri, S, Technau, K, Chimbetete, C, Rabie, H, Boulle, A, Tanser, F, Wood, R, Wools-Kaloustian, K, Vreeman, R, Oyaro, P, Ayaya, S, Nakigozi, G, Musick, B, Yiannoutsos, C, Amorissani-Folquet, M, Takassi, E, Sylla, M, Renner, L, Malateste, K, Desmonde, S, Leroy, V, Kurniati, N, Hansudewechakul, R, Nguyen, L, Ly, P, Truong, K, Kariminia, A, Sohn, A, Edmonds, A, Yumo, H, Dusingize, J, Yotebieng, M, Judd, A, Rojo, P, Smit, C, Grabar, S, Warszwarski, J, Chene, G, Raban, D, Patel, K, Seage, G, Van Dyke, R, Oleske, J, Williams, P, Abzug, M, Succi, R, Machado, D, Pinto, J, Rouzier, V, Luque, M, Mejia, F, Khol, V, Tucker, J, Kumarasamy, N, Saghayam, S, Chandrasekaran, E, Wati, D, Vedaswari, D, Malino, I, Muktiarti, D, Fong, S, Lim, M, Daut, F, Nik Yusoff, N, Mohamad, P, Mohamed, T, Drawis, M, Nallusamy, R, Chan, K, Sudjaritruk, T, Sirisanthana, V, Aurpibul, L, Oberdorfer, P, Denjanta, S, Watanaporn, S, Kongphonoi, A, Lumbiganon, P, Kosalaraksa, P, Tharnprisan, P, Udomphanit, T, Jourdain, G, Puthanakit, T, Anugulruengkitt, S, Phadungphon, C, Chokephaibulkit, K, Lapphra, K, Phongsamart, W, Sricharoenchai, S, Du, Q, Nguyen, C, Do, V, Ha, T, An, V, Khu, D, Pham, A, Le, O, Ross, J, Sethaputra, C, Law, M, Cahn, P, Cesar, C, Fink, V, Sued, O, Dell'Isola, E, Perez, H, Valiente, J, Yamamoto, C, Grinsztejn, B, Veloso, V, Luz, P, de Boni, R, Wagner, S, Friedman, R, Moreira, R, Ferreira, F, Maia, M, de Menezes Succi, R, Barbosa Gouv E A, A, Wolff, M, Cortes, C, Rodriguez, M, Allendes, G, Pape, J, Marcelin, A, Perodin, C, Padgett, D, Madero, J, Ramirez, B, Belaunzaran, P, Vega, Y, Gotuzzo, E, Carriquiry, G, Mcgowan, C, Shepherd, B, Sterling, T, Jayathilake, K, Person, A, Rebeiro, P, Giganti, M, Castilho, J, Duda, S, Maruri, F, Vansell, H, P E Lagie, N, Gateretse, P, Munezero, J, Nitereka, V, Niyongabo, T, Twizere, C, Bukuru, H, Nahimana, T, Biziragusenyuka, J, Manyundo, R, Atsu, K, Mbuh, T, Ajeh, R, Benwi, M, Dzudie, A, Mbuh, A, Ngamani, M, Nkome, V, Amadou, D, Ngassam, E, Pefura Yone, E, Ewanoge, A, Fuhngwa, N, Moki, C, Akele, C, Kitetele, F, Lelo, P, Tabala, M, Okitolonda, E, Wenzi, L, Diafouka, M, Ekat, M, Nsonde, D, Mafou, A, Ntarambirwa, F, Tuyishimire, Y, Hakizimana, T, Ayinkamiye, J, Mukantwali, S, Kayitesi, H, Uwamahoro, O, Habumuremyi, V, Mukamana, J, Kubwimana, G, Mugenzi, P, Muhoza, B, Munyaneza, A, Ndahiro, E, Nyiransabimana, D, D'Amour Sinayobye, J, Sugira, V, Benekigeri, C, Mbaraga, G, Adedimeji, A, Anastos, K, Dilorenzo, M, Murchison, L, Addison, D, Baker, M, Brazier, E, Jones, H, Kelvin, E, Kulkarni, S, Nash, D, Tymejczyk, O, Elul, B, Cai, X, Hoover, D, Kim, H, Li, C, Shi, Q, Lancaster, K, Kuniholm, M, Parcesepe, A, Kimmel, A, Mcnairy, M, Diero, L, Plus, A, Bukusi, E, Ssali, J, Nalugoda, F, Somi, G, Lyamuya, R, Ngonyani, K, Lugina, E, Urassa, M, Michael, D, Zannou, M, Poda, A, Sarfo, F, Messou, E, Chenal, H, Minga, K, Bissagnene, E, Tanon, A, Seydi, M, Patassi, A, Koumakpai-Adeothy, S, N'Gbeche, S, Bosse, C, Kouakou, K, Folquet, M, Eboua, F, Traore, F, Dabis, F, Arrive, E, Balestre, E, Becquet, R, Bernard, C, Arikawa, S, Doring, A, Jaquet, A, Rabourdin, E, Tiendrebeogo, T, Jesson, J, Ekouevi, D, Azani, J, Coffi E, P, Gnepa, G, Kouadio, C, Tchounga, B, Maartens, G, Lettow, M, Muhairwe, J, Jores, A, Kamenova, K, Fox, M, Prozesky, H, Zangerle, R, Touloumi, G, Warszawski, J, Meyer, L, Krause, M, Ghosn, J, Leport, C, Wittkop, L, Reiss, P, Wit, F, Prins, M, Bucher, H, Gibb, D, Fatkenheuer, G, Del Amo, J, Obel, N, Thorne, C, Mocroft, A, Kirk, O, Stephan, C, Perez-Hoyos, S, Hamouda, O, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Antinori, A, D'Arminio Monforte, A, Brockmeyer, N, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Mussini, C, Tookey, P, Casabona, J, Miro, J, Castagna, A, Konopnick, D, Goetghebuer, T, Sonnerborg, A, Torti, C, Sabin, C, Teira, R, Garrido, M, Haerry, D, de Wit, S, Costagliola, D, Raben, D, Barger, D, Schwimmer, C, Termote, M, Campbell, M, Frederiksen, C, Friis-Moller, N, Kjaer, J, Brandt, R, Berenguer, J, Bohlius, J, Bouteloup, V, Cozzi-Lepri, A, Dorrucci, M, Dunn, D, Furrer, H, Guiguet, M, Lambotte, O, Lodi, S, Matheron, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Rohner, E, Schomaker, M, Sterne, J, Thiebaut, R, van der Valk, M, Hazra, R, Heckman, B, O'Gara, E, Siminski, S, Panayidou K., Davies M. -A., Anderegg N., Egger M., Fatti G., Vinikoor M., Sawry S., Ehmer J., Eley B., Phiri S., Technau K. -G. u. N., Chimbetete C., Rabie H., Boulle A., Tanser F., Wood R., Wools-Kaloustian K., Vreeman R., Oyaro P., Ayaya S., Nakigozi G., Musick B., Yiannoutsos C., Amorissani-Folquet M., Takassi E., Sylla M., Renner L., Malateste K., Desmonde S., Leroy V., Kurniati N., Hansudewechakul R., Nguyen L. V., Ly P. S., Truong K. H., Kariminia A., Sohn A. H., Edmonds A., Yumo H. A., Dusingize J. C., Yotebieng M., Judd A., Rojo P., Smit C., Grabar S., Warszwarski J., Chene G., Raban D., Patel K., Seage G. R., Van Dyke R. B., Oleske J., Williams P. L., Abzug M. J., Succi R., Machado D. M., Pinto J., Rouzier V., Luque M., Mejia F., Khol V., Tucker J., Kumarasamy N., Saghayam S., Chandrasekaran E., Wati D. K., Vedaswari D., Malino I. Y., Muktiarti D., Fong S. M., Lim M., Daut F., Nik Yusoff N. K., Mohamad P., Mohamed T. J., Drawis M. R., Nallusamy R., Chan K. C., Sudjaritruk T., Sirisanthana V., Aurpibul L., Oberdorfer P., Denjanta S., Watanaporn S., Kongphonoi A., Lumbiganon P., Kosalaraksa P., Tharnprisan P., Udomphanit T., Jourdain G., Puthanakit T., Anugulruengkitt S., Phadungphon C., Chokephaibulkit K., Lapphra K., Phongsamart W., Sricharoenchai S., Du Q. T., Nguyen C. H., Do V. C., Ha T. M., An V. T., Khu D. T. K., Pham A. N., Nguyen L. T., Le O. N., Ross J. L., Sethaputra C., Law M. G., Cahn P., Cesar C., Fink V., Sued O., Dell'isola E., Perez H., Valiente J., Yamamoto C., Grinsztejn B., Veloso V., Luz P., de Boni R., Wagner S. C., Friedman R., Moreira R., Ferreira F., Maia M., de Menezes Succi R. C., Barbosa Gouv E A A. F. a. T., Wolff M., Cortes C., Rodriguez M. F., Allendes G., Pape J. W., Marcelin A., Perodin C., Luque M. T., Padgett D., Madero J. S., Ramirez B. C., Belaunzaran P., Vega Y. C., Gotuzzo E., Carriquiry G., McGowan C. C., Shepherd B. E., Sterling T., Jayathilake K., Person A. K., Rebeiro P. F., Giganti M., Castilho J., Duda S. N., Maruri F., Vansell H., P E Lagie N., Gateretse P., Munezero J., Nitereka V., Niyongabo T., Twizere C., Bukuru H., Nahimana T., Biziragusenyuka J., Manyundo R. S., Atsu K., Mbuh T., Ajeh R., Benwi M., Dzudie A., Mbuh A., Ngamani M. L., Nkome V., Amadou D., Ngassam E., Pefura Yone E. W., Ewanoge A. N., Fuhngwa N., Moki C., Akele C., Kitetele F., Lelo P., Tabala M., Okitolonda E. W., Wenzi L., Diafouka M., Ekat M. H., Nsonde D. M., Mafou A., Ntarambirwa F., Tuyishimire Y., Hakizimana T., Ayinkamiye J., Mukantwali S., Kayitesi H., Uwamahoro O., Habumuremyi V., Mukamana J., Kubwimana G., Mugenzi P., Muhoza B., Munyaneza A., Ndahiro E., Nyiransabimana D., D'Amour Sinayobye J., Sugira V., Benekigeri C., Mbaraga G., Adedimeji A., Anastos K., Dilorenzo M., Murchison L., Ross J., Addison D., Baker M., Brazier E., Jones H., Kelvin E., Kulkarni S., Nash D., Tymejczyk O., Elul B., Cai X., Hoover D., Kim H. -Y., Li C., Shi Q., Lancaster K., Kuniholm M., Parcesepe A., Duda S., Kimmel A., McNairy M., Diero L., Plus A. M. P. A. T. H., Bukusi E., Ssali J., Nalugoda F., Somi G. R., Lyamuya R. E., Ngonyani K., Lugina E., Urassa M., Michael D., Zannou M. D., Poda A., Sarfo F. S., Messou E., Chenal H., Minga K. A., Bissagnene E., Tanon A., Seydi M., Patassi A. A., Koumakpai-Adeothy S. A., Renner L. A., N'gbeche S. M., Bosse C. A., Kouakou K., Folquet M. A., Eboua F. c. O. T., Traore F. D., Dabis F. c. O., Arrive E., Balestre E., Becquet R., Bernard C., Arikawa S. C., Doring A., Jaquet A., Rabourdin E., Tiendrebeogo T., Jesson J., Ekouevi D. K., Azani J. -C., Coffi E P., Gnepa G., Kouadio C. G. K., Tchounga B., Maartens G., Lettow M. V., Muhairwe J., Jores A., Kamenova K., Fox M. P., Prozesky H., Zangerle R., Touloumi G., Warszawski J., Meyer L., Krause M. M., Ghosn J., Leport C., Wittkop L., Reiss P., Wit F., Prins M., Bucher H., Gibb D., Fatkenheuer G., Del Amo J., Obel N., Thorne C., Mocroft A., Kirk O., Stephan C., Perez-Hoyos S., Hamouda O., Bartmeyer B., Chkhartishvili N., Noguera-Julian A., Antinori A., D'Arminio Monforte A., Brockmeyer N., Prieto L., Conejo P. R., Soriano-Arandes A., Battegay M., Kouyos R., Mussini C., Tookey P., Casabona J., Miro J. M., Castagna A., Konopnick D., Goetghebuer T., Sonnerborg A., Torti C., Sabin C., Teira R., Garrido M., Haerry D., de Wit S., Costagliola D., Raben D., Barger D., Schwimmer C., Termote M., Campbell M., Frederiksen C. M., Friis-Moller N., Kjaer J., Brandt R. S., Berenguer J., Bohlius J., Bouteloup V., Cozzi-Lepri A., Dorrucci M., Dunn D., Furrer H., Guiguet M., Lambotte O., Lodi S., Matheron S., Miro J. M. a., Monge S., Nakagawa F., Paredes R., Phillips A., Puoti M., Rohner E., Schomaker M., Sterne J., Thiebaut R., van der Valk M., Hazra R., Heckman B., O'gara E., Siminski S., Panayidou, K, Davies, M, Anderegg, N, Egger, M, Fatti, G, Vinikoor, M, Sawry, S, Ehmer, J, Eley, B, Phiri, S, Technau, K, Chimbetete, C, Rabie, H, Boulle, A, Tanser, F, Wood, R, Wools-Kaloustian, K, Vreeman, R, Oyaro, P, Ayaya, S, Nakigozi, G, Musick, B, Yiannoutsos, C, Amorissani-Folquet, M, Takassi, E, Sylla, M, Renner, L, Malateste, K, Desmonde, S, Leroy, V, Kurniati, N, Hansudewechakul, R, Nguyen, L, Ly, P, Truong, K, Kariminia, A, Sohn, A, Edmonds, A, Yumo, H, Dusingize, J, Yotebieng, M, Judd, A, Rojo, P, Smit, C, Grabar, S, Warszwarski, J, Chene, G, Raban, D, Patel, K, Seage, G, Van Dyke, R, Oleske, J, Williams, P, Abzug, M, Succi, R, Machado, D, Pinto, J, Rouzier, V, Luque, M, Mejia, F, Khol, V, Tucker, J, Kumarasamy, N, Saghayam, S, Chandrasekaran, E, Wati, D, Vedaswari, D, Malino, I, Muktiarti, D, Fong, S, Lim, M, Daut, F, Nik Yusoff, N, Mohamad, P, Mohamed, T, Drawis, M, Nallusamy, R, Chan, K, Sudjaritruk, T, Sirisanthana, V, Aurpibul, L, Oberdorfer, P, Denjanta, S, Watanaporn, S, Kongphonoi, A, Lumbiganon, P, Kosalaraksa, P, Tharnprisan, P, Udomphanit, T, Jourdain, G, Puthanakit, T, Anugulruengkitt, S, Phadungphon, C, Chokephaibulkit, K, Lapphra, K, Phongsamart, W, Sricharoenchai, S, Du, Q, Nguyen, C, Do, V, Ha, T, An, V, Khu, D, Pham, A, Le, O, Ross, J, Sethaputra, C, Law, M, Cahn, P, Cesar, C, Fink, V, Sued, O, Dell'Isola, E, Perez, H, Valiente, J, Yamamoto, C, Grinsztejn, B, Veloso, V, Luz, P, de Boni, R, Wagner, S, Friedman, R, Moreira, R, Ferreira, F, Maia, M, de Menezes Succi, R, Barbosa Gouv E A, A, Wolff, M, Cortes, C, Rodriguez, M, Allendes, G, Pape, J, Marcelin, A, Perodin, C, Padgett, D, Madero, J, Ramirez, B, Belaunzaran, P, Vega, Y, Gotuzzo, E, Carriquiry, G, Mcgowan, C, Shepherd, B, Sterling, T, Jayathilake, K, Person, A, Rebeiro, P, Giganti, M, Castilho, J, Duda, S, Maruri, F, Vansell, H, P E Lagie, N, Gateretse, P, Munezero, J, Nitereka, V, Niyongabo, T, Twizere, C, Bukuru, H, Nahimana, T, Biziragusenyuka, J, Manyundo, R, Atsu, K, Mbuh, T, Ajeh, R, Benwi, M, Dzudie, A, Mbuh, A, Ngamani, M, Nkome, V, Amadou, D, Ngassam, E, Pefura Yone, E, Ewanoge, A, Fuhngwa, N, Moki, C, Akele, C, Kitetele, F, Lelo, P, Tabala, M, Okitolonda, E, Wenzi, L, Diafouka, M, Ekat, M, Nsonde, D, Mafou, A, Ntarambirwa, F, Tuyishimire, Y, Hakizimana, T, Ayinkamiye, J, Mukantwali, S, Kayitesi, H, Uwamahoro, O, Habumuremyi, V, Mukamana, J, Kubwimana, G, Mugenzi, P, Muhoza, B, Munyaneza, A, Ndahiro, E, Nyiransabimana, D, D'Amour Sinayobye, J, Sugira, V, Benekigeri, C, Mbaraga, G, Adedimeji, A, Anastos, K, Dilorenzo, M, Murchison, L, Addison, D, Baker, M, Brazier, E, Jones, H, Kelvin, E, Kulkarni, S, Nash, D, Tymejczyk, O, Elul, B, Cai, X, Hoover, D, Kim, H, Li, C, Shi, Q, Lancaster, K, Kuniholm, M, Parcesepe, A, Kimmel, A, Mcnairy, M, Diero, L, Plus, A, Bukusi, E, Ssali, J, Nalugoda, F, Somi, G, Lyamuya, R, Ngonyani, K, Lugina, E, Urassa, M, Michael, D, Zannou, M, Poda, A, Sarfo, F, Messou, E, Chenal, H, Minga, K, Bissagnene, E, Tanon, A, Seydi, M, Patassi, A, Koumakpai-Adeothy, S, N'Gbeche, S, Bosse, C, Kouakou, K, Folquet, M, Eboua, F, Traore, F, Dabis, F, Arrive, E, Balestre, E, Becquet, R, Bernard, C, Arikawa, S, Doring, A, Jaquet, A, Rabourdin, E, Tiendrebeogo, T, Jesson, J, Ekouevi, D, Azani, J, Coffi E, P, Gnepa, G, Kouadio, C, Tchounga, B, Maartens, G, Lettow, M, Muhairwe, J, Jores, A, Kamenova, K, Fox, M, Prozesky, H, Zangerle, R, Touloumi, G, Warszawski, J, Meyer, L, Krause, M, Ghosn, J, Leport, C, Wittkop, L, Reiss, P, Wit, F, Prins, M, Bucher, H, Gibb, D, Fatkenheuer, G, Del Amo, J, Obel, N, Thorne, C, Mocroft, A, Kirk, O, Stephan, C, Perez-Hoyos, S, Hamouda, O, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Antinori, A, D'Arminio Monforte, A, Brockmeyer, N, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Mussini, C, Tookey, P, Casabona, J, Miro, J, Castagna, A, Konopnick, D, Goetghebuer, T, Sonnerborg, A, Torti, C, Sabin, C, Teira, R, Garrido, M, Haerry, D, de Wit, S, Costagliola, D, Raben, D, Barger, D, Schwimmer, C, Termote, M, Campbell, M, Frederiksen, C, Friis-Moller, N, Kjaer, J, Brandt, R, Berenguer, J, Bohlius, J, Bouteloup, V, Cozzi-Lepri, A, Dorrucci, M, Dunn, D, Furrer, H, Guiguet, M, Lambotte, O, Lodi, S, Matheron, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Rohner, E, Schomaker, M, Sterne, J, Thiebaut, R, van der Valk, M, Hazra, R, Heckman, B, O'Gara, E, Siminski, S, Panayidou K., Davies M. -A., Anderegg N., Egger M., Fatti G., Vinikoor M., Sawry S., Ehmer J., Eley B., Phiri S., Technau K. -G. u. N., Chimbetete C., Rabie H., Boulle A., Tanser F., Wood R., Wools-Kaloustian K., Vreeman R., Oyaro P., Ayaya S., Nakigozi G., Musick B., Yiannoutsos C., Amorissani-Folquet M., Takassi E., Sylla M., Renner L., Malateste K., Desmonde S., Leroy V., Kurniati N., Hansudewechakul R., Nguyen L. V., Ly P. S., Truong K. H., Kariminia A., Sohn A. H., Edmonds A., Yumo H. A., Dusingize J. C., Yotebieng M., Judd A., Rojo P., Smit C., Grabar S., Warszwarski J., Chene G., Raban D., Patel K., Seage G. R., Van Dyke R. B., Oleske J., Williams P. L., Abzug M. J., Succi R., Machado D. M., Pinto J., Rouzier V., Luque M., Mejia F., Khol V., Tucker J., Kumarasamy N., Saghayam S., Chandrasekaran E., Wati D. K., Vedaswari D., Malino I. Y., Muktiarti D., Fong S. M., Lim M., Daut F., Nik Yusoff N. K., Mohamad P., Mohamed T. J., Drawis M. R., Nallusamy R., Chan K. C., Sudjaritruk T., Sirisanthana V., Aurpibul L., Oberdorfer P., Denjanta S., Watanaporn S., Kongphonoi A., Lumbiganon P., Kosalaraksa P., Tharnprisan P., Udomphanit T., Jourdain G., Puthanakit T., Anugulruengkitt S., Phadungphon C., Chokephaibulkit K., Lapphra K., Phongsamart W., Sricharoenchai S., Du Q. T., Nguyen C. H., Do V. C., Ha T. M., An V. T., Khu D. T. K., Pham A. N., Nguyen L. T., Le O. N., Ross J. L., Sethaputra C., Law M. G., Cahn P., Cesar C., Fink V., Sued O., Dell'isola E., Perez H., Valiente J., Yamamoto C., Grinsztejn B., Veloso V., Luz P., de Boni R., Wagner S. C., Friedman R., Moreira R., Ferreira F., Maia M., de Menezes Succi R. C., Barbosa Gouv E A A. F. a. T., Wolff M., Cortes C., Rodriguez M. F., Allendes G., Pape J. W., Marcelin A., Perodin C., Luque M. T., Padgett D., Madero J. S., Ramirez B. C., Belaunzaran P., Vega Y. C., Gotuzzo E., Carriquiry G., McGowan C. C., Shepherd B. E., Sterling T., Jayathilake K., Person A. K., Rebeiro P. F., Giganti M., Castilho J., Duda S. N., Maruri F., Vansell H., P E Lagie N., Gateretse P., Munezero J., Nitereka V., Niyongabo T., Twizere C., Bukuru H., Nahimana T., Biziragusenyuka J., Manyundo R. S., Atsu K., Mbuh T., Ajeh R., Benwi M., Dzudie A., Mbuh A., Ngamani M. L., Nkome V., Amadou D., Ngassam E., Pefura Yone E. W., Ewanoge A. N., Fuhngwa N., Moki C., Akele C., Kitetele F., Lelo P., Tabala M., Okitolonda E. W., Wenzi L., Diafouka M., Ekat M. H., Nsonde D. M., Mafou A., Ntarambirwa F., Tuyishimire Y., Hakizimana T., Ayinkamiye J., Mukantwali S., Kayitesi H., Uwamahoro O., Habumuremyi V., Mukamana J., Kubwimana G., Mugenzi P., Muhoza B., Munyaneza A., Ndahiro E., Nyiransabimana D., D'Amour Sinayobye J., Sugira V., Benekigeri C., Mbaraga G., Adedimeji A., Anastos K., Dilorenzo M., Murchison L., Ross J., Addison D., Baker M., Brazier E., Jones H., Kelvin E., Kulkarni S., Nash D., Tymejczyk O., Elul B., Cai X., Hoover D., Kim H. -Y., Li C., Shi Q., Lancaster K., Kuniholm M., Parcesepe A., Duda S., Kimmel A., McNairy M., Diero L., Plus A. M. P. A. T. H., Bukusi E., Ssali J., Nalugoda F., Somi G. R., Lyamuya R. E., Ngonyani K., Lugina E., Urassa M., Michael D., Zannou M. D., Poda A., Sarfo F. S., Messou E., Chenal H., Minga K. A., Bissagnene E., Tanon A., Seydi M., Patassi A. A., Koumakpai-Adeothy S. A., Renner L. A., N'gbeche S. M., Bosse C. A., Kouakou K., Folquet M. A., Eboua F. c. O. T., Traore F. D., Dabis F. c. O., Arrive E., Balestre E., Becquet R., Bernard C., Arikawa S. C., Doring A., Jaquet A., Rabourdin E., Tiendrebeogo T., Jesson J., Ekouevi D. K., Azani J. -C., Coffi E P., Gnepa G., Kouadio C. G. K., Tchounga B., Maartens G., Lettow M. V., Muhairwe J., Jores A., Kamenova K., Fox M. P., Prozesky H., Zangerle R., Touloumi G., Warszawski J., Meyer L., Krause M. M., Ghosn J., Leport C., Wittkop L., Reiss P., Wit F., Prins M., Bucher H., Gibb D., Fatkenheuer G., Del Amo J., Obel N., Thorne C., Mocroft A., Kirk O., Stephan C., Perez-Hoyos S., Hamouda O., Bartmeyer B., Chkhartishvili N., Noguera-Julian A., Antinori A., D'Arminio Monforte A., Brockmeyer N., Prieto L., Conejo P. R., Soriano-Arandes A., Battegay M., Kouyos R., Mussini C., Tookey P., Casabona J., Miro J. M., Castagna A., Konopnick D., Goetghebuer T., Sonnerborg A., Torti C., Sabin C., Teira R., Garrido M., Haerry D., de Wit S., Costagliola D., Raben D., Barger D., Schwimmer C., Termote M., Campbell M., Frederiksen C. M., Friis-Moller N., Kjaer J., Brandt R. S., Berenguer J., Bohlius J., Bouteloup V., Cozzi-Lepri A., Dorrucci M., Dunn D., Furrer H., Guiguet M., Lambotte O., Lodi S., Matheron S., Miro J. M. a., Monge S., Nakagawa F., Paredes R., Phillips A., Puoti M., Rohner E., Schomaker M., Sterne J., Thiebaut R., van der Valk M., Hazra R., Heckman B., O'gara E., and Siminski S.
Abstract: Introduction: The CD4 cell count and percent at initiation of combination antiretroviral therapy (cART) are measures of advanced HIV disease and thus are important indicators of programme performance for children living with HIV. In particular, World Health Organization (WHO) 2017 guidelines on advanced HIV disease noted that >80% of children aged <5 years started cART with WHO Stage 3 or 4 disease or severe immune suppression. We compared temporal trends in CD4 measures at cART start in children from low-, middle- and high-income countries, and examined the effect of WHO treatment initiation guidelines on reducing the proportion of children initiating cART with advanced disease. Methods: We included children aged <16 years from the International Epidemiology Databases to Evaluate acquired immunodeficiency syndrome (AIDS) (IeDEA) Collaboration (Caribbean, Central and South America, Asia-Pacific, and West, Central, East and Southern Africa), the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), the North American Pediatric HIV/AIDS Cohort Study (PHACS) and International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 219C study. Severe immunodeficiency was defined using WHO guidelines. We used generalized weighted additive mixed effect models to analyse temporal trends in CD4 measurements and piecewise regression to examine the impact of 2006 and 2010 WHO cART initiation guidelines. Results: We included 52,153 children from fourteen low-, eight lower middle-, five upper middle- and five high-income countries. From 2004 to 2013, the estimated percentage of children starting cART with severe immunodeficiency declined from 70% to 42% (low-income), 67% to 64% (lower middle-income) and 61% to 43% (upper middle-income countries). In high-income countries, severe immunodeficiency at cART initiation declined from 45% (1996) to 14% (2012). There were annual decreases in the percentage of children with severe immuno
Published: 2018

10. Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?

Author: Monge, S, Mocroft, A, Sabin, A, Touloumi, G, Sighem, A, Abgrall, S, Dray-Spira, R, Spire, B, Castagna, A, Mussini, C, Zangerle, R, Hessamfar, M, Anderson, J, Hamouda, O, Ehren, K, Obel, N, Kirk, O, Antinori, A, Girardi, E, Saracino, A, Calmy, A, Wit, S, Wittkop, L, Bucher, C, Montoliu, A, Raben, D, Prins, M, Meyer, L, Chene, G, Burns, F, Amo, J, Judd, A, Warszawski, J, Dabis, F, Krause, M, Ghosn, J, Leport, C, Reiss, P, Wit, F, Bucher, H, Gibb, D, Fatkenheuer, G, Thorne, C, Stephan, C, Perez-Hoyos, S, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Monforte, A, Brockmeyer, N, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Tookey, P, Casabona, J, Miro, J, Konopnick, D, Goetghebuer, T, Sonnerborg, A, Torti, C, Sabin, C, Teira, R, Garrido, M, Haerry, D, Miro, M, Costagliola, D, d'Arminio-Monforte, A, Barger, D, Schwimmer, C, Termote, M, Campbell, M, Frederiksen, C, Friis-Moller, N, Kjaer, J, Brandt, R, Berenguer, J, Bohlius, J, Bouteloup, V, Cozzi-Lepri, A, Davies, M, Dorrucci, M, Dunn, D, Egger, M, Furrer, H, Guiguet, M, Grabar, S, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Rohner, E, Schomaker, M, Smit, C, Sterne, J, Thiebaut, R, Valk, M, Monge S., Mocroft A., Sabin A., Touloumi G., Sighem A., Abgrall S., Dray-Spira R., Spire B., Castagna A., Mussini C., Zangerle R., Hessamfar M., Anderson J., Hamouda O., Ehren K., Obel N., Kirk O., Antinori A., Girardi E., Saracino A., Calmy A., Wit S., Wittkop L., Bucher C., Montoliu A., Raben D., Prins M., Meyer L., Chene G., Burns F., Amo J., Judd A., Warszawski J., Dabis F., Krause M., Ghosn J., Leport C., Reiss P., Wit F., Bucher H., Gibb D., Fatkenheuer G., Thorne C., Stephan C., Perez-Hoyos S., Bartmeyer B., Chkhartishvili N., Noguera-Julian A., Monforte A., Brockmeyer N., Prieto L., Conejo P., Soriano-Arandes A., Battegay M., Kouyos R., Tookey P., Casabona J., Miro J., Konopnick D., Goetghebuer T., Sonnerborg A., Torti C., Sabin C., Teira R., Garrido M., Haerry D., Miro M., Costagliola D., d'Arminio-Monforte A., Barger D., Schwimmer C., Termote M., Campbell M., Frederiksen C. M., Friis-Moller N., Kjaer J., Brandt R., Berenguer J., Bohlius J., Bouteloup V., Cozzi-Lepri A., Davies M. -A., Dorrucci M., Dunn D., Egger M., Furrer H., Guiguet M., Grabar S., Lambotte O., Leroy V., Lodi S., Matheron S., Nakagawa F., Paredes R., Phillips A., Puoti M., Rohner E., Schomaker M., Smit C., Sterne J., Thiebaut R., Valk M., Monge, S, Mocroft, A, Sabin, A, Touloumi, G, Sighem, A, Abgrall, S, Dray-Spira, R, Spire, B, Castagna, A, Mussini, C, Zangerle, R, Hessamfar, M, Anderson, J, Hamouda, O, Ehren, K, Obel, N, Kirk, O, Antinori, A, Girardi, E, Saracino, A, Calmy, A, Wit, S, Wittkop, L, Bucher, C, Montoliu, A, Raben, D, Prins, M, Meyer, L, Chene, G, Burns, F, Amo, J, Judd, A, Warszawski, J, Dabis, F, Krause, M, Ghosn, J, Leport, C, Reiss, P, Wit, F, Bucher, H, Gibb, D, Fatkenheuer, G, Thorne, C, Stephan, C, Perez-Hoyos, S, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Monforte, A, Brockmeyer, N, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Tookey, P, Casabona, J, Miro, J, Konopnick, D, Goetghebuer, T, Sonnerborg, A, Torti, C, Sabin, C, Teira, R, Garrido, M, Haerry, D, Miro, M, Costagliola, D, d'Arminio-Monforte, A, Barger, D, Schwimmer, C, Termote, M, Campbell, M, Frederiksen, C, Friis-Moller, N, Kjaer, J, Brandt, R, Berenguer, J, Bohlius, J, Bouteloup, V, Cozzi-Lepri, A, Davies, M, Dorrucci, M, Dunn, D, Egger, M, Furrer, H, Guiguet, M, Grabar, S, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Rohner, E, Schomaker, M, Smit, C, Sterne, J, Thiebaut, R, Valk, M, Monge S., Mocroft A., Sabin A., Touloumi G., Sighem A., Abgrall S., Dray-Spira R., Spire B., Castagna A., Mussini C., Zangerle R., Hessamfar M., Anderson J., Hamouda O., Ehren K., Obel N., Kirk O., Antinori A., Girardi E., Saracino A., Calmy A., Wit S., Wittkop L., Bucher C., Montoliu A., Raben D., Prins M., Meyer L., Chene G., Burns F., Amo J., Judd A., Warszawski J., Dabis F., Krause M., Ghosn J., Leport C., Reiss P., Wit F., Bucher H., Gibb D., Fatkenheuer G., Thorne C., Stephan C., Perez-Hoyos S., Bartmeyer B., Chkhartishvili N., Noguera-Julian A., Monforte A., Brockmeyer N., Prieto L., Conejo P., Soriano-Arandes A., Battegay M., Kouyos R., Tookey P., Casabona J., Miro J., Konopnick D., Goetghebuer T., Sonnerborg A., Torti C., Sabin C., Teira R., Garrido M., Haerry D., Miro M., Costagliola D., d'Arminio-Monforte A., Barger D., Schwimmer C., Termote M., Campbell M., Frederiksen C. M., Friis-Moller N., Kjaer J., Brandt R., Berenguer J., Bohlius J., Bouteloup V., Cozzi-Lepri A., Davies M. -A., Dorrucci M., Dunn D., Egger M., Furrer H., Guiguet M., Grabar S., Lambotte O., Leroy V., Lodi S., Matheron S., Nakagawa F., Paredes R., Phillips A., Puoti M., Rohner E., Schomaker M., Smit C., Sterne J., Thiebaut R., and Valk M.
Abstract: Objectives: The aim of the study was to evaluate differences in immunovirological response to combination antiretroviral therapy (cART) in migrant and native men and women within a European collaboration of HIV cohorts Collaboration of Observational HIV Epidemiological Research in Europ (COHERE) in EuroCoord, 2004–2013. Methods: Migrants were defined as those with geographical origin (GO) different from the reporting country and were grouped as originating from Western Europe and Western Countries (WEWC), Eastern Europe (EE), North Africa and the Middle East (NAME), sub-Saharan Africa (SSA), Latin America (LA), Caribbean (CRB) and Asia/Oceania (ASIA/OCE). Native (NAT) individuals were defined as those originating from the reporting country. CD4 cell counts were modelled using piecewise linear mixed-effects models with two slopes, whereas models to estimate subdistribution hazard ratios (sHRs) were used for time to virological response (VR) (i.e. time from cART initiation to the first of two successive HIV RNA measurements < 400 HIV-1 RNA copies/ml). Results: Of 32 817 individuals, 25 799 (78.6%) were men. The percentage of migrants was higher in women (48.9%) than in men (21.2%) and migrants from SSA accounted for the largest migrant group (29.9% in men and 63.3% in women). Migrant men and women from SSA started at lower CD4 cell counts than NAT individuals, which remained lower over time. VR was ≥ 85% at 12 months for all groups except CRB women (77.7%). Compared with NAT men and women, lower VR was experienced by NAME [sHR 0.91; 95% confidence interval (CI) 0.86–0.97] and SSA (sHR 0.88; 95% CI 0.82–0.95) men and CRB (sHR 0.77; 85% CI 0.67–0.89) women, respectively. Conclusions: Immunovirological response to cART in Western Europe varies by GO and sex of patients. ART benefits are not equal for all, underlining the point that efforts need to prioritize those most in need.
Published: 2018

11. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 Study in collaboration with the Mortalité 2005 survey, ANRS EN19)

Author: Rosenthal, E, Salmon-Céron, D, Lewden, C, Bouteloup, V, Pialoux, G, Bonnet, F, Karmochkine, M, May, T, François, M, Burty, C, Jougla, E, Costagliola, D, Morlat, P, Chêne, G, and Cacoub, P
Published: 2009
Full Text: View/download PDF

12. Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation

Author: Panayidou K., Davies M. -A., Anderegg N., Egger M., Fatti G., Vinikoor M., Sawry S., Ehmer J., Eley B., Phiri S., Technau K. -G. u. N., Chimbetete C., Rabie H., Boulle A., Tanser F., Wood R., Wools-Kaloustian K., Vreeman R., Oyaro P., Ayaya S., Nakigozi G., Musick B., Yiannoutsos C., Amorissani-Folquet M., Takassi E., Sylla M., Renner L., Malateste K., Desmonde S., Leroy V., Kurniati N., Hansudewechakul R., Nguyen L. V., Ly P. S., Truong K. H., Kariminia A., Sohn A. H., Edmonds A., Yumo H. A., Dusingize J. C., Yotebieng M., Judd A., Rojo P., Smit C., Grabar S., Warszwarski J., Chene G., Raban D., Patel K., Seage G. R., Van Dyke R. B., Oleske J., Williams P. L., Abzug M. J., Succi R., Machado D. M., Pinto J., Rouzier V., Luque M., Mejia F., Khol V., Tucker J., Kumarasamy N., Saghayam S., Chandrasekaran E., Wati D. K., Vedaswari D., Malino I. Y., Muktiarti D., Fong S. M., Lim M., Daut F., Nik Yusoff N. K., Mohamad P., Mohamed T. J., Drawis M. R., Nallusamy R., Chan K. C., Sudjaritruk T., Sirisanthana V., Aurpibul L., Oberdorfer P., Denjanta S., Watanaporn S., Kongphonoi A., Lumbiganon P., Kosalaraksa P., Tharnprisan P., Udomphanit T., Jourdain G., Puthanakit T., Anugulruengkitt S., Phadungphon C., Chokephaibulkit K., Lapphra K., Phongsamart W., Sricharoenchai S., Du Q. T., Nguyen C. H., Do V. C., Ha T. M., An V. T., Khu D. T. K., Pham A. N., Nguyen L. T., Le O. N., Ross J. L., Sethaputra C., Law M. G., Cahn P., Cesar C., Fink V., Sued O., Dell'isola E., Perez H., Valiente J., Yamamoto C., Grinsztejn B., Veloso V., Luz P., de Boni R., Wagner S. C., Friedman R., Moreira R., Ferreira F., Maia M., de Menezes Succi R. C., Barbosa Gouv E A A. F. a. T., Wolff M., Cortes C., Rodriguez M. F., Allendes G., Pape J. W., Marcelin A., Perodin C., Luque M. T., Padgett D., Madero J. S., Ramirez B. C., Belaunzaran P., Vega Y. C., Gotuzzo E., Carriquiry G., McGowan C. C., Shepherd B. E., Sterling T., Jayathilake K., Person A. K., Rebeiro P. F., Giganti M., Castilho J., Duda S. N., Maruri F., Vansell H., P E Lagie N., Gateretse P., Munezero J., Nitereka V., Niyongabo T., Twizere C., Bukuru H., Nahimana T., Biziragusenyuka J., Manyundo R. S., Atsu K., Mbuh T., Ajeh R., Benwi M., Dzudie A., Mbuh A., Ngamani M. L., Nkome V., Amadou D., Ngassam E., Pefura Yone E. W., Ewanoge A. N., Fuhngwa N., Moki C., Akele C., Kitetele F., Lelo P., Tabala M., Okitolonda E. W., Wenzi L., Diafouka M., Ekat M. H., Nsonde D. M., Mafou A., Ntarambirwa F., Tuyishimire Y., Hakizimana T., Ayinkamiye J., Mukantwali S., Kayitesi H., Uwamahoro O., Habumuremyi V., Mukamana J., Kubwimana G., Mugenzi P., Muhoza B., Munyaneza A., Ndahiro E., Nyiransabimana D., D'Amour Sinayobye J., Sugira V., Benekigeri C., Mbaraga G., Adedimeji A., Anastos K., Dilorenzo M., Murchison L., Ross J., Addison D., Baker M., Brazier E., Jones H., Kelvin E., Kulkarni S., Nash D., Tymejczyk O., Elul B., Cai X., Hoover D., Kim H. -Y., Li C., Shi Q., Lancaster K., Kuniholm M., Parcesepe A., Duda S., Kimmel A., McNairy M., Diero L., Plus A. M. P. A. T. H., Bukusi E., Ssali J., Nalugoda F., Somi G. R., Lyamuya R. E., Ngonyani K., Lugina E., Urassa M., Michael D., Zannou M. D., Poda A., Sarfo F. S., Messou E., Chenal H., Minga K. A., Bissagnene E., Tanon A., Seydi M., Patassi A. A., Koumakpai-Adeothy S. A., Renner L. A., N'gbeche S. M., Bosse C. A., Kouakou K., Folquet M. A., Eboua F. c. O. T., Traore F. D., Dabis F. c. O., Arrive E., Balestre E., Becquet R., Bernard C., Arikawa S. C., Doring A., Jaquet A., Rabourdin E., Tiendrebeogo T., Jesson J., Ekouevi D. K., Azani J. -C., Coffi E P., Gnepa G., Kouadio C. G. K., Tchounga B., Maartens G., Lettow M. V., Muhairwe J., Jores A., Kamenova K., Fox M. P., Prozesky H., Zangerle R., Touloumi G., Warszawski J., Meyer L., Krause M. M., Ghosn J., Leport C., Wittkop L., Reiss P., Wit F., Prins M., Bucher H., Gibb D., Fatkenheuer G., Del Amo J., Obel N., Thorne C., Mocroft A., Kirk O., Stephan C., Perez-Hoyos S., Hamouda O., Bartmeyer B., Chkhartishvili N., Noguera-Julian A., Antinori A., D'Arminio Monforte A., Brockmeyer N., Prieto L., Conejo P. R., Soriano-Arandes A., Battegay M., Kouyos R., Mussini C., Tookey P., Casabona J., Miro J. M., Castagna A., Konopnick D., Goetghebuer T., Sonnerborg A., Torti C., Sabin C., Teira R., Garrido M., Haerry D., de Wit S., Costagliola D., Raben D., Barger D., Schwimmer C., Termote M., Campbell M., Frederiksen C. M., Friis-Moller N., Kjaer J., Brandt R. S., Berenguer J., Bohlius J., Bouteloup V., Cozzi-Lepri A., Dorrucci M., Dunn D., Furrer H., Guiguet M., Lambotte O., Lodi S., Matheron S., Miro J. M. ª., Monge S., Nakagawa F., Paredes R., Phillips A., Puoti M., Rohner E., Schomaker M., Sterne J., Thiebaut R., van der Valk M., Hazra R., Heckman B., O'gara E., Siminski S., Panayidou, K, Davies, M, Anderegg, N, Egger, M, Fatti, G, Vinikoor, M, Sawry, S, Ehmer, J, Eley, B, Phiri, S, Technau, K, Chimbetete, C, Rabie, H, Boulle, A, Tanser, F, Wood, R, Wools-Kaloustian, K, Vreeman, R, Oyaro, P, Ayaya, S, Nakigozi, G, Musick, B, Yiannoutsos, C, Amorissani-Folquet, M, Takassi, E, Sylla, M, Renner, L, Malateste, K, Desmonde, S, Leroy, V, Kurniati, N, Hansudewechakul, R, Nguyen, L, Ly, P, Truong, K, Kariminia, A, Sohn, A, Edmonds, A, Yumo, H, Dusingize, J, Yotebieng, M, Judd, A, Rojo, P, Smit, C, Grabar, S, Warszwarski, J, Chene, G, Raban, D, Patel, K, Seage, G, Van Dyke, R, Oleske, J, Williams, P, Abzug, M, Succi, R, Machado, D, Pinto, J, Rouzier, V, Luque, M, Mejia, F, Khol, V, Tucker, J, Kumarasamy, N, Saghayam, S, Chandrasekaran, E, Wati, D, Vedaswari, D, Malino, I, Muktiarti, D, Fong, S, Lim, M, Daut, F, Nik Yusoff, N, Mohamad, P, Mohamed, T, Drawis, M, Nallusamy, R, Chan, K, Sudjaritruk, T, Sirisanthana, V, Aurpibul, L, Oberdorfer, P, Denjanta, S, Watanaporn, S, Kongphonoi, A, Lumbiganon, P, Kosalaraksa, P, Tharnprisan, P, Udomphanit, T, Jourdain, G, Puthanakit, T, Anugulruengkitt, S, Phadungphon, C, Chokephaibulkit, K, Lapphra, K, Phongsamart, W, Sricharoenchai, S, Du, Q, Nguyen, C, Do, V, Ha, T, An, V, Khu, D, Pham, A, Le, O, Ross, J, Sethaputra, C, Law, M, Cahn, P, Cesar, C, Fink, V, Sued, O, Dell'Isola, E, Perez, H, Valiente, J, Yamamoto, C, Grinsztejn, B, Veloso, V, Luz, P, de Boni, R, Wagner, S, Friedman, R, Moreira, R, Ferreira, F, Maia, M, de Menezes Succi, R, Barbosa Gouv E A, A, Wolff, M, Cortes, C, Rodriguez, M, Allendes, G, Pape, J, Marcelin, A, Perodin, C, Padgett, D, Madero, J, Ramirez, B, Belaunzaran, P, Vega, Y, Gotuzzo, E, Carriquiry, G, Mcgowan, C, Shepherd, B, Sterling, T, Jayathilake, K, Person, A, Rebeiro, P, Giganti, M, Castilho, J, Duda, S, Maruri, F, Vansell, H, P E Lagie, N, Gateretse, P, Munezero, J, Nitereka, V, Niyongabo, T, Twizere, C, Bukuru, H, Nahimana, T, Biziragusenyuka, J, Manyundo, R, Atsu, K, Mbuh, T, Ajeh, R, Benwi, M, Dzudie, A, Mbuh, A, Ngamani, M, Nkome, V, Amadou, D, Ngassam, E, Pefura Yone, E, Ewanoge, A, Fuhngwa, N, Moki, C, Akele, C, Kitetele, F, Lelo, P, Tabala, M, Okitolonda, E, Wenzi, L, Diafouka, M, Ekat, M, Nsonde, D, Mafou, A, Ntarambirwa, F, Tuyishimire, Y, Hakizimana, T, Ayinkamiye, J, Mukantwali, S, Kayitesi, H, Uwamahoro, O, Habumuremyi, V, Mukamana, J, Kubwimana, G, Mugenzi, P, Muhoza, B, Munyaneza, A, Ndahiro, E, Nyiransabimana, D, D'Amour Sinayobye, J, Sugira, V, Benekigeri, C, Mbaraga, G, Adedimeji, A, Anastos, K, Dilorenzo, M, Murchison, L, Addison, D, Baker, M, Brazier, E, Jones, H, Kelvin, E, Kulkarni, S, Nash, D, Tymejczyk, O, Elul, B, Cai, X, Hoover, D, Kim, H, Li, C, Shi, Q, Lancaster, K, Kuniholm, M, Parcesepe, A, Kimmel, A, Mcnairy, M, Diero, L, Plus, A, Bukusi, E, Ssali, J, Nalugoda, F, Somi, G, Lyamuya, R, Ngonyani, K, Lugina, E, Urassa, M, Michael, D, Zannou, M, Poda, A, Sarfo, F, Messou, E, Chenal, H, Minga, K, Bissagnene, E, Tanon, A, Seydi, M, Patassi, A, Koumakpai-Adeothy, S, N'Gbeche, S, Bosse, C, Kouakou, K, Folquet, M, Eboua, F, Traore, F, Dabis, F, Arrive, E, Balestre, E, Becquet, R, Bernard, C, Arikawa, S, Doring, A, Jaquet, A, Rabourdin, E, Tiendrebeogo, T, Jesson, J, Ekouevi, D, Azani, J, Coffi E, P, Gnepa, G, Kouadio, C, Tchounga, B, Maartens, G, Lettow, M, Muhairwe, J, Jores, A, Kamenova, K, Fox, M, Prozesky, H, Zangerle, R, Touloumi, G, Warszawski, J, Meyer, L, Krause, M, Ghosn, J, Leport, C, Wittkop, L, Reiss, P, Wit, F, Prins, M, Bucher, H, Gibb, D, Fatkenheuer, G, Del Amo, J, Obel, N, Thorne, C, Mocroft, A, Kirk, O, Stephan, C, Perez-Hoyos, S, Hamouda, O, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Antinori, A, D'Arminio Monforte, A, Brockmeyer, N, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Mussini, C, Tookey, P, Casabona, J, Miro, J, Castagna, A, Konopnick, D, Goetghebuer, T, Sonnerborg, A, Torti, C, Sabin, C, Teira, R, Garrido, M, Haerry, D, de Wit, S, Costagliola, D, Raben, D, Barger, D, Schwimmer, C, Termote, M, Campbell, M, Frederiksen, C, Friis-Moller, N, Kjaer, J, Brandt, R, Berenguer, J, Bohlius, J, Bouteloup, V, Cozzi-Lepri, A, Dorrucci, M, Dunn, D, Furrer, H, Guiguet, M, Lambotte, O, Lodi, S, Matheron, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Rohner, E, Schomaker, M, Sterne, J, Thiebaut, R, van der Valk, M, Hazra, R, Heckman, B, O'Gara, E, and Siminski, S
Subjects: 0301 basic medicine, Male, sub-Saharan Africa, Databases, Factual, CD4 cell count, HIV Infections, Global Health, Cohort Studies, 0302 clinical medicine, Central and South America, Advanced disease, Medicine, 030212 general & internal medicine, Prospective Studies, Cd4 cell count, skin and connective tissue diseases, Child, Research Articles, humanities, 3. Good health, Europe, Infectious Diseases, Child, Preschool, Income, Drug Therapy, Combination, Female, advanced HIV disease, antiretroviral therapy, Asia, Caribbean, North America, WHO guidelines, Adolescent, Adult, Anti-HIV Agents, CD4 Lymphocyte Count, Drug Administration Schedule, Follow-Up Studies, Humans, Poverty, World Health Organization, Research Article, medicine.medical_specialty, education, 610 Medicine & health, 03 medical and health sciences, Acquired immunodeficiency syndrome (AIDS), 360 Social problems & social services, Intensive care medicine, business.industry, Public Health, Environmental and Occupational Health, medicine.disease, 030112 virology, Antiretroviral therapy, Who guidelines, sense organs, business, sub‐Saharan Africa
Abstract: Introduction: The CD4 cell count and percent at initiation of combination antiretroviral therapy (cART) are measures of advanced HIV disease and thus are important indicators of programme performance for children living with HIV. In particular, World Health Organization (WHO) 2017 guidelines on advanced HIV disease noted that >80% of children aged 40% of children in low- and middle-income countries started cART with severe immunodeficiency compared to
Published: 2018
Full Text: View/download PDF

13. Étude en TEP cérébrale au 18FDG de l’impact du stress dans la cohorte MEMENTO chez des patients non-déments consultant un centre mémoire

Author: Guedj, E., primary, Koric, L., additional, Wojak, J., additional, Habert, M.O., additional, Bouteloup, V., additional, Bertin, H., additional, Chêne, G., additional, Dufouil, C., additional, and Ceccaldi, M., additional
Published: 2019
Full Text: View/download PDF

14. Mortality in migrants living with HIV in western Europe (1997–2013): a collaborative cohort study

Author: Monge, S., Jarrin, I., Mocroft, A., Sabin, C. A., Touloumi, G., van Sighem, A., Abgrall, S., Dray-Spira, R., Spire, B., Castagna, A., Mussini, C., Zangerle, R., Hessamfar, M., Anderson, J., Hamouda, O., Ehren, K., Obel, N., Kirk, O., de Monteynard, L. A., Antinori, A., Girardi, E., Saracino, A. L., Calmy, A., De Wit, S., Wittkop, L., Bucher, H. C., Montoliu, A., Raben, D., Prins, M., Meyer, L., Chene, G., Burns, F., Warszawski, J., Dabis, F., Krause, M. M., Ghosn, J., Leport, C., Reiss, P., Wit, F., Bucher, H., Gibb, D., Fatkenheuer, G., Del Amo, J., Thorne, C., Stephan, C., Perez-Hoyos, S., Bartmeyer, B., Chkhartishvili, N., Noguera-Julian, A., d'Arminio Monforte, A., Brockmeyer, N., Prieto, L., Conejo, P. R., Soriano-Arandes, A., Battegay, M., Kouyos, R., Tookey, P., Casabona, J., Miro, J. M., Konopnick, D., Goetghebuer, T., Sonnerborg, A., Torti, C., Sabin, C., Teira, R., Garrido, M., Haerry, D., Costagliola, D., Barger, D., Schwimmer, C., Termote, M., Campbell, M., Frederiksen, C. M., Friis-Moller, N., Kjaer, J., Brandt, R. S., Berenguer, J., Bohlius, J., Bouteloup, V., Cozzi-Lepri, A., Davies, M. -A., del Amo, J., Dorrucci, M., Dunn, D., Egger, M., Furrer, H., Guiguet, M., Grabar, S., Judd, A., Lambotte, O., Leroy, V., Lodi, S., Matheron, S., Nakagawa, F., Paredes, R., Phillips, A., Puoti, M., Schomaker, M., Smit, C., Sterne, J., Thiebaut, R., van der Valk, M., Wyss, N., Infectious diseases, The Migrants Working Group on behalf of COHERE in, Eurocoord, and Castagna, Antonella
Subjects: Adult, Male, Epidemiology, Sexual Behavior, Immunology, HIV diagnosis, Human immunodeficiency virus (HIV), HIV Infections, Infectious Disease, medicine.disease_cause, Risk Assessment, Health Services Accessibility, Health services, Virology, medicine, Humans, Cooperative Behavior, Socioeconomic status, Aged, Transients and Migrants, business.industry, Disease progression, virus diseases, Health Status Disparities, Middle Aged, Antiretroviral therapy, Europe, Review Literature as Topic, Infectious Diseases, Socioeconomic Factors, Western europe, Female, business, Cohort study, Demography
Abstract: Background: Many migrants face adverse socioeconomic conditions and barriers to health services that can impair timely HIV diagnosis and access to life-saving treatments. We aimed to assess the differences in overall mortality by geographical origin in HIV-positive men and women using data from COHERE, a large European collaboration of HIV cohorts from 1997 to 2013. Methods: In this observational cohort study, we included HIV-positive, antiretroviral-naive people accessing care in western Europe from COHERE. Individuals were eligible if enrolled in a cohort that collected information on geographical origin or ethnic origin from Jan 1, 1997, to March 19, 2013, aged 18-75 years, they had available information about sex, they were not infected perinatally or after the receipt of clotting factor concentrates, and were naive to combination antiretroviral therapy at cohort entry. Migrants' origins were grouped into seven regions: western Europe and similar countries (Australia, Canada, New Zealand, and the USA); eastern Europe; North Africa and the Middle East; sub-Saharan Africa; Latin America; the Caribbean; and Asia and the rest of Oceania (excluding Australia and New Zealand). Crude and adjusted mortality rate ratios were calculated by use of Poisson regression stratified by sex, comparing each group with the native population. Multiple imputation with chained equations was used to account for missing values. Findings: Between Oct 25, 1979, and March 19, 2013, we recruited 279 659 individuals to the COHERE collaboration in EuroCoord. Of these 123 344 men and 45 877 women met the inclusion criteria. Our data suggested effect modification by transmission route (pinteraction=0Â·12 for men; pinteraction=0Â·002 for women). No significant difference in mortality was identified by geographical origin in men who have sex with men. In heterosexual populations, most migrant men had mortality lower than or equal to that of native men, whereas no group of migrant women had mortality lower than that in native women. High mortality was identified in heterosexual men from Latin America (rate ratio [RR] 1Â·46, 95% CI 1Â·00-2Â·12, p=0Â·049) and heterosexual women from the Caribbean (1Â·48, 1Â·29-1Â·70, p
Published: 2015
Full Text: View/download PDF

15. Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study

Author: Rohner E., Butikofer L., Schmidlin K., Sengayi M., Maskew M., Giddy J., Garone D., Moore R. D., D'Souza G., Goedert J. J., Achenbach C., Gill M. J., Kitahata M. M., Patel P., Silverberg M. J., Castilho J., McGowan C., Chen Y. -M. A., Law M., Taylor N., Paparizos V., Bonnet F., Verbon A., Fatkenheuer G., Post F. A., Sabin C., Mocroft A., Le Moing V., Dronda F., Obel N., Grabar S., Spagnuolo V., Antinori A., Quiros-Roldan E., Mussini C., Miro J. M., Meyer L., Hasse B., Konopnicki D., Roca B., Barger D., Raben D., Clifford G. M., Franceschi S., Brockmeyer N., Chakraborty R., Egger M., Bohlius J., Judd A., Zangerle R., Touloumi G., Warszawski J., Dabis F., Krause M. M., Ghosn J., Leport C., Wittkop L., Reiss P., Wit F., Prins M., Bucher H., Gibb D., Del Amo J., Thorne C., Kirk O., Stephan C., Perez-Hoyos S., Hamouda O., Bartmeyer B., Chkhartishvili N., Noguera-Julian A., Monforte A. D., Prieto L., Conejo P. R., Soriano-Arandes A., Battegay M., Kouyos R., Tookey P., Casabona J., Castagna A., Konopnick D., Goetghebuer T., Sonnerborg A., Teira R., Garrido M., Haerry D., De Wit S., Costagliola D., D'Arminio-Monforte A., Chene G., Schwimmer C., Termote M., Campbell M., Frederiksen C. M., Friis-Moller N., Kjaer J., Brandt R. S., Berenguer J., Bouteloup V., Cozzi-Lepri A., Davies M. -A., Dorrucci M., Dunn D., Furrer H., Guiguet M., Lambotte O., Leroy V., Lodi S., Matheron S., Monge S., Nakagawa F., Paredes R., Phillips A., Puoti M., Schomaker M., Smit C., Sterne J., Thiebaut R., Torti C., Van Der Valk M., Tanser F., Vinikoor M., MacEte E., Wood R., Stinson K., Fatti G., Phiri S., Chimbetete C., Malisita K., Eley B., Fritz C., Hobbins M., Kamenova K., Fox M., Prozesky H., Technau K., Sawry S., Benson C. A., Bosch R. J., Kirk G. D., Boswell S., Mayer K. H., Grasso C., Hogg R. S., Harrigan P. R., Montaner J. S. G., Yip B., Zhu J., Salters K., Gabler K., Buchacz K., Brooks J. T., Gebo K. A., Carey J. T., Rodriguez B., Horberg M. A., Thorne J. E., Rabkin C., Margolick J. B., Jacobson L. P., Klein M. B., Rourke S. B., Rachlis A. R., Cupido P., Hunter-Mellado R. F., Mayor A. M., Deeks S. G., Martin J. N., Saag M. S., Mugavero M. J., Willig J., Eron J. J., Napravnik S., Crane H. M., Drozd D. R., Haas D., Rebeiro P., Turner M., Bebawy S., Rogers B., Justice A. C., Dubrow R., Fiellin D., Gange S. J., Anastos K., Althoff K. N., McKaig R. G., Freeman A. M., Lent C., Van Rompaey S. E., Morton L., McReynolds J., Lober W. B., Abraham A. G., Lau B., Zhang J., Jing J., Modur S., Wong C., Hogan B., Desir F., Liu B., You B., Cahn P., Cesar C., Fink V., Sued O., Dell'Isola E., Perez H., Valiente J., Yamamoto C., Grinsztejn B., Veloso V., Luz P., De Boni R., Wagner S. C., Friedman R., Moreira R., Pinto J., Ferreira F., Maia M., De Menezes Succi R. C., MacHado D. M., De Fatima Barbosa Gouvea A., Wolff M., Cortes C., Rodriguez M. F., Allendes G., Pape J. W., Rouzier V., Marcelin A., Perodin C., Luque M. T., Padgett D., Madero J. S., Ramirez B. C., Belaunzaran P., Vega Y. C., Gotuzzo E., Mejia F., Carriquiry G., McGowan C. C., Shepherd B. E., Sterling T., Jayathilake K., Person A. K., Rebeiro P. F., Giganti M., Duda S. N., Maruri F., Vansell H., Ly P. S., Khol V., Zhang F. J., Zhao H. X., Han N., Lee M. P., Li P. C. K., Lam W., Chan Y. T., Kumarasamy N., Saghayam S., Ezhilarasi C., Pujari S., Joshi K., Gaikwad S., Chitalikar A., Merati T. P., Wirawan D. N., Yuliana F., Yunihastuti E., Imran D., Widhani A., Tanuma J., Oka S., Nishijima T., Choi J. Y., Na S., Kim J. M., Sim B. L. H., Gani Y. M., David R., Kamarulzaman A., Syed Omar S. F., Ponnampalavanar S., Azwa I., Ditangco R., Uy E., Bantique R., Wong W. W., Ku W. W., Wu P. C., Ng O. T., Lim P. L., Lee L. S., Ohnmar P. S., Avihingsanon A., Gatechompol S., Phanuphak P., Phadungphon C., Kiertiburanakul S., Sungkanuparph S., Chumla L., Sanmeema N., Chaiwarith R., Sirisanthana T., Kotarathititum W., Praparattanapan J., Kantipong P., Kambua P., Ratanasuwan W., Sriondee R., Nguyen K. V., Bui H. V., Nguyen D. T. H., Nguyen D. T., Cuong D. D., An N. V., Luan N. T., Sohn A. H., Ross J. L., Petersen B., Cooper D. A., Law M. G., Jiamsakul A., Boettiger D. C., Ellis D., Bloch M., Agrawal S., Vincent T., Allen D., Smith D., Rankin A., Baker D., Templeton D. J., Jackson E., McCallum K., Ryder N., Sweeney G., Cooper D., Carr A., MacRae K., Hesse K., Finlayson R., Gupta S., Langton-Lockton J., Shakeshaft J., Brown K., Idle S., Arvela N., Varma R., Lu H., Couldwell D., Eswarappa S., Smith D. E., Furner V., Cabrera G., Fernando S., Cogle A., Lawrence C., Mulhall B., Boyd M., Petoumenos K., Puhr R., Huang R., Han A., Gunathilake M., Payne R., O'Sullivan M., Croydon A., Russell D., Cashman C., Roberts C., Sowden D., Taing K., Marshall P., Orth D., Youds D., Rowling D., Latch N., Warzywoda E., Dickson B., Donohue W., Moore R., Edwards S., Boyd S., Roth N. J., Lau H., Read T., Silvers J., Zeng W., Hoy J., Watson K., Bryant M., Price S., Woolley I., Giles M., Korman T., Williams J., Nolan D., Allen A., Guelfi G., Mills G., Wharry C., Raymond N., Bargh K., Templeton D., Medical Microbiology & Infectious Diseases, Global Health, Infectious diseases, APH - Aging & Later Life, AII - Infectious diseases, APH - Global Health, Graduate School, APH - Digital Health, APH - Personalized Medicine, Bohlius, Julia, Cohere In, Eurocoord, Castagna, Antonella, Rohner, E, Butikofer, L, Schmidlin, K, Sengayi, M, Maskew, M, Giddy, J, Garone, D, Moore, R, D'Souza, G, Goedert, J, Achenbach, C, Gill, M, Kitahata, M, Patel, P, Silverberg, M, Castilho, J, Mcgowan, C, Chen, Y, Law, M, Taylor, N, Paparizos, V, Bonnet, F, Verbon, A, Fatkenheuer, G, Post, F, Sabin, C, Mocroft, A, Le Moing, V, Dronda, F, Obel, N, Grabar, S, Spagnuolo, V, Antinori, A, Quiros-Roldan, E, Mussini, C, Miro, J, Meyer, L, Hasse, B, Konopnicki, D, Roca, B, Barger, D, Raben, D, Clifford, G, Franceschi, S, Brockmeyer, N, Chakraborty, R, Egger, M, Bohlius, J, Judd, A, Zangerle, R, Touloumi, G, Warszawski, J, Dabis, F, Krause, M, Ghosn, J, Leport, C, Wittkop, L, Reiss, P, Wit, F, Prins, M, Bucher, H, Gibb, D, Del Amo, J, Thorne, C, Kirk, O, Stephan, C, Perez-Hoyos, S, Hamouda, O, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Monforte, A, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Tookey, P, Casabona, J, Castagna, A, Konopnick, D, Goetghebuer, T, Sonnerborg, A, Teira, R, Garrido, M, Haerry, D, De Wit, S, Costagliola, D, D'Arminio-Monforte, A, Chene, G, Schwimmer, C, Termote, M, Campbell, M, Frederiksen, C, Friis-Moller, N, Kjaer, J, Brandt, R, Berenguer, J, Bouteloup, V, Cozzi-Lepri, A, Davies, M, Dorrucci, M, Dunn, D, Furrer, H, Guiguet, M, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Schomaker, M, Smit, C, Sterne, J, Thiebaut, R, Torti, C, Van Der Valk, M, Tanser, F, Vinikoor, M, Macete, E, Wood, R, Stinson, K, Fatti, G, Phiri, S, Chimbetete, C, Malisita, K, Eley, B, Fritz, C, Hobbins, M, Kamenova, K, Fox, M, Prozesky, H, Technau, K, Sawry, S, Benson, C, Bosch, R, Kirk, G, Boswell, S, Mayer, K, Grasso, C, Hogg, R, Harrigan, P, Montaner, J, Yip, B, Zhu, J, Salters, K, Gabler, K, Buchacz, K, Brooks, J, Gebo, K, Carey, J, Rodriguez, B, Horberg, M, Thorne, J, Rabkin, C, Margolick, J, Jacobson, L, Klein, M, Rourke, S, Rachlis, A, Cupido, P, Hunter-Mellado, R, Mayor, A, Deeks, S, Martin, J, Saag, M, Mugavero, M, Willig, J, Eron, J, Napravnik, S, Crane, H, Drozd, D, Haas, D, Rebeiro, P, Turner, M, Bebawy, S, Rogers, B, Justice, A, Dubrow, R, Fiellin, D, Gange, S, Anastos, K, Althoff, K, Mckaig, R, Freeman, A, Lent, C, Van Rompaey, S, Morton, L, Mcreynolds, J, Lober, W, Abraham, A, Lau, B, Zhang, J, Jing, J, Modur, S, Wong, C, Hogan, B, Desir, F, Liu, B, You, B, Cahn, P, Cesar, C, Fink, V, Sued, O, Dell'Isola, E, Perez, H, Valiente, J, Yamamoto, C, Grinsztejn, B, Veloso, V, Luz, P, De Boni, R, Wagner, S, Friedman, R, Moreira, R, Pinto, J, Ferreira, F, Maia, M, De Menezes Succi, R, Machado, D, De Fatima Barbosa Gouvea, A, Wolff, M, Cortes, C, Rodriguez, M, Allendes, G, Pape, J, Rouzier, V, Marcelin, A, Perodin, C, Luque, M, Padgett, D, Madero, J, Ramirez, B, Belaunzaran, P, Vega, Y, Gotuzzo, E, Mejia, F, Carriquiry, G, Shepherd, B, Sterling, T, Jayathilake, K, Person, A, Giganti, M, Duda, S, Maruri, F, Vansell, H, Ly, P, Khol, V, Zhang, F, Zhao, H, Han, N, Lee, M, Li, P, Lam, W, Chan, Y, Kumarasamy, N, Saghayam, S, Ezhilarasi, C, Pujari, S, Joshi, K, Gaikwad, S, Chitalikar, A, Merati, T, Wirawan, D, Yuliana, F, Yunihastuti, E, Imran, D, Widhani, A, Tanuma, J, Oka, S, Nishijima, T, Choi, J, Na, S, Kim, J, Sim, B, Gani, Y, David, R, Kamarulzaman, A, Syed Omar, S, Ponnampalavanar, S, Azwa, I, Ditangco, R, Uy, E, Bantique, R, Wong, W, Ku, W, Wu, P, Ng, O, Lim, P, Lee, L, Ohnmar, P, Avihingsanon, A, Gatechompol, S, Phanuphak, P, Phadungphon, C, Kiertiburanakul, S, Sungkanuparph, S, Chumla, L, Sanmeema, N, Chaiwarith, R, Sirisanthana, T, Kotarathititum, W, Praparattanapan, J, Kantipong, P, Kambua, P, Ratanasuwan, W, Sriondee, R, Nguyen, K, Bui, H, Nguyen, D, Cuong, D, An, N, Luan, N, Sohn, A, Ross, J, Petersen, B, Cooper, D, Jiamsakul, A, Boettiger, D, Ellis, D, Bloch, M, Agrawal, S, Vincent, T, Allen, D, Smith, D, Rankin, A, Baker, D, Templeton, D, Jackson, E, Mccallum, K, Ryder, N, Sweeney, G, Carr, A, Macrae, K, Hesse, K, Finlayson, R, Gupta, S, Langton-Lockton, J, Shakeshaft, J, Brown, K, Idle, S, Arvela, N, Varma, R, Lu, H, Couldwell, D, Eswarappa, S, Furner, V, Cabrera, G, Fernando, S, Cogle, A, Lawrence, C, Mulhall, B, Boyd, M, Petoumenos, K, Puhr, R, Huang, R, Han, A, Gunathilake, M, Payne, R, O'Sullivan, M, Croydon, A, Russell, D, Cashman, C, Roberts, C, Sowden, D, Taing, K, Marshall, P, Orth, D, Youds, D, Rowling, D, Latch, N, Warzywoda, E, Dickson, B, Donohue, W, Edwards, S, Boyd, S, Roth, N, Lau, H, Read, T, Silvers, J, Zeng, W, Hoy, J, Watson, K, Bryant, M, Price, S, Woolley, I, Giles, M, Korman, T, Williams, J, Nolan, D, Allen, A, Guelfi, G, Mills, G, Wharry, C, Raymond, N, and Bargh, K
Subjects: Male, viruses, HIV Infections, Men who have sex with men, Cohort Studies, 0302 clinical medicine, Risk Factors, Antiretroviral therapy, Cohort study, HIV, Kaposi sarcoma, Adolescent, Adult, Anti-Retroviral Agents, CD4 Lymphocyte Count, Female, HIV-1, Humans, Middle Aged, Sarcoma, Kaposi, Viral Load, Young Adult, 030212 general & internal medicine, Articles and Commentaries, Incidence (epidemiology), Hazard ratio, virus diseases, Sarcoma, 3. Good health, Infectious Diseases, 030220 oncology & carcinogenesis, Cohort, Coinfection, Microbiology (medical), antiretroviral therapy, 610 Medicine & health, Kaposi, 03 medical and health sciences, SDG 3 - Good Health and Well-being, 360 Social problems & social services, medicine, cohort study, business.industry, medicine.disease, Confidence interval, business, Demography
Abstract: Background We compared Kaposi sarcoma (KS) risk in adults who started antiretroviral therapy (ART) across the Asia-Pacific, South Africa, Europe, Latin, and North America. Methods We included cohort data of human immunodeficiency virus (HIV)-positive adults who started ART after 1995 within the framework of 2 large collaborations of observational HIV cohorts. We present incidence rates and adjusted hazard ratios (aHRs). Results We included 208140 patients from 57 countries. Over a period of 1066572 person-years, 2046 KS cases were diagnosed. KS incidence rates per 100000 person-years were 52 in the Asia-Pacific and ranged between 180 and 280 in the other regions. KS risk was 5 times higher in South African women (aHR, 4.56; 95% confidence intervals [CI], 2.73-7.62) than in their European counterparts, and 2 times higher in South African men (2.21; 1.34-3.63). In Europe, Latin, and North America KS risk was 6 times higher in men who have sex with men (aHR, 5.95; 95% CI, 5.09-6.96) than in women. Comparing patients with current CD4 cell counts ≥700 cells/µL with those whose counts were
Published: 2017
Full Text: View/download PDF

16. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients

Author: Bouteloup V., Sabin C., Mocroft A., Gras L., Pantazis N., Le Moing V., d'Arminio Monforte A., Mary-Krause M., Roca B., Miro J. M., Battegay M., Brockmeyer N., Berenguer J., Morlat P., Obel N., De Wit S., Fatkenheuer G., Zangerle R., Ghosn J., Perez-Hoyos S., Campbell M., Prins M., Chene G., Meyer L., Dorrucci M., Torti C., Thiebaut R., Touloumi G., Warszawski J., Dabis F., Leport C., Wittkop L., Reiss P., Wit F., Bucher H., Gibb D., Amo J. D., Thorne C., Kirk O., Stephan C., Hamouda O., Bartmeyer B., Chkhartishvili N., Noguera-Julian A., Antinori A., Prieto L., Conejo P. R., Soriano-Arandes A., Rauch A., Mussini C., Tookey P., Casabona J., Castagna A., Deborah Konopnick, Goetghebuer T., Sonnerborg A., Teira R., Garrido M., Haerry D., Costagliola D., del Amo J., Raben D., Judd A., Barger D., Colin C., Schwimmer C., Termote M., Friis-Moller N., Kjaer J., Brandt R. S., Bohlius J., Cozzi-Lepri A., Davies M. -A., Dunn D., Egger M., Furrer H., Guiguet M., Grabar S., Lambotte O., Leroy V., Lodi S., Matheron S., Monge S., Nakagawa F., Paredes R., Phillips A., Puoti M., Schomaker M., Smit C., Sterne J., van der Valk M., Wyss N., AII - Infectious diseases, APH - Global Health, Infectious diseases, APH - Aging & Later Life, Global Health, Bouteloup, V, Sabin, C, Mocroft, A, Gras, L, Pantazis, N, Le Moing, V, d'Arminio Monforte, A, Mary-Krause, M, Roca, B, Miro, Jm, Battegay, M, Brockmeyer, N, Berenguer, J, Morlat, P, Obel, N, De Wit, S, Fätkenheuer, G, Zangerle, R, Ghosn, J, Pérez-Hoyos, S, Campbell, M, Prins, M, Chêne, G, Dorrucci, M, Torti, C, Thiébaut, R, the Standard Reference Distribution of CD4 Response to HAART Project Team for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in, Eurocoord, Castagna, Antonella, Miro, J, Fatkenheuer, G, Perez-Hoyos, S, Chene, G, Meyer, L, Thiebaut, R, Touloumi, G, Warszawski, J, Dabis, F, Leport, C, Wittkop, L, Reiss, P, Wit, F, Bucher, H, Gibb, D, Amo, J, Thorne, C, Kirk, O, Stephan, C, Hamouda, O, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Antinori, A, Prieto, L, Conejo, P, Soriano-Arandes, A, Rauch, A, Mussini, C, Tookey, P, Casabona, J, Castagna, A, Deborah, K, Goetghebuer, T, Sonnerborg, A, Teira, R, Garrido, M, Haerry, D, Costagliola, D, del Amo, J, Raben, D, Judd, A, Barger, D, Colin, C, Schwimmer, C, Termote, M, Friis-Moller, N, Kjaer, J, Brandt, R, Bohlius, J, Cozzi-Lepri, A, Davies, M, Dunn, D, Egger, M, Furrer, H, Guiguet, M, Grabar, S, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Schomaker, M, Smit, C, Sterne, J, van der Valk, M, Wyss, N, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Research Department of Infection and Population Health [London], University College of London [London] (UCL), Stichting HIV Monitoring [Amsterdam], Universiteit van Amsterdam (UvA), Department of Hygiene, Epidemiology and Medical Statistics [Athens], University of Athens Medical School [Athens], Université de Montpellier (UM), Università degli Studi di Milano [Milano] (UNIMI), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospital General De Castellon, Clinical and experimental neuroimmunology [IDIBAPS], Institut d'Investigacions Biomèdiques August Pi i Sunyer, University Hospital Basel [Basel], Ruhr-Universität Bochum [Bochum], Hospital General Universitario 'Gregorio Marañón' [Madrid], Hôpital Saint-André, University of Copenhagen = Københavns Universitet (KU), Université libre de Bruxelles (ULB), University Hospital of Cologne [Cologne], Universität Innsbruck [Innsbruck], Hôpital Hôtel-Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Universitat Autònoma de Barcelona (UAB), University of Illinois at Urbana-Champaign [Urbana], University of Illinois System, Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Istituto Superiore di Sanita [Rome], Università degli Studi 'Magna Graecia' di Catanzaro [Catanzaro, Italie] (UMG), Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Statistics In System biology and Translational Medicine (SISTM), Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)- Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Università degli Studi di Milano = University of Milan (UNIMI), University of Copenhagen = Københavns Universitet (UCPH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Istituto Superiore di Sanità (ISS), Università degli Studi 'Magna Graecia' di Catanzaro = University of Catanzaro (UMG), Laboratoire de Météorologie Dynamique (UMR 8539) (LMD), Département des Géosciences - ENS Paris, École normale supérieure - Paris (ENS Paris)-École normale supérieure - Paris (ENS Paris)-Centre National de la Recherche Scientifique (CNRS)-École des Ponts ParisTech (ENPC)-École polytechnique (X)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC), CRAHI-UPC, Edifici NEXUS 104-106, Calle Gran Capità 2-4, 08034 Barcelona, Spain, affiliation inconnue, Pork CRC Roseworthy, Alfred-Wegener-Institut, Helmholtz-Zentrum für Polar- und Meeresforschung (AWI), Laboratoire Evolution, Génomes et Spéciation (LEGS), and Centre National de la Recherche Scientifique (CNRS)
Subjects: 0301 basic medicine, CD4-Positive T-Lymphocytes, Male, Pediatrics, Percentile, longitudinal data, [SDV]Life Sciences [q-bio], CD4 response, HIV monitoring, antiretroviral treatment monitoring, longitudinal data, HIV Infections, Cohort Studies, 0302 clinical medicine, antiretroviral treatment monitoring, CD4 response, HIV monitoring, Adolescent, Adult, Aged, Anti-Retroviral Agents, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Drug Monitoring, Europe, Female, HIV-1, Humans, Middle Aged, Treatment Outcome, Viral Load, Young Adult, Interquartile range, [MATH.MATH-ST]Mathematics [math]/Statistics [math.ST], Epidemiology, HIV Infection, Pharmacology (medical), 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Health Policy, virus diseases, 3. Good health, Infectious Diseases, CD4-Positive T-Lymphocyte, Cohort, Viral load, Human, Cart, medicine.medical_specialty, 03 medical and health sciences, Acquired immunodeficiency syndrome (AIDS), medicine, business.industry, medicine.disease, 030112 virology, Antiretroviral therapy, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Anti-Retroviral Agent, Cohort Studie, business
Abstract: Objectives: The aim of this work was to provide a reference for the CD4 T-cell count response in the early months after the initiation of combination antiretroviral therapy (cART) in HIV-1-infected patients. Methods: All patients in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) cohort who were aged â¥ 18 years and started cART for the first time between 1 January 2005 and 1 January 2010 and who had at least one available measurement of CD4 count and a viral load â¤ 50 HIV-1 RNA copies/mL at 6 months (Â± 3 months) after cART initiation were included in the study. Unadjusted and adjusted references curves and predictions were obtained using quantile regressions. Results: A total of 28 992 patients were included in the study. The median CD4 T-cell count at treatment initiation was 249 [interquartile range (IQR) 150, 336] cells/Î¼L. The median observed CD4 counts at 6, 9 and 12 months were 382 (IQR 256, 515), 402 (IQR 274, 543) and 420 (IQR 293, 565) cells/Î¼L. The two main factors explaining the variation of CD4 count at 6 months were AIDS stage and CD4 count at cART initiation. A CD4 count increase of â¥ 100 cells/mL is generally required in order that patients stay âon trackâ (i.e. with a CD4 count at the same percentile as when they started), with slightly higher gains required for those starting with CD4 counts in the higher percentiles. Individual predictions adjusted for factors influencing CD4 count were more precise. Conclusions: Reference curves aid the evaluation of the immune response early after antiretroviral therapy initiation that leads to viral control.
Published: 2017
Full Text: View/download PDF

17. Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIRaben-1 subtype B and non-subtype B receiving a salvage regimen

Author: De Luca, A, Flandre, P, Dunn, D, Zazzi, M, Wensing, A, Santoro, M, Gunthard, H, Wittkop, L, Kordossis, T, Garcia, F, Castagna, A, Cozzi-Lepri, A, Churchill, D, De Wit, S, Brockmeyer, N, Imaz, A, Mussini, C, Obel, N, Perno, C, Roca, B, Reiss, P, Schulter, E, Torti, C, van Sighem, A, Zangerle, R, Descamps, D, Mocroft, A, Kirk, O, Sabin, C, Casadi, W, Casabona, J, Miro, J, Touloumi, G, Garrido, M, Teira, R, Wit, F, Warszawski, J, Meyer, L, Dabis, F, Krause, M, Ghosn, J, Leport, C, Prins, M, Bucher, H, Gibb, D, Fatkenheuer, G, del Amo, J, Thorne, C, Stephan, C, Perez-Hoyos, S, Hamouda, O, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Antinori, A, d'Arminio Monforte, A, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Tookey, P, Konopnick, D, Goetghebuer, T, Sonnerborg, A, Haerry, D, de Wit, S, Costagliola, D, Raben, D, Chene, G, Ceccherini-Silberstein, F, Judd, A, Barger, D, Schwimmer, C, Termote, M, Campbell, M, Frederiksen, C, Friis-Moller, N, Kjaer, J, Brandt, R, Berenguer, J, Bohlius, J, Bouteloup, V, Davies, M, Dorrucci, M, Egger, M, Furrer, H, Guiguet, M, Grabar, S, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Schomaker, M, Smit, C, Sterne, J, Thiebaut, R, van der Valk, M, Wyss, N, Aubert, V, Bernasconi, E, Boni, J, Burton-Jeangros, C, Calmy, A, Cavassini, M, Dollenmaier, G, Elzi, L, Fehr, J, Fellay, J, Fux, C, Gorgievski, M, Hasse, B, Hirsch, H, Hoffmann, M, Hosli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kovari, H, Ledergerber, B, Martinetti, G, Martinez de Tejada, B, Metzner, K, Muller, N, Nadal, D, Nicca, D, Pantaleo, G, Rauch, A, Regenass, S, Rickenbach, M, Rudin, C, Schoni-Affolter, F, Schmid, P, Schupbach, J, Speck, R, Tarr, P, Telenti, A, Trkola, A, Vernazza, P, Weber, R, Yerly, S, De Luca A., Flandre P., Dunn D., Zazzi M., Wensing A., Santoro M. M., Gunthard H. F., Wittkop L., Kordossis T., Garcia F., Castagna A., Cozzi-Lepri A., Churchill D., De Wit S., Brockmeyer N. H., Imaz A., Mussini C., Obel N., Perno C. F., Roca B., Reiss P., Schulter E., Torti C., van Sighem A., Zangerle R., Descamps D., Mocroft A., Kirk O., Sabin C., Casadi W., Casabona J., Miro J. M., Touloumi G., Garrido M., Teira R., Wit F., Warszawski J., Meyer L., Dabis F., Krause M. M., Ghosn J., Leport C., Prins M., Bucher H., Gibb D., Fatkenheuer G., del Amo J., Thorne C., Stephan C., Perez-Hoyos S., Hamouda O., Bartmeyer B., Chkhartishvili N., Noguera-Julian A., Antinori A., d'Arminio Monforte A., Prieto L., Conejo P. R., Soriano-Arandes A., Battegay M., Kouyos R., Tookey P., Konopnick D., Goetghebuer T., Sonnerborg A., Haerry D., de Wit S., Costagliola D., Raben D., Chene G., Ceccherini-Silberstein F., Gunthard H., Judd A., Barger D., Schwimmer C., Termote M., Campbell M., Frederiksen C. M., Friis-Moller N., Kjaer J., Brandt R. S., Berenguer J., Bohlius J., Bouteloup V., Davies M. -A., Dorrucci M., Egger M., Furrer H., Guiguet M., Grabar S., Lambotte O., Leroy V., Lodi S., Matheron S., Monge S., Nakagawa F., Paredes R., Phillips A., Puoti M., Schomaker M., Smit C., Sterne J., Thiebaut R., van der Valk M., Wyss N., Aubert V., Bernasconi E., Boni J., Burton-Jeangros C., Calmy A., Cavassini M., Dollenmaier G., Elzi L., Fehr J., Fellay J., Fux C. A., Gorgievski M., Hasse B., Hirsch H. H., Hoffmann M., Hosli I., Kahlert C., Kaiser L., Keiser O., Klimkait T., Kovari H., Ledergerber B., Martinetti G., Martinez de Tejada B., Metzner K., Muller N., Nadal D., Nicca D., Pantaleo G., Rauch A., Regenass S., Rickenbach M., Rudin C., Schoni-Affolter F., Schmid P., Schupbach J., Speck R., Tarr P., Telenti A., Trkola A., Vernazza P., Weber R., Yerly S., De Luca, A, Flandre, P, Dunn, D, Zazzi, M, Wensing, A, Santoro, M, Gunthard, H, Wittkop, L, Kordossis, T, Garcia, F, Castagna, A, Cozzi-Lepri, A, Churchill, D, De Wit, S, Brockmeyer, N, Imaz, A, Mussini, C, Obel, N, Perno, C, Roca, B, Reiss, P, Schulter, E, Torti, C, van Sighem, A, Zangerle, R, Descamps, D, Mocroft, A, Kirk, O, Sabin, C, Casadi, W, Casabona, J, Miro, J, Touloumi, G, Garrido, M, Teira, R, Wit, F, Warszawski, J, Meyer, L, Dabis, F, Krause, M, Ghosn, J, Leport, C, Prins, M, Bucher, H, Gibb, D, Fatkenheuer, G, del Amo, J, Thorne, C, Stephan, C, Perez-Hoyos, S, Hamouda, O, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Antinori, A, d'Arminio Monforte, A, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Tookey, P, Konopnick, D, Goetghebuer, T, Sonnerborg, A, Haerry, D, de Wit, S, Costagliola, D, Raben, D, Chene, G, Ceccherini-Silberstein, F, Judd, A, Barger, D, Schwimmer, C, Termote, M, Campbell, M, Frederiksen, C, Friis-Moller, N, Kjaer, J, Brandt, R, Berenguer, J, Bohlius, J, Bouteloup, V, Davies, M, Dorrucci, M, Egger, M, Furrer, H, Guiguet, M, Grabar, S, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Schomaker, M, Smit, C, Sterne, J, Thiebaut, R, van der Valk, M, Wyss, N, Aubert, V, Bernasconi, E, Boni, J, Burton-Jeangros, C, Calmy, A, Cavassini, M, Dollenmaier, G, Elzi, L, Fehr, J, Fellay, J, Fux, C, Gorgievski, M, Hasse, B, Hirsch, H, Hoffmann, M, Hosli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kovari, H, Ledergerber, B, Martinetti, G, Martinez de Tejada, B, Metzner, K, Muller, N, Nadal, D, Nicca, D, Pantaleo, G, Rauch, A, Regenass, S, Rickenbach, M, Rudin, C, Schoni-Affolter, F, Schmid, P, Schupbach, J, Speck, R, Tarr, P, Telenti, A, Trkola, A, Vernazza, P, Weber, R, Yerly, S, De Luca A., Flandre P., Dunn D., Zazzi M., Wensing A., Santoro M. M., Gunthard H. F., Wittkop L., Kordossis T., Garcia F., Castagna A., Cozzi-Lepri A., Churchill D., De Wit S., Brockmeyer N. H., Imaz A., Mussini C., Obel N., Perno C. F., Roca B., Reiss P., Schulter E., Torti C., van Sighem A., Zangerle R., Descamps D., Mocroft A., Kirk O., Sabin C., Casadi W., Casabona J., Miro J. M., Touloumi G., Garrido M., Teira R., Wit F., Warszawski J., Meyer L., Dabis F., Krause M. M., Ghosn J., Leport C., Prins M., Bucher H., Gibb D., Fatkenheuer G., del Amo J., Thorne C., Stephan C., Perez-Hoyos S., Hamouda O., Bartmeyer B., Chkhartishvili N., Noguera-Julian A., Antinori A., d'Arminio Monforte A., Prieto L., Conejo P. R., Soriano-Arandes A., Battegay M., Kouyos R., Tookey P., Konopnick D., Goetghebuer T., Sonnerborg A., Haerry D., de Wit S., Costagliola D., Raben D., Chene G., Ceccherini-Silberstein F., Gunthard H., Judd A., Barger D., Schwimmer C., Termote M., Campbell M., Frederiksen C. M., Friis-Moller N., Kjaer J., Brandt R. S., Berenguer J., Bohlius J., Bouteloup V., Davies M. -A., Dorrucci M., Egger M., Furrer H., Guiguet M., Grabar S., Lambotte O., Leroy V., Lodi S., Matheron S., Monge S., Nakagawa F., Paredes R., Phillips A., Puoti M., Schomaker M., Smit C., Sterne J., Thiebaut R., van der Valk M., Wyss N., Aubert V., Bernasconi E., Boni J., Burton-Jeangros C., Calmy A., Cavassini M., Dollenmaier G., Elzi L., Fehr J., Fellay J., Fux C. A., Gorgievski M., Hasse B., Hirsch H. H., Hoffmann M., Hosli I., Kahlert C., Kaiser L., Keiser O., Klimkait T., Kovari H., Ledergerber B., Martinetti G., Martinez de Tejada B., Metzner K., Muller N., Nadal D., Nicca D., Pantaleo G., Rauch A., Regenass S., Rickenbach M., Rudin C., Schoni-Affolter F., Schmid P., Schupbach J., Speck R., Tarr P., Telenti A., Trkola A., Vernazza P., Weber R., and Yerly S.
Abstract: Objectives: The objective of this studywas to improve the prediction of the impact of HIV-1 protease mutations in different viral subtypes on virological response to darunavir. Methods: Darunavir-containing treatment change episodes (TCEs) in patients previously failing PIs were selected from large European databases. HIV-1 subtype B-infected patients were used as the derivation dataset and HIV- 1 non-B-infected patients were used as the validation dataset. The adjusted association of each mutation with week 8 HIV RNA change from baseline was analysed by linear regression. A prediction model was derived based on best subset least squares estimation with mutational weights corresponding to regression coefficients. Virological outcome prediction accuracy was compared with that from existing genotypic resistance interpretation systems (GISs) (ANRS 2013, Rega 9.1.0 and HIVdb 7.0). Results: TCEs were selected from 681 subtype B-infected and 199 non-B-infected adults. Accompanying drugs were NRTIs in 87%, NNRTIs in 27%and raltegravir ormaraviroc or enfuvirtide in 53%. The predictionmodel included weighted protease mutations, HIV RNA, CD4 and activity of accompanying drugs. The model's association with week 8 HIV RNA change in the subtype B (derivation) set was R2=0.47 [average squared error (ASE)=0.67, P>10-6]; in the non-B (validation) set, ASE was 0.91. Accuracy investigated by means of area under the receiver operating characteristic curves with a binary response (above the threshold value of HIV RNA reduction) showed that our finalmodel outperformed models with existing interpretation systems in both training and validation sets. Conclusions: A model with a new darunavir-weighted mutation score outperformed existing GISs in both B and non-B subtypes in predicting virological response to darunavir.
Published: 2016

18. Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIRaben-1 subtype B and non-subtype B receiving a salvage regimen

Author: De Luca A., Flandre P., Dunn D., Zazzi M., Wensing A., Santoro M. M., Gunthard H. F., Wittkop L., Kordossis T., Garcia F., Castagna A., Cozzi-Lepri A., Churchill D., De Wit S., Brockmeyer N. H., Imaz A., Mussini C., Obel N., Perno C. F., Roca B., Reiss P., Schulter E., Torti C., van Sighem A., Zangerle R., Descamps D., Mocroft A., Kirk O., Sabin C., Casadi W., Casabona J., Miro J. M., Touloumi G., Garrido M., Teira R., Wit F., Warszawski J., Meyer L., Dabis F., Krause M. M., Ghosn J., Leport C., Prins M., Bucher H., Gibb D., Fatkenheuer G., del Amo J., Thorne C., Stephan C., Perez-Hoyos S., Hamouda O., Bartmeyer B., Chkhartishvili N., Noguera-Julian A., Antinori A., d'Arminio Monforte A., Prieto L., Conejo P. R., Soriano-Arandes A., Battegay M., Kouyos R., Tookey P., Konopnick D., Goetghebuer T., Sonnerborg A., Haerry D., de Wit S., Costagliola D., Raben D., Chene G., Ceccherini-Silberstein F., Gunthard H., Judd A., Barger D., Schwimmer C., Termote M., Campbell M., Frederiksen C. M., Friis-Moller N., Kjaer J., Brandt R. S., Berenguer J., Bohlius J., Bouteloup V., Davies M. -A., Dorrucci M., Egger M., Furrer H., Guiguet M., Grabar S., Lambotte O., Leroy V., Lodi S., Matheron S., Monge S., Nakagawa F., Paredes R., Phillips A., Puoti M., Schomaker M., Smit C., Sterne J., Thiebaut R., van der Valk M., Wyss N., Aubert V., Bernasconi E., Boni J., Burton-Jeangros C., Calmy A., Cavassini M., Dollenmaier G., Elzi L., Fehr J., Fellay J., Fux C. A., Gorgievski M., Hasse B., Hirsch H. H., Hoffmann M., Hosli I., Kahlert C., Kaiser L., Keiser O., Klimkait T., Kovari H., Ledergerber B., Martinetti G., Martinez de Tejada B., Metzner K., Muller N., Nadal D., Nicca D., Pantaleo G., Rauch A., Regenass S., Rickenbach M., Rudin C., Schoni-Affolter F., Schmid P., Schupbach J., Speck R., Tarr P., Telenti A., Trkola A., Vernazza P., Weber R., Yerly S., De Luca, A, Flandre, P, Dunn, D, Zazzi, M, Wensing, A, Santoro, M, Gunthard, H, Wittkop, L, Kordossis, T, Garcia, F, Castagna, A, Cozzi-Lepri, A, Churchill, D, De Wit, S, Brockmeyer, N, Imaz, A, Mussini, C, Obel, N, Perno, C, Roca, B, Reiss, P, Schulter, E, Torti, C, van Sighem, A, Zangerle, R, Descamps, D, Mocroft, A, Kirk, O, Sabin, C, Casadi, W, Casabona, J, Miro, J, Touloumi, G, Garrido, M, Teira, R, Wit, F, Warszawski, J, Meyer, L, Dabis, F, Krause, M, Ghosn, J, Leport, C, Prins, M, Bucher, H, Gibb, D, Fatkenheuer, G, del Amo, J, Thorne, C, Stephan, C, Perez-Hoyos, S, Hamouda, O, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Antinori, A, d'Arminio Monforte, A, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Tookey, P, Konopnick, D, Goetghebuer, T, Sonnerborg, A, Haerry, D, de Wit, S, Costagliola, D, Raben, D, Chene, G, Ceccherini-Silberstein, F, Judd, A, Barger, D, Schwimmer, C, Termote, M, Campbell, M, Frederiksen, C, Friis-Moller, N, Kjaer, J, Brandt, R, Berenguer, J, Bohlius, J, Bouteloup, V, Davies, M, Dorrucci, M, Egger, M, Furrer, H, Guiguet, M, Grabar, S, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Schomaker, M, Smit, C, Sterne, J, Thiebaut, R, van der Valk, M, Wyss, N, Aubert, V, Bernasconi, E, Boni, J, Burton-Jeangros, C, Calmy, A, Cavassini, M, Dollenmaier, G, Elzi, L, Fehr, J, Fellay, J, Fux, C, Gorgievski, M, Hasse, B, Hirsch, H, Hoffmann, M, Hosli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kovari, H, Ledergerber, B, Martinetti, G, Martinez de Tejada, B, Metzner, K, Muller, N, Nadal, D, Nicca, D, Pantaleo, G, Rauch, A, Regenass, S, Rickenbach, M, Rudin, C, Schoni-Affolter, F, Schmid, P, Schupbach, J, Speck, R, Tarr, P, Telenti, A, Trkola, A, Vernazza, P, Weber, R, Yerly, S, University of Zurich, De Luca, Andrea, Santoro, Mm, Günthard, Hf, Brockmeyer, Nh, Perno, Cf, Schülter, E, on behalf of CHAIN and COHERE in, Eurocoord, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Global Health, Infectious diseases, and Medical Microbiology and Infection Prevention
Subjects: 0301 basic medicine, Oncology, Male, Enfuvirtide, Genotyping Techniques, HIV Infections, 2726 Microbiology (medical), 10234 Clinic for Infectious Diseases, 0302 clinical medicine, HIV Protease, Genotype, 2736 Pharmacology (medical), Medicine, HIV Infection, Pharmacology (medical), 030212 general & internal medicine, Non-U.S. Gov't, Darunavir, Aged, 80 and over, Microbial Sensitivity Test, Medicine (all), Research Support, Non-U.S. Gov't, Proteolytic enzymes, Middle Aged, Settore MED/07 - Microbiologia e Microbiologia Clinica, Prognosis, Europe, 3004 Pharmacology, Treatment Outcome, Infectious Diseases, Mutation (genetic algorithm), Female, Human, medicine.drug, Microbiology (medical), Adult, medicine.medical_specialty, Adolescent, Pharmacology, Prognosi, Anti-HIV Agents, 610 Medicine & health, Microbial Sensitivity Tests, Settore MED/17 - MALATTIE INFETTIVE, Research Support, Article, 03 medical and health sciences, Young Adult, Internal medicine, Linear regression, Drug Resistance, Viral, Journal Article, Humans, Aged, Receiver operating characteristic, business.industry, Anti-HIV Agent, 2725 Infectious Diseases, Raltegravir, 030112 virology, Virology, HIV Darunavir, Mutation, HIV-1, genotypic, Genotyping Technique, business
Abstract: Objectives: The objective of this studywas to improve the prediction of the impact of HIV-1 protease mutations in different viral subtypes on virological response to darunavir. Methods: Darunavir-containing treatment change episodes (TCEs) in patients previously failing PIs were selected from large European databases. HIV-1 subtype B-infected patients were used as the derivation dataset and HIV- 1 non-B-infected patients were used as the validation dataset. The adjusted association of each mutation with week 8 HIV RNA change from baseline was analysed by linear regression. A prediction model was derived based on best subset least squares estimation with mutational weights corresponding to regression coefficients. Virological outcome prediction accuracy was compared with that from existing genotypic resistance interpretation systems (GISs) (ANRS 2013, Rega 9.1.0 and HIVdb 7.0). Results: TCEs were selected from 681 subtype B-infected and 199 non-B-infected adults. Accompanying drugs were NRTIs in 87%, NNRTIs in 27%and raltegravir ormaraviroc or enfuvirtide in 53%. The predictionmodel included weighted protease mutations, HIV RNA, CD4 and activity of accompanying drugs. The model's association with week 8 HIV RNA change in the subtype B (derivation) set was R2=0.47 [average squared error (ASE)=0.67, P>10-6]; in the non-B (validation) set, ASE was 0.91. Accuracy investigated by means of area under the receiver operating characteristic curves with a binary response (above the threshold value of HIV RNA reduction) showed that our finalmodel outperformed models with existing interpretation systems in both training and validation sets. Conclusions: A model with a new darunavir-weighted mutation score outperformed existing GISs in both B and non-B subtypes in predicting virological response to darunavir.
Published: 2016

19. Chronic hepatitis B and C virus infection and risk for non-hodgkin lymphoma in HIV-infected patients: A cohort study

Author: Wang, Q. De Luca, A. Smith, C. Zangerle, R. Sambatakou, H. Bonnet, F. Smit, C. Schommers, P. Thornton, A. Berenguer, J. Peters, L. Spagnuolo, V. Ammassari, A. Antinori, A. Roldan, E.Q. Mussini, C. Miro, J.M. Konopnicki, D. Fehr, J. Campbell, M.A. Termote, M. Bucher, H.C. De Wit, S. Costagliola, D. D'Arminio-Monforte, A. Castagna, A. Del Amo, J. Mocroft, A. Raben, D. Chêne, G. Touloumi, G. Warszawski, J. Meyer, L. Dabis, F. Krause, M.M. Ghosn, J. Leport, C. Wittkop, L. Reiss, P. Wit, F. Prins, M. Sabin, C. Gibb, D. Fätkenheuer, G. Obel, N. Thorne, C. Kirk, O. Stephan, C. Pérez-Hoyos, S. Hamouda, O. Bartmeyer, B. Chkhartishvili, N. Noguera-Julian, A. Brockmeyer, N. Prieto, L. Conejo, P.R. Soriano-Arandes, A. Battegay, M. Rauch, A. Tookey, P. Casabona, J. Goetghebuer, T. Sönnerborg, A. Torti, C. Teira, R. Garrido, M. Haerry, D. Bohlius, J. Bouteloup, V. Cozzi-Lepri, A. Davies, M.-A. Dorrucci, M. Dunn, D. Egger, M. Furrer, H. Guiguet, M. Grabar, S. Judd, A. Lambotte, O. Leroy, V. Lodi, S. Matheron, S. Monge, S. Nakagawa, F. Paredes, R. Phillips, A. Puoti, M. Schomaker, M. Sterne, J. Thiebaut, R. Van Der Valk, M. Wyss, N. Barger, D. Schwimmer, C. Friis-Møller, N. Kjaer, J. Brandt, R.S. The Hepatitis Coinfection Non Hodgkin Lymphoma project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord
Subjects: virus diseases, digestive system diseases
Abstract: Background: Non-Hodgkin lymphoma (NHL) is the most common AIDS-defining condition in the era of antiretroviral therapy (ART). Whether chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection promote NHL in HIV-infected patients is unclear. Objective: To investigate whether chronic HBV and HCV infection are associated with increased incidence of NHL in HIVinfected patients. Design: Cohort study. Setting: 18 of 33 cohorts from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Patients: HIV-infected patients with information on HBV surface antigen measurements and detectable HCV RNA, or a positive HCV antibody test result if HCV RNA measurements were not available. Measurements: Time-dependent Cox models to assess risk for NHL in treatment-naive patients and those initiating ART, with inverse probability weighting to control for informative censoring. Results: A total of 52 479 treatment-naive patients (1339 [2.6%] with chronic HBV infection and 7506 [14.3%] with HCV infection) were included, of whom 40 219 (77%) later started ART. The median follow-up was 13 months for treatment-naive patients and 50 months for those receiving ART. A total of 252 treatmentnaive patients and 310 treated patients developed NHL, with incidence rates of 219 and 168 cases per 100 000 person-years, respectively. The hazard ratios for NHL with HBV and HCV infection were 1.33 (95% CI, 0.69 to 2.56) and 0.67 (CI, 0.40 to 1.12), respectively, in treatment-naive patients and 1.74 (CI, 1.08 to 2.82) and 1.73 (CI, 1.21 to 2.46), respectively, in treated patients. Limitation: Many treatment-naive patients later initiated ART, which limited the study of the associations of chronic HBV and HCV infection with NHL in this patient group. Conclusion: In HIV-infected patients receiving ART, chronic coinfection with HBV and HCV is associated with an increased risk for NHL. © 2017 American College of Physicians.
Published: 2017

20. CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: A multinational, multicohort European study

Author: Wittkop, L. Arsandaux, J. Trevino, A. van der Loeff, M.S. Anderson, J. van Sighem, A. Böni, J. Brun-Vezinet, F. Soriano, V. Boufassa, F. Brockmeyer, N. Calmy, A. Dabis, F. Jarrin, I. Dorrucci, M. Duque, V. Fätkenheuer, G. Zangerle, R. Ferrer, E. Porter, K. Judd, A. Sipsas, N.V. Lambotte, O. Shepherd, L. Leport, C. Morrison, C. Mussini, C. Obel, N. Ruelle, J. Schwarze-Zander, C. Sonnerborg, A. Teira, R. Torti, C. Valadas, E. Colin, C. Friis-Møller, N. Costagliola, D. Thiebaut, R. Chene, G. Matheron, S. Touloumi, G. Warszawski, J. Meyer, L. Krause, M.M. Ghosn, J. Reiss, P. Wit, F. Prins, M. Bucher, H. Gibb, D. Del Amo, J. Thorne, C. Mocroft, A. Kirk, O. Stephan, C. Pérez-Hoyos, S. Hamouda, O. Bartmeyer, B. Chkhartishvili, N. Noguera-Julian, A. Antinori, A. Monforte, A. Prieto, L. Conejo, P.R. Soriano-Arandes, A. Battegay, M. Kouyos, R. Tookey, P. Casabona, J. Mirò, J.M. Castagna, A. Konopnick, D. Goetghebuer, T. Sönnerborg, A. Sabin, C. Garrido, M. Haerry, D. Berenguer, J. Bohlius, J. Bouteloup, V. Cozzi-Lepri, A. Monforte, A.A. Davies, M.-A. Amo, J. Dunn, D. Egger, M. Furrer, H. Guiguet, M. Grabar, S. Leroy, V. Lodi, S. Monge, S. Nakagawa, F. Paredes, R. Phillips, A. Puoti, M. Schomaker, M. Smit, C. Sterne, J. van der Valk, M. Wyss, N. n behalf of the COHERE in EuroCoord ACHIeV2e Study Group
Subjects: virus diseases
Abstract: Background: CD4 cell recovery following first-line combination ART (cART) is poorer in HIV-2+ than in HIV-1+ patients. Only large comparisons may allow adjustments for demographic and pretreatment plasma viral load (pVL). Methods: ART-naive HIV+ adults from two European multicohort collaborations, COHERE (HIV-1 alone) and ACHIeV2e (HIV-2 alone), were included, if they started first-line cART (without NNRTIs or fusion inhibitors) between 1997 and 2011. Patients without at least one CD4 cell count before start of cART, without a pretreatment pVL and with missing a priori-defined covariables were excluded. Evolution of CD4 cell count was studied using adjusted linear mixed models. Results: We included 185 HIV-2+ and 30321 HIV-1+ patients with median age of 46 years (IQR 36-52) and 37 years (IQR 31-44), respectively. Median observed pretreatment CD4 cell counts/mm3 were 203 (95% CI 100-290) in HIV-2+ patients and 223 (95% CI 100-353) in HIV-1+ patients. Mean observed CD4 cell count changes from start of cART to 12months were +105 (95% CI 77-134) in HIV-2+ patients and +202 (95% CI 199-205) in HIV-1+ patients, an observed difference of 97 cells/mm3 in 1 year. In adjusted analysis, the mean CD4 cell increase was overall 25 CD4 cells/mm3/year lower (95% CI 5-44; P=0.0127) in HIV-2+ patients compared with HIV-1+ patients. Conclusions: A poorer CD4 cell increase during first-line cART was observed in HIV-2+patients, even after adjusting for pretreatment pVL and other potential confounders. Our results underline the need to identify more potent therapeutic regimens or strategies against HIV-2.
Published: 2017

21. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naive patients

Author: Bouteloup, V. Sabin, C. Mocroft, A. Gras, L. Pantazis, N. Le Moing, V. d'Arminio Monforte, A. Mary-Krause, M. and Roca, B. Miro, J. M. Battegay, M. Brockmeyer, N. and Berenguer, J. Morlat, P. Obel, N. De Wit, S. and Faetkenheuer, G. Zangerle, R. Ghosn, J. Perez-Hoyos, S. and Campbell, M. Prins, M. Chene, G. Meyer, L. Dorrucci, M. and Torti, C. Thiebaut, R. Stand Reference Distribution CD4 R
Abstract: ObjectivesThe aim of this work was to provide a reference for the CD4 T-cell count response in the early months after the initiation of combination antiretroviral therapy (cART) in HIV-1-infected patients. MethodsAll patients in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) cohort who were aged 18 years and started cART for the first time between 1 January 2005 and 1 January 2010 and who had at least one available measurement of CD4 count and a viral load 50 HIV-1 RNA copies/mL at 6 months ( 3 months) after cART initiation were included in the study. Unadjusted and adjusted references curves and predictions were obtained using quantile regressions. ResultsA total of 28 992 patients were included in the study. The median CD4 T-cell count at treatment initiation was 249 [interquartile range (IQR) 150, 336] cells/L. The median observed CD4 counts at 6, 9 and 12 months were 382 (IQR 256, 515), 402 (IQR 274, 543) and 420 (IQR 293, 565) cells/L. The two main factors explaining the variation of CD4 count at 6 months were AIDS stage and CD4 count at cART initiation. A CD4 count increase of 100 cells/mL is generally required in order that patients stay on track’ (i.e. with a CD4 count at the same percentile as when they started), with slightly higher gains required for those starting with CD4 counts in the higher percentiles. Individual predictions adjusted for factors influencing CD4 count were more precise. ConclusionsReference curves aid the evaluation of the immune response early after antiretroviral therapy initiation that leads to viral control.
Published: 2017

22. Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes

Author: Audelin, A., Castagna, A., Costagliola, D., Cozzi-Lepri, A., De Luca, A., De Wit, S., de Wolf, F., Dorrucci, M., Duval, X., Fatkenheuer, G., Garcia, F., Ghosn, J., Gunthard, H., Jansen, K., Judd, A., Ledergerber, B., Lo Caputo, S., Lodwick, R., Masquelier, B., Meyer, L., Mocroft, A., Mussini, C., Noguera-Julian, A., Obel, N., Paraskevis, D., Paredes, R., Perez-Hoyos, S., Phillips, A., Pillay, D., Podzamczer, D., Ramos, J. T., Stephan, C., Tookey, P. A., Torti, C., Touloumi, G., van Sighem, A., Warsawski, J., Zangerle, R., Warszawski, J., Dabis, F., Krause, M. M., Leport, C., Reiss, P., Prins, M., Bucher, H., Sabin, C., Gibb, D., Del Amo, J., Thorne, C., Kirk, O., Antinori, A., d'Arminio Monforte, A., Brockmeyer, N., Ramos, J., Battegay, M., Rauch, A., Tookey, P., Casabona, J., Miro, J. M., de Wit, S., Goetghebuer, T., Teira, R., Garrido, M., Haerry, D., Weller, I., d'Arminio-Monforte, A., Grarup, J., Chene, G., Bohlius, J., Bouteloup, V., Egger, M., Engsig, F., Furrer, H., Lambotte, O., Lewden, C., Matheron, S., Miro, J., Puoti, M., Reekie, J., Scherrer, A., Smit, C., Sterne, J., Thiebaut, R., von Wyl, V., Wittkop, L., Ledergerber, Bruno, Cohere, Cohort, Castagna, Antonella, Other departments, Amsterdam institute for Infection and Immunity, Amsterdam Public Health, Global Health, and Infectious diseases
Subjects: Adult, Male, medicine.medical_specialty, Efavirenz, Infectious Disease, HIV Infections, Settore MED/17 - MALATTIE INFETTIVE, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, antiretroviral agent, Internal medicine, Medicine, Immunology and Allergy, Humans, Protease inhibitor (pharmacology), HIV Infection, 030212 general & internal medicine, Anti-Retroviral Agents, CD4 Lymphocyte Count, Female, Middle Aged, Treatment Failure, Viral Load, Generalized estimating equation, HIV cohort study, business.industry, CD4 lymphocyte count, Raltegravir, Confidence interval, 3. Good health, VIROLOGIC FAILURE, Infectious Diseases, chemistry, 030220 oncology & carcinogenesis, Immunology, Cohort, triple-class virologic failure, HIV-1, Anti-Retroviral Agent, business, Viral load, medicine.drug, Human
Abstract: Background. Low CD4+ T-cell counts are the main factor leading to clinical progression in human immunodeficiency virus type 1 (HIV-1) infection. We aimed to investigate factors affecting CD4+ T-cell counts after triple-class virological failure.Methods. We included individuals from the COHERE database who started antiretroviral therapy from 1998 onward and who experienced triple-class virological failure. CD4+ T-cell counts obtained after triple-class virologic failure were analyzed using generalized estimating equations.Results. The analyses included 2424 individuals with a total of 23 922 CD4+ T-cell count measurements. In adjusted models (excluding current viral load and year), CD4+ T-cell counts were higher with regimens that included boosted protease inhibitors (increase, 22 cells/Î¼L [95% confidence interval CI, 3.9-41]; P =. 017) or drugs from the new classes (increase, 39 cells/Î¼L [95% CI, 15-62]; P =. 001), compared with nonnucleoside reverse-transcriptase inhibitor-based regimens. These associations disappeared when current viral load and/or calendar year were included. Compared with viral levels of 5.5 log10 copies/mL were associated with CD4+ T-cell count decreases of 51, 84, 137, and 186 cells/Î¼L, respectively (P
Published: 2013
Full Text: View/download PDF

23. All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration

Author: Lewden, C, Bouteloup, V, De Wit, S, Sabin, C, Mocroft, A, Wasmuth, Jc, van Sighem, A, Kirk, O, Obel, N, Panos, G, Ghosn, J, Dabis, F, Mary Krause, M, Leport, C, Perez Hoyos, S, Sobrino Vegas, P, Stephan, C, Castagna, A, Antinori, A, d'Arminio Monforte, A, Torti, C, Mussini, Cristina, Isern, V, Calmy, A, Teira, R, Egger, M, Grarup, J, Chêne, G, Collaboration of Observational HIV Epidemiological Research Europe in EuroCoord, Other departments, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Global Health, Infectious diseases, Lewden, Charlotte, Bouteloup, Vincent, De Wit, Stephane, Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Group, and Castagna, A
Subjects: CD4, HIV, AIDS, mortality, Adult, Male, medicine.medical_specialty, Epidemiology, Anti-HIV Agents, Population, 610 Medicine & health, HIV Infections, Article, Europe/epidemiology, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Acquired immunodeficiency syndrome (AIDS), Risk Factors, Cause of Death, medicine, Humans, 030212 general & internal medicine, Poisson Distribution, education, Cause of death, ddc:616, 0303 health sciences, education.field_of_study, 030306 microbiology, business.industry, Mortality rate, General Medicine, medicine.disease, 3. Good health, CD4 Lymphocyte Count, Europe, HIV Infections/drug therapy/mortality, Anti-HIV Agents/therapeutic use, Immunology, Cohort, Observational study, Female, business, Cohort study, Demography
Abstract: Background Using data from a large European collaborative study, we aimed to identify the circumstances in which treated HIV-infected individuals will experience similar mortality rates to those of the general population. Methods Adults were eligible if they initiated combination anti-retroviral treatment (cART) between 1998 and 2008 and had one prior CD4 measurement within 6 months. Standardized mortality ratios (SMRs) and excess mortality rates compared with the general population were estimated using Poisson regression. Periods of follow-up were classified according to the current CD4 count. Results Of the 80 642 individuals, 70% were men, 16% were injecting drug users (IDUs), the median age was 37 years, median CD4 count 225/mm3 at cART initiation and median follow-up was 3.5 years. The overall mortality rate was 1.2/100 person-years (PY) (men: 1.3, women: 0.9), 4.2 times as high as that in the general population (SMR for men: 3.8, for women: 7.4). Among 35 316 individuals with a CD4 count ≥500/mm3, the mortality rate was 0.37/100 PY (SMR 1.5); mortality rates were similar to those of the general population in non-IDU men [SMR 0.9, 95% confidence interval (95% CI) 0.7-1.3] and, after 3 years, in women (SMR 1.1, 95% CI 0.7-1.7). Mortality rates in IDUs remained elevated, though a trend to decrease with longer durations with high CD4 count was seen. A prior AIDS diagnosis was associated with higher mortality. Conclusions Mortality patterns in most non-IDU HIV-infected individuals with high CD4 counts on cART are similar to those in the general population. The persistent role of a prior AIDS diagnosis underlines the importance of early diagnosis of HIV infection
Published: 2012
Full Text: View/download PDF

24. Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIRaben-1 subtype B and non-subtype B receiving a salvage regimen

Author: De Luca, A. Flandre, P. Dunn, D. Zazzi, M. Wensing, A. Santoro, M.M. Günthard, H.F. Wittkop, L. Kordossis, T. Garcia, F. Castagna, A. Cozzi-Lepri, A. Churchill, D. De Wit, S. Brockmeyer, N.H. Imaz, A. Mussini, C. Obel, N. Perno, C.F. Roca, B. Reiss, P. Schülter, E. Torti, C. van Sighem, A. Zangerle, R. Descamps, D. Mocroft, A. Kirk, O. Sabin, C. Casadi, W. Casabona, J. Miró, J.M. Touloumi, G. Garrido, M. Teira, R. Wit, F. Warszawski, J. Meyer, L. Dabis, F. Krause, M.M. Ghosn, J. Leport, C. Prins, M. Bucher, H. Gibb, D. Fätkenheuer, G. del Amo, J. Thorne, C. Stephan, C. Pérez-Hoyos, S. Hamouda, O. Bartmeyer, B. Chkhartishvili, N. Noguera-Julian, A. Antinori, A. d'Arminio Monforte, A. Prieto, L. Conejo, P.R. Soriano-Arandes, A. Battegay, M. Kouyos, R. Tookey, P. Konopnick, D. Goetghebuer, T. Sönnerborg, A. Haerry, D. Costagliola, D. Raben, D. Chêne, G. Ceccherini-Silberstein, F. Günthard, H. Judd, A. Barger, D. Schwimmer, C. Termote, M. Campbell, M. Frederiksen, C.M. Friis-Møller, N. Kjaer, J. Brandt, R.S. Berenguer, J. Bohlius, J. Bouteloup, V. Davies, M.-A. Dorrucci, M. Egger, M. Furrer, H. Guiguet, M. Grabar, S. Lambotte, O. Leroy, V. Lodi, S. Matheron, S. Monge, S. Nakagawa, F. Paredes, R. Phillips, A. Puoti, M. Schomaker, M. Smit, C. Sterne, J. Thiebaut, R. van der Valk, M. Wyss, N. Aubert, V. Battegay, M. Bernasconi, E. Böni, J. Burton-Jeangros, C. Calmy, A. Cavassini, M. Dollenmaier, G. Egger, M. Elzi, L. Fehr, J. Fellay, J. Furrer, H. Fux, C.A. Gorgievski, M. Günthard, H. Haerry, D. Hasse, B. Hirsch, H.H. Hoffmann, M. Hösli, I. Kahlert, C. Kaiser, L. Keiser, O. Klimkait, T. Kouyos, R. Kovari, H. Ledergerber, B. Martinetti, G. Martinez de Tejada, B. Metzner, K. Müller, N. Nadal, D. Nicca, D. Pantaleo, G. Rauch, A. Regenass, S. Rickenbach, M. Rudin, C. Schöni-Affolter, F. Schmid, P. Schüpbach, J. Speck, R. Tarr, P. Telenti, A. Trkola, A. Vernazza, P. Weber, R. Yerly, S. CHAIN COHERE in EuroCoord
Abstract: Objectives: The objective of this studywas to improve the prediction of the impact of HIV-1 protease mutations in different viral subtypes on virological response to darunavir. Methods: Darunavir-containing treatment change episodes (TCEs) in patients previously failing PIs were selected from large European databases. HIV-1 subtype B-infected patients were used as the derivation dataset and HIV- 1 non-B-infected patients were used as the validation dataset. The adjusted association of each mutation with week 8 HIV RNA change from baseline was analysed by linear regression. A prediction model was derived based on best subset least squares estimation with mutational weights corresponding to regression coefficients. Virological outcome prediction accuracy was compared with that from existing genotypic resistance interpretation systems (GISs) (ANRS 2013, Rega 9.1.0 and HIVdb 7.0). Results: TCEs were selected from 681 subtype B-infected and 199 non-B-infected adults. Accompanying drugs were NRTIs in 87%, NNRTIs in 27%and raltegravir ormaraviroc or enfuvirtide in 53%. The predictionmodel included weighted protease mutations, HIV RNA, CD4 and activity of accompanying drugs. The model's association with week 8 HIV RNA change in the subtype B (derivation) set was R2=0.47 [average squared error (ASE)=0.67, P>10-6]; in the non-B (validation) set, ASE was 0.91. Accuracy investigated by means of area under the receiver operating characteristic curves with a binary response (above the threshold value of HIV RNA reduction) showed that our finalmodel outperformed models with existing interpretation systems in both training and validation sets. Conclusions: A model with a new darunavir-weighted mutation score outperformed existing GISs in both B and non-B subtypes in predicting virological response to darunavir. © The Author 2016.
Published: 2016

25. Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe

Author: Judd, A. Lodwick, R. Noguera-Julian, A. Gibb, D.M. Butler, K. Costagliola, D. Sabin, C. van Sighem, A. Ledergerber, B. Torti, C. Mocroft, A. Podzamczer, D. Dorrucci, M. De Wit, S. Obel, N. Dabis, F. Cozzi-Lepri, A. García, F. Brockmeyer, N.H. Warszawski, J. Gonzalez-Tome, M.I. Mussini, C. Touloumi, G. Zangerle, R. Ghosn, J. Castagna, A. Fätkenheuer, G. Stephan, C. Meyer, L. Campbell, M.A. Chene, G. Phillips, A. The Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord Mary Krause, M. Leport, C. Wittkop, L. Reiss, P. Wit, F. Prins, M. Bucher, H. Gibb, D. Amo, J.D. Thorne, C. Kirk, O. Pérez-Hoyos, S. Hamouda, O. Bartmeyer, B. Chkhartishvili, N. Antinori, A. Monforte, A.D. Prieto, L. Rojo, P. Soriano-Arandes, A. Battegay, M. Kouyos, R. Tookey, P. Casabona, J. Miró, J.M. Konopnick, D. Goetghebuer, T. Sönnerborg, A. Teira, R. Garrido, M. Haerry, D. Raben, D. Chêne, G. Barger, D. Schwimmer, C. Termote, M. Frederiksen, C.M. Friis-Møller, N. Kjaer, J. Salbøl Brandt, R. Berenguer, J. Bohlius, J. Bouteloup, V. Davies, M.-A. Dunn, D. Egger, M. Furrer, H. Guiguet, M. Grabar, S. Lambotte, O. Leroy, V. Lodi, S. Matheron, S. Monge, S. Nakagawa, F. Paredes, R. Puoti, M. Schomaker, M. Smit, C. Sterne, J. Thiebaut, R. Thorne, C. van der Valk, M. Wyss, N. and Judd, A. Lodwick, R. Noguera-Julian, A. Gibb, D.M. Butler, K. Costagliola, D. Sabin, C. van Sighem, A. Ledergerber, B. Torti, C. Mocroft, A. Podzamczer, D. Dorrucci, M. De Wit, S. Obel, N. Dabis, F. Cozzi-Lepri, A. García, F. Brockmeyer, N.H. Warszawski, J. Gonzalez-Tome, M.I. Mussini, C. Touloumi, G. Zangerle, R. Ghosn, J. Castagna, A. Fätkenheuer, G. Stephan, C. Meyer, L. Campbell, M.A. Chene, G. Phillips, A. The Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord Mary Krause, M. Leport, C. Wittkop, L. Reiss, P. Wit, F. Prins, M. Bucher, H. Gibb, D. Amo, J.D. Thorne, C. Kirk, O. Pérez-Hoyos, S. Hamouda, O. Bartmeyer, B. Chkhartishvili, N. Antinori, A. Monforte, A.D. Prieto, L. Rojo, P. Soriano-Arandes, A. Battegay, M. Kouyos, R. Tookey, P. Casabona, J. Miró, J.M. Konopnick, D. Goetghebuer, T. Sönnerborg, A. Teira, R. Garrido, M. Haerry, D. Raben, D. Chêne, G. Barger, D. Schwimmer, C. Termote, M. Frederiksen, C.M. Friis-Møller, N. Kjaer, J. Salbøl Brandt, R. Berenguer, J. Bohlius, J. Bouteloup, V. Davies, M.-A. Dunn, D. Egger, M. Furrer, H. Guiguet, M. Grabar, S. Lambotte, O. Leroy, V. Lodi, S. Matheron, S. Monge, S. Nakagawa, F. Paredes, R. Puoti, M. Schomaker, M. Smit, C. Sterne, J. Thiebaut, R. Thorne, C. van der Valk, M. Wyss, N.
Abstract: Objectives: The aim of the study was to determine the time to, and risk factors for, triple-class virological failure (TCVF) across age groups for children and adolescents with perinatally acquired HIV infection and older adolescents and adults with heterosexually acquired HIV infection. Methods: We analysed individual patient data from cohorts in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). A total of 5972 participants starting antiretroviral therapy (ART) from 1998, aged < 20 years at the start of ART for those with perinatal infection and 15–29 years for those with heterosexual infection, with ART containing at least two nucleoside reverse transcriptase inhibitors (NRTIs) and a nonnucleoside reverse transcriptase inhibitor (NNRTI) or a boosted protease inhibitor (bPI), were followed from ART initiation until the most recent viral load (VL) measurement. Virological failure of a drug was defined as VL > 500 HIV-1 RNA copies/mL despite ≥ 4 months of use. TCVF was defined as cumulative failure of two NRTIs, an NNRTI and a bPI. Results: The median number of weeks between diagnosis and the start of ART was higher in participants with perinatal HIV infection compared with participants with heterosexually acquired HIV infection overall [17 (interquartile range (IQR) 4–111) vs. 8 (IQR 2–38) weeks, respectively], and highest in perinatally infected participants aged 10–14 years [49 (IQR 9–267) weeks]. The cumulative proportion with TCVF 5 years after starting ART was 9.6% [95% confidence interval (CI) 7.0−12.3%] in participants with perinatally acquired infection and 4.7% (95% CI 3.9−5.5%) in participants with heterosexually acquired infection, and highest in perinatally infected participants aged 10–14 years when starting ART (27.7%; 95% CI 13.2−42.1%). Across all participants, significant predictors of TCVF were those with perinatal HIV aged 10–14 years, African origin, pre-ART AIDS, NNRTI-based initial regimens, higher pre-ART v
Published: 2017

26. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients

Author: Bouteloup, V, Sabin, C, Mocroft, A, Gras, L, Pantazis, N, Le Moing, V, d'Arminio Monforte, A, Mary-Krause, M, Roca, B, Miro, J M, Battegay, M, Brockmeyer, N, Berenguer, J, Morlat, P, Obel, N, De Wit, S, Fätkenheuer, G, Zangerle, R, Ghosn, J, Pérez-Hoyos, S, Campbell, M, Prins, M, Chêne, G, Meyer, L, Dorrucci, M, Torti, C, Thiébaut, R, Bouteloup, V, Sabin, C, Mocroft, A, Gras, L, Pantazis, N, Le Moing, V, d'Arminio Monforte, A, Mary-Krause, M, Roca, B, Miro, J M, Battegay, M, Brockmeyer, N, Berenguer, J, Morlat, P, Obel, N, De Wit, S, Fätkenheuer, G, Zangerle, R, Ghosn, J, Pérez-Hoyos, S, Campbell, M, Prins, M, Chêne, G, Meyer, L, Dorrucci, M, Torti, C, and Thiébaut, R
Published: 2017

27. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients

Author: Bouteloup, V., De Wit, Stéphane, Bouteloup, V., and De Wit, Stéphane
Abstract: 0, SCOPUS: ar.j, FLWIN, info:eu-repo/semantics/published
Published: 2017

28. CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: A multinational, multicohort European study

Author: Wittkop, L, Arsandaux, J, Trevino, A, van der Loeff, M, Anderson, J, van Sighem, A, Böni, J, Brun-Vezinet, F, Soriano, V, Boufassa, F, Brockmeyer, N, Calmy, A, Dabis, F, Jarrin, I, Dorrucci, M, Duque, V, Fätkenheuer, G, Zangerle, R, Ferrer, E, Porter, K, Judd, A, Sipsas, N, Lambotte, O, Shepherd, L, Leport, C, Morrison, C, Mussini, C, Obel, N, Ruelle, J, Schwarze-Zander, C, Sonnerborg, A, Teira, R, Torti, C, Valadas, E, Colin, C, Friis-Møller, N, Costagliola, D, Thiebaut, R, Chene, G, Matheron, S, Touloumi, G, Warszawski, J, Meyer, L, Krause, M, Ghosn, J, Reiss, P, Wit, F, Prins, M, Bucher, H, Gibb, D, Del Amo, J, Thorne, C, Mocroft, A, Kirk, O, Stephan, C, Pérez-Hoyos, S, Hamouda, O, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Antinori, A, Monforte, A, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Tookey, P, Casabona, J, Mirò, J, Castagna, A, Konopnick, D, Goetghebuer, T, Sönnerborg, A, Sabin, C, Garrido, M, Haerry, D, Berenguer, J, Bohlius, J, Bouteloup, V, Cozzi-Lepri, A, Davies, M, Amo, J, Dunn, D, Egger, M, Furrer, H, Guiguet, M, Grabar, S, Leroy, V, Lodi, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Schomaker, M, Smit, C, Sterne, J, van der Valk, M, Wyss, N, van der Loeff, MS, Sipsas, NV, Krause, MM, Conejo, PR, Mirò, JM, Monforte, AA, Davies, MA, Wittkop, L, Arsandaux, J, Trevino, A, van der Loeff, M, Anderson, J, van Sighem, A, Böni, J, Brun-Vezinet, F, Soriano, V, Boufassa, F, Brockmeyer, N, Calmy, A, Dabis, F, Jarrin, I, Dorrucci, M, Duque, V, Fätkenheuer, G, Zangerle, R, Ferrer, E, Porter, K, Judd, A, Sipsas, N, Lambotte, O, Shepherd, L, Leport, C, Morrison, C, Mussini, C, Obel, N, Ruelle, J, Schwarze-Zander, C, Sonnerborg, A, Teira, R, Torti, C, Valadas, E, Colin, C, Friis-Møller, N, Costagliola, D, Thiebaut, R, Chene, G, Matheron, S, Touloumi, G, Warszawski, J, Meyer, L, Krause, M, Ghosn, J, Reiss, P, Wit, F, Prins, M, Bucher, H, Gibb, D, Del Amo, J, Thorne, C, Mocroft, A, Kirk, O, Stephan, C, Pérez-Hoyos, S, Hamouda, O, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Antinori, A, Monforte, A, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Tookey, P, Casabona, J, Mirò, J, Castagna, A, Konopnick, D, Goetghebuer, T, Sönnerborg, A, Sabin, C, Garrido, M, Haerry, D, Berenguer, J, Bohlius, J, Bouteloup, V, Cozzi-Lepri, A, Davies, M, Amo, J, Dunn, D, Egger, M, Furrer, H, Guiguet, M, Grabar, S, Leroy, V, Lodi, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Schomaker, M, Smit, C, Sterne, J, van der Valk, M, Wyss, N, van der Loeff, MS, Sipsas, NV, Krause, MM, Conejo, PR, Mirò, JM, Monforte, AA, and Davies, MA
Abstract: Background: CD4 cell recovery following first-line combination ART (cART) is poorer in HIV-2+ than in HIV-1+ patients. Only large comparisons may allow adjustments for demographic and pretreatment plasma viral load (pVL). Methods: ART-naive HIV+ adults from two European multicohort collaborations, COHERE (HIV-1 alone) and ACHIeV2e (HIV-2 alone), were included, if they started first-line cART (without NNRTIs or fusion inhibitors) between 1997 and 2011. Patients without at least one CD4 cell count before start of cART, without a pretreatment pVL and with missing a priori-defined covariables were excluded. Evolution of CD4 cell count was studied using adjusted linear mixed models. Results: We included 185 HIV-2+ and 30321 HIV-1+ patients with median age of 46 years (IQR 36-52) and 37 years (IQR 31-44), respectively. Median observed pretreatment CD4 cell counts/mm3 were 203 (95% CI 100-290) in HIV-2+ patients and 223 (95% CI 100-353) in HIV-1+ patients. Mean observed CD4 cell count changes from start of cART to 12months were +105 (95% CI 77-134) in HIV-2+ patients and +202 (95% CI 199-205) in HIV-1+ patients, an observed difference of 97 cells/mm3 in 1 year. In adjusted analysis, the mean CD4 cell increase was overall 25 CD4 cells/mm3/year lower (95% CI 5-44; P=0.0127) in HIV-2+ patients compared with HIV-1+ patients. Conclusions: A poorer CD4 cell increase during first-line cART was observed in HIV-2+patients, even after adjusting for pretreatment pVL and other potential confounders. Our results underline the need to identify more potent therapeutic regimens or strategies against HIV-2.
Published: 2017

29. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery

Author: Engsig, F. N., Zangerle, R., Katsarou, O., Dabis, F., Reiss, P., Gill, J., Porter, K., Sabin, C., Riordan, A., Fatkenheuer, G., Gutierrez, F., Raffi, F., Kirk, O., Mary-Krause, M., Stephan, C., de Olalla, P. G., Guest, J., Samji, H., Castagna, A., d'Arminio Monforte, A., Skaletz-Rorowski, A., Ramos, J., Lapadula, G., Mussini, C., Force, L., Meyer, L., Lampe, F., Boufassa, F., Bucher, H. C., De Wit, S., Burkholder, G. A., Teira, R., Justice, A. C., Sterling, T. R., M. Crane, H., Gerstoft, J., Grarup, J., May, M., Chene, G., Ingle, S. M., Sterne, J., Obel, N., Burkholder, G., Justice, A., R Sterling, T., Crane, H. M., Boulle, A., Brodt, H.-R., Casabona, J., Cavassini, M., Costagliola, D., D'Arminio Monforte, A., del Amo, J., Van Sighem, A., Hans-Ulrich Haerry, D., Hogg, R., Mocroft, A., Kitahata, M., Saag, M., Williams, M., Ingle, S., Touloumi, G., Warszawski, J., Krause, M. M., Ghosn, J., Leport, C., Wit, F., Prins, M., Gibb, D., Del Amo, J., Thorne, C., Perez-Hoyos, S., Hamouda, O., Gussenheimer-Bartmeyer, B., Noguera-Julian, A., Antinori, A., Brockmeyer, N., Battegay, M., Rauch, A., Tookey, P., Miro, J. M., de Wit, S., Goetghebuer, T., Torti, C., Garrido, M., Judd, A., Conejo, P. R., Haerry, D., Weller, I., d'Arminio-Monforte, A., Colin, C., Schwimmer, C., Termote, M., Kjaer, J., Campbell, M., Raben, D., Bohlius, J., Bouteloup, V., Bucher, H., Cozzi-Lepri, A., Dorrucci, M., Egger, M., Engsig, F., Furrer, H., Lambotte, O., Lewden, C., Lodi, S., Lodwick, R., Matheron, S., Miro, J., Monge, S., Nakagawa, F., Paredes, R., Phillips, A., Puoti, M., Reekie, J., Scherrer, A., Smit, C., Thiebaut, R., Wittkop, L., 2nd Blood Transfusion Center and Hemophilia Center, 'Laiko' General Hospital, Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Structures et propriétés d'architectures moléculaire (SPRAM - UMR 5819), Institut Nanosciences et Cryogénie (INAC), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes (UGA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes (UGA)-Centre National de la Recherche Scientifique (CNRS), Observatoire des Micro et Nano Technologies (OMNT - UMS 2920), Laboratoire d'Electronique et des Technologies de l'Information (CEA-LETI), Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes (UGA)-Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes (UGA)-Centre National de la Recherche Scientifique (CNRS), Southern Alberta Clinic, Research Department of Infection and Population Health [London], University College of London [London] (UCL), Equipe Perception et design sonores, Sciences et Technologies de la Musique et du Son (STMS), Université Pierre et Marie Curie - Paris 6 (UPMC)-IRCAM-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-IRCAM-Centre National de la Recherche Scientifique (CNRS), Equipe Interactions musicales temps-réel, Maladies infectieuses et tropicales, Université Pierre et Marie Curie - Paris 6 (UPMC), Institute of Biology, Neuchatel, Université de Neuchâtel (UNINE), School of Psychology, St Andrews, University of St Andrews [Scotland], Infectious Diseases, San Raffaele Scientific Institute, EA 4100, Histoire culturelle et sociale de l'art (HiCSA), Université Panthéon-Sorbonne (UP1)-Université Panthéon-Sorbonne (UP1), Laboratory of Inorganic Chemistry, Eidgenössische Technische Hochschule - Swiss Federal Institute of Technology in Zürich [Zürich] (ETH Zürich), Princeton University, Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Population Sciences, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Paläontologisches Institut und Museum, Universität Zürich [Zürich] (UZH), Laboratory, GD Deventer, Rigshospitalet [Copenhagen], Department of Social Medicine, University of Bristol [Bristol], Department of Infectious Diseases, Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Commissariat à l'énergie atomique et aux énergies alternatives - Laboratoire d'Electronique et de Technologie de l'Information (CEA-LETI), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherche et Coordination Acoustique/Musique (IRCAM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche et Coordination Acoustique/Musique (IRCAM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), School of Psychology and Neuroscience [University of St. Andrews], Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris 1 Panthéon-Sorbonne (UP1), Eidgenössische Technische Hochschule - Swiss Federal Institute of Technology [Zürich] (ETH Zürich), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Universität Zürich [Zürich] = University of Zurich (UZH), Royal GD [Deventer], Copenhagen University Hospital, Copenhagen University Hospital-Copenhagen University Hospital, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Engsig, F. N., Zangerle, R., Katsarou, O., Dabis, F., Reiss, P., Gill, J., Porter, K., Sabin, C., Riordan, A., Fatkenheuer, G., Gutierrez, F., Raffi, F., Kirk, O., Mary-Krause, M., Stephan, C., De Olalla, P. G., Guest, J., Samji, H., Castagna, A., D'arminio Monforte, A., Skaletz-Rorowski, A., Ramos, J., Lapadula, G., Mussini, C., Force, L., Meyer, L., Lampe, F., Boufassa, F., Bucher, H. C., De Wit, S., Burkholder, G. A., Teira, R., Justice, A. C., Sterling, T. R., M. Crane, H., Gerstoft, J., Grarup, J., May, M., Chene, G., Ingle, S. M., Sterne, J., Obel, N., Engsig, F, Zangerle, R, Katsarou, O, Dabis, F, Reiss, P, Gill, J, Porter, K, Sabin, C, Riordan, A, Fatkenheuer, G, Gutierrez, F, Raffi, F, Kirk, O, Mary-Krause, M, Stephan, C, De Olalla, P, Guest, J, Samji, H, Castagna, A, D'arminio Monforte, A, Skaletz-Rorowski, A, Ramos, J, Lapadula, G, Mussini, C, Force, L, Meyer, L, Lampe, F, Boufassa, F, Bucher, H, De Wit, S, Burkholder, G, Teira, R, Justice, A, Sterling, T, M. Crane, H, Gerstoft, J, Grarup, J, May, M, Chene, G, Ingle, S, Sterne, J, Obel, N, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Global Health, and Infectious diseases
Subjects: Male, Oncology, MESH: CD4 Lymphocyte Count, [SDV]Life Sciences [q-bio], HIV Infections, MESH: Logistic Models, Cohort Studies, MESH: Cause of Death, 0302 clinical medicine, Risk Factors, MESH: Risk Factors, Cause of Death, Medicine, HIV Infection, 030212 general & internal medicine, MESH: Anti-HIV Agents, MESH: Cohort Studies, Immunodeficiency, Cause of death, 0303 health sciences, MESH: Middle Aged, Hazard ratio, MESH: HIV Infections, Middle Aged, Viral Load, 3. Good health, Infectious Diseases, MESH: Substance-Related Disorders, HIV/AIDS, Female, MESH: Viral Load, Viral load, MESH: Heterosexuality, Human, Adult, Microbiology (medical), Cart, medicine.medical_specialty, Logistic Model, Anti-HIV Agents, Substance-Related Disorders, 03 medical and health sciences, Acquired immunodeficiency syndrome (AIDS), Internal medicine, Humans, sustained viral suppression, Heterosexuality, 030304 developmental biology, MESH: Humans, business.industry, Proportional hazards model, Risk Factor, Anti-HIV Agent, HIV, MESH: Adult, Substance-Related Disorder, medicine.disease, mortality, CD4 cell recovery, Confidence interval, MESH: Male, CD4 Lymphocyte Count, Logistic Models, Immunology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Cohort Studie, business, MESH: Female
Abstract: Background. Some human immunodeficiency virus (HIV)-infected individuals initiating combination antiretroviral therapy (cART) with low CD4 counts achieve viral suppression but not CD4 cell recovery. We aimed to identify (1) risk factors for failure to achieve CD4 count >200 cells/μL after 3 years of sustained viral suppression and (2) the association of the achieved CD4 count with subsequent mortality.Methods. We included treated HIV-infected adults from 2 large international HIV cohorts, who had viral suppression (≤500 HIV type 1 RNA copies/mL) for >3 years with CD4 count ≤200 cells/μL at start of the suppressed period. Logistic regression was used to identify risk factors for incomplete CD4 recovery (≤200 cells/μL) and Cox regression to identify associations with mortality.Results. Of 5550 eligible individuals, 835 (15%) did not reach a CD4 count >200 cells/μL after 3 years of suppression. Increasing age, lower initial CD4 count, male heterosexual and injection drug use transmission, cART initiation after 1998, and longer time from initiation of cART to start of the virally suppressed period were risk factors for not achieving a CD4 count >200 cells/μL. Individuals with CD4 ≤200 cells/μL after 3 years of viral suppression had substantially increased mortality (adjusted hazard ratio, 2.60; 95% confidence interval, 1.86-3.61) compared with those who achieved CD4 count >200 cells/μL. The increased mortality was seen across different patient groups and for all causes of death.Conclusions. Virally suppressed HIV-positive individuals on cART who do not achieve a CD4 count >200 cells/μL have substantially increased long-term mortality. © The Author 2014.
Published: 2014

30. The incidence of AIDS-defining illnesses at a current CD4 count ≥200 cells/μL in the post-combination antiretroviral therapy era

Author: Mocroft, A., Furrer, H. J., Miro, J. M., Reiss, P., Mussini, C., Kirk, O., Abgrall, S., Ayayi, S., Bartmeyer, B., Braun, D., Castagna, A., d'Arminio Monforte, A., Gazzard, B., Gutierrez, F., Hurtado, I., Jansen, K., Meyer, L., Munoz, P., Obel, N., Soler Palacin, P., Papadopoulos, A., Raffi, F., Ramos, J. T., Rockstroh, J. K., Salmon, D., Torti, Carlo, Warszawski, J., de Wit, S., Zangerle, R., Fabre Colin, C., Kjaer, J., Chene, G., Grarup, J., Lundgren, J. D., Furrer, H., Rockstroh, J., Lundgren, J., Miiro, J., Palacin, P. S., Torti, C., Ramos, J., Judd, A., Haerry, D., Weller, I., Casabona, J., Costagliola, D., Battegay, M., Prins, M., de Wolf, F., Colin, C., Schwimmer, C., Touzeau, G., Campbell, M., Bohlius, J., Bouteloup, V., Bucher, H., Cozzi Lepri, A., Dabis, F., Dorrucci, M., Egger, M., Engsig, F., Lambotte, O., Lewden, C., Lodwick, R., Matheron, S., Miro, J., Paredes, R., Phillips, A., Puoti, M., Reekie, J., Sabin, C., Scherrer, A., Smit, C., Sterne, J., Thiebaut, R., Thorne, C., von Wyl, V., Wittkop, L., Young, J., Mocroft, A., Furrer, H. J., Miro, J. M., Reiss, P., Mussini, C., Kirk, O., Abgrall, S., Ayayi, S., Bartmeyer, B., Braun, D., Castagna, A., D'Arminio Monforte, A., Gazzard, B., Gutierrez, F., Hurtado, I., Jansen, K., Meyer, L., Munoz, P., Obel, N., Soler-Palacin, P., Papadopoulos, A., Raffi, F., Ramos, J. T., Rockstroh, J. K., Salmon, D., Torti, C., Warszawski, J., De Wit, S., Zangerle, R., Fabre-Colin, C., Kjaer, J., Chene, G., Grarup, J., Lundgren, J. D., AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Global Health, Other departments, Infectious diseases, University of Zurich, and Mocroft, A
Subjects: Microbiology (medical), Adult, CD4-Positive T-Lymphocytes, Male, medicine.medical_specialty, Virologic suppression, AIDS defining illnesses, Human immunodeficiency virus (HIV), 610 Medicine & health, HIV Infections, Rate ratio, medicine.disease_cause, 2726 Microbiology (medical), 10234 Clinic for Infectious Diseases, Cohort Studies, 03 medical and health sciences, symbols.namesake, 0302 clinical medicine, Acquired immunodeficiency syndrome (AIDS), 360 Social problems & social services, Internal medicine, medicine, CART, Humans, 030212 general & internal medicine, Poisson regression, Poisson Distribution, 0303 health sciences, 030306 microbiology, business.industry, Incidence (epidemiology), Incidence, CD4, cART, immune reconstitution, virologic suppression, Anti-Retroviral Agents, CD4 Lymphocyte Count, Europe, Female, 2725 Infectious Diseases, Immune reconstitution, medicine.disease, Antiretroviral therapy, Confidence interval, 3. Good health, Infectious Diseases, Immunology, symbols, business, Viral load
Abstract: Background. Few studies consider the incidence of individual AIDS-defining illnesses (ADIs) at higher CD4 counts, relevant on a population level for monitoring and resource allocation. Methods. Individuals from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) aged ≥14 years with ≥1 CD4 count of ≥200 μL between 1998 and 2010 were included. Incidence rates (per 1000 personyears of follow-up [PYFU]) were calculated for each ADI within different CD4 strata; Poisson regression, using generalized estimating equations and robust standard errors, was used to model rates of ADIs with current CD4 ≥500/μL. Results. A total of 12 135 ADIs occurred at a CD4 count of ≥200 cells/μL among 207 539 persons with 1 154 803 PYFU. Incidence rates declined from 20.5 per 1000 PYFU (95% confidence interval [CI], 20.0-21.1 per 1000 PYFU) with current CD4 200-349 cells/μL to 4.1 per 1000 PYFU (95% CI, 3.6-4.6 per 1000 PYFU) with current CD4 ≥ 1000 cells/μL. Persons with a current CD4 of 500-749 cells/μL had a significantly higher rate of ADIs (adjusted incidence rate ratio [aIRR], 1.20; 95% CI, 1.10-1.32), whereas those with a current CD4 of ≥1000 cells/μL had a similar rate (aIRR, 0.92; 95% CI, .79-1.07), compared to a current CD4 of 750-999 cells/μL. Results were consistent in persons with high or low viral load. Findings were stronger for malignant ADIs (aIRR, 1.52; 95% CI, 1.25-1.86) than for nonmalignant ADIs (aIRR, 1.12; 95% CI, 1.01-1.25), comparing persons with a current CD4 of 500-749 cells/μL to 750-999 cells/μL. Discussion. The incidence of ADIs was higher in individuals with a current CD4 count of 500-749 cells/μL compared to those with a CD4 count of 750-999 cells/μL, but did not decrease further at higher CD4 counts. Results were similar in patients virologically suppressed on combination antiretroviral therapy, suggesting that immune reconstitution is not complete until the CD4 increases to >750 cells/μL. © The Author 2013. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.
Published: 2013
Full Text: View/download PDF

31. CD4 cell count and the risk of AIDS or death in HIV-Infected adults oncombination antiretroviral therapy with a suppressed viral load: a longitudinalcohort study from COHERE

Author: Collaborators: Young J, Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe in E. u. r. o. C. o. o. r. d., Psichogiou, M, Meyer, L, Ayayi, S, Grabar, S, Raffi, F, Reiss, P, Gazzard, B, Sharland, M, Gutierrez, F, Obel, N, Kirk, O, Miro, Jm, Furrer, H, Castagna, A, De Wit, S, Muñoz, J, Kjær, J, Colin, C, Grarup, J, Chêne, G, Bucher, H, Miro, J, Zangerle, R, Antoniadou, A, Ghosn, J, Morlat, P, Le Moing, V, Fisher, M, Mocroft, A, Stephan, C, Girardi, E, Torti, Carlo, Mussini, C, Galli, L, Ledergerber, B, Teira, R, Touloumi, G, Warszawski, J, Dabis, F, Krause, Mm, Leport, C, de Wolf, F, Prins, M, Bücher, H, Sabin, C, Gibb, D, Fätkenheuer, G, Del Amo, J, Thorne, C, Pérez Hoyos, S, Noguera Julian, A, Antinori, A, d'Arminio Monforte, A, Brockmeyer, N, Ramos, J, Battegay, M, Rauch, A, Tookey, P, Casabona, J, de Wit, S, Goetghebuer, T, Torti, C, Garrido, M, Haerry, D, Weller, I, Costagliola, D, Schwimmer, C, Touzeau, G, Paulsen, M, Bohlius, J, Bouteloup, V, Cozzi Lepri, A, Dorrucci, M, Egger, M, Engsig, F, Lambotte, O, Lewden, C, Lodwick, R, Matheron, S, Paredes, R, Phillips, A, Puoti, M, Reekie, J, Scherrer, A, Smit, C, Sterne, J, Thiebaut, R, von Wyl, V, Wittkop, L, and Young, J.
Published: 2012

32. Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe

Author: Pursuing Later Treatment Options II project team, Collaboration of Observational HIV Epidemiological Research Europe Group, Nakagawa, F, Lodwick, R, Costagliola, D, van Sighem, A, Torti, Carlo, Podzamczer, D, Mocroft, A, Ledergerber, B, Dorrucci, M, Cozzi Lepri, A, Jansen, K, Masquelier, B, García, F, De Wit, S, Stephan, C, Obel, N, Fätkenhaeuer, G, Castagna, A, Sambatakou, H, Mussini, C, Ghosn, J, Zangerle, R, Duval, X, Meyer, L, Perez Hoyos, S, Fabre Colin, C, Kjaer, J, Chene, G, Grarup, J, Collaborators: Castagna A, Phillips A., De Luca, A, de Wolf, F, Fätkenheuer, G, Günthard, H, Jørgensen, L, Judd, A, Lo Caputo, S, Noguera Julian, A, Paraskevis, D, Paredes, R, Pérez Hoyos, S, Phillips, A, Pillay, D, Ramos, Jt, Tookey, Pa, Torti, C, Touloumi, G, Warsawski, J, Warszawski, J, Dabis, F, Krause, Mm, Leport, C, Reiss, P, Prins, M, Bücher, H, Sabin, C, Gibb, D, Del Amo, J, Thorne, C, Kirk, O, Antinori, A, Monforte, Ad, Brockmeyer, N, Ramos, J, Battegay, M, Rauch, A, Tookey, P, Casabona, J, Miró, Jm, de Wit, S, Goetghebuer, T, Teira, R, Garrido, M, Haerry, D, Weller, I, d'Arminio Monforte, A, Colin, C, Schwimmer, C, Touzeau, G, Paulsen, M, Bohlius, J, Bouteloup, V, Bucher, H, Egger, M, Engsig, F, Furrer, H, Lambotte, O, Lewden, C, Matheron, S, Miro, J, Puoti, M, Reekie, J, Scherrer, A, Smit, C, Sterne, J, Thiebaut, R, von Wyl, V, Wittkop, L, and Youn, J.
Published: 2012

33. Risk of triple-class virological failure in children with HIV: a retrospective cohort study

Author: Pursuing Later Treatment Options II project team for the Collaboration of Observational HIV Epidemiological Research Europe, Castro, H, Judd, A, Gibb, Dm, Butler, K, Lodwick, Rk, van Sighem, A, Ramos, Jt, Warsawski, J, Thorne, C, Noguera Julian, A, Obel, N, Costagliola, D, Tookey, Pa, Colin, C, Kjaer, J, Grarup, J, Chene, G, Collaborators: Antinori A, Phillips A., Castagna, A, Cozzi Lepri, A, De Luca, A, De Wit, S, Dorrucci, M, Duval, X, García, F, Ghosn, J, Günthard, H, Ledergerber, B, Lo Caputo, S, Lodwick, R, Masquelier, B, Meyer, L, Mocroft, A, Mussini, C, Paraskevis, D, Paredes, R, Pérez Hoyos, S, Phillips, A, Pillay, D, Podzamczer, D, Reiss, P, Stephan, C, Teira, R, Torti, Carlo, Touloumi, G, Zangerle, R, Warszawski, J, Dabis, F, Krause, Mm, Leport, C, de Wolf, F, Prins, M, Bücher, Hc, Sabin, C, Gibb, D, Fätkenheuer, G, Del Amo, J, Kirk, O, Antinori, A, Monforte, Ad, Tovo, Pa, de Martino, M, Brockmeyer, Nh, Battegay, M, Francioli, P, Carnicer Pont, D, Casabona, J, Miró, Jm, de Wit, S, Goetghebuer, T, Torti, C, Garrido, M, Dedes, N, Weller, I, d'Arminio Monforte, A, Collin Filleul, F, Schwimmer, C, Ellefson, M, Paulsen, M, Bohlius, J, Bouteloup, V, Bucher, Hc, Egger, M, Furrer, H, Lambotte, O, Lewden, C, Matheron, S, Miro, J, Puoti, M, Reekie, J, Smit, C, Sterne, J, Thiebaut, R, and Wittkop, L.
Published: 2011

34. Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)

Author: Sansom, Stephanie L, Mocroft, A, Lundgren, JD, Sabin, ML, D'Arminio Monforte, A, Brockmeyer, N, Casabona, J, Castagna, A, Costagliola, D, Dabis, F, De Wit, S, Fätkenheuer, G, Furrer, H, Johnson, AM, Lazanas, MK, Leport, C, Moreno, S, Obel, N, Post, FA, Reekie, J ; https://orcid.org/0000-0001-8529-3559, Reiss, P, Sabin, C, Skaletz-Rorowski, A, Suarez-Lozano, I, Torti, C, Warszawski, J, Zangerle, R, Fabre-Colin, C, Kjaer, J, Chene, G, Grarup, J, Kirk, O, Sabin, M, Suarez-Loano, I, Touloumi, G, Meyer, L, Krause, MM, Ghosn, J, de Wolf, F, Prins, M, Bucher, H, Gibb, D, Hamouda, O, Bartmeyer, B, Del Amo, J, Thorne, C, Stephan, C, Pérez-Hoyos, S, Noguera-Julian, A, Antinori, A, Ramos, J, Battegay, M, Rauch, A, Mussini, C, Tookey, P, Miró, JM, Goetghebuer, T, Teira, R, Garrido, M, Judd, A, Haerry, D, Weller, I, Schwimmer, C, Termote, M, Touzeau, G, Campbell, M, Friis-Møller, N, Bohlius, J, Bouteloup, V, Cozzi-Lepri, A, Dorrucci, M, Egger, M, Engsig, F, Lambotte, O, Lewden, C, Lodwick, R, Matheron, S, Miro, J, Paredes, R, Phillips, A, Puoti, M, Scherrer, A, Smit, C, Sterne, J, Thiebaut, R, von Wyl, V, Wittkop, L, Sansom, Stephanie L, Mocroft, A, Lundgren, JD, Sabin, ML, D'Arminio Monforte, A, Brockmeyer, N, Casabona, J, Castagna, A, Costagliola, D, Dabis, F, De Wit, S, Fätkenheuer, G, Furrer, H, Johnson, AM, Lazanas, MK, Leport, C, Moreno, S, Obel, N, Post, FA, Reekie, J ; https://orcid.org/0000-0001-8529-3559, Reiss, P, Sabin, C, Skaletz-Rorowski, A, Suarez-Lozano, I, Torti, C, Warszawski, J, Zangerle, R, Fabre-Colin, C, Kjaer, J, Chene, G, Grarup, J, Kirk, O, Sabin, M, Suarez-Loano, I, Touloumi, G, Meyer, L, Krause, MM, Ghosn, J, de Wolf, F, Prins, M, Bucher, H, Gibb, D, Hamouda, O, Bartmeyer, B, Del Amo, J, Thorne, C, Stephan, C, Pérez-Hoyos, S, Noguera-Julian, A, Antinori, A, Ramos, J, Battegay, M, Rauch, A, Mussini, C, Tookey, P, Miró, JM, Goetghebuer, T, Teira, R, Garrido, M, Judd, A, Haerry, D, Weller, I, Schwimmer, C, Termote, M, Touzeau, G, Campbell, M, Friis-Møller, N, Bohlius, J, Bouteloup, V, Cozzi-Lepri, A, Dorrucci, M, Egger, M, Engsig, F, Lambotte, O, Lewden, C, Lodwick, R, Matheron, S, Miro, J, Paredes, R, Phillips, A, Puoti, M, Scherrer, A, Smit, C, Sterne, J, Thiebaut, R, von Wyl, V, and Wittkop, L
Abstract: Background:Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality.Methods and Findings:LP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diagnosis with a CD4 count <350/mm3or an AIDS diagnosis within 6 months of HIV diagnosis among persons presenting for care between 1 January 2000 and 30 June 2011. Logistic regression was used to identify factors associated with LP and Poisson regression to explore the impact on AIDS/death. 84,524 individuals from 23 cohorts in 35 countries contributed data; 45,488 were LP (53.8%). LP was highest in heterosexual males (66.1%), Southern European countries (57.0%), and persons originating from Africa (65.1%). LP decreased from 57.3% in 2000 to 51.7% in 2010/2011 (adjusted odds ratio [aOR] 0.96; 95% CI 0.95-0.97). LP decreased over time in both Central and Northern Europe among homosexual men, and male and female heterosexuals, but increased over time for female heterosexuals and male intravenous drug users (IDUs) from Southern Europe and in male and female IDUs from Eastern Europe. 8,187 AIDS/deaths occurred during 327,003 person-years of follow-up. In the first year after HIV diagnosis, LP was associated with over a 13-fold increased incidence of AIDS/death in Southern Europe (adjusted incidence rate ratio [aIRR] 13.02; 95% CI 8.19-20.70) and over a 6-fold increased rate in Eastern Europe (aIRR 6.64; 95% CI 3.55-12.43).Conclusions:LP has decreased over time across Europe, but remains a significant issue in the region in all HIV exposure groups. LP increased in male IDUs and female heterosexuals from Southern Europe and IDUs in Eastern Europe. LP was associated with an increased rate of AIDS/deaths, particularly in the first year after HIV diagnosis, with significant variation across Europe. Earlier and more widespread testing, timely referrals af
Published: 2013

35. Causes de décès des personnes infectées par le virus de l’immunodéficience humaine nées en Afrique subsaharienne, vivant en France (études Mortalité 2000 et 2005)

Author: Bouteloup, V., primary, Semaille, C., additional, Dehillotte, C., additional, Aouba, A., additional, May, T., additional, and Chêne, G., additional
Published: 2011
Full Text: View/download PDF

36. Outils pour l’amélioration continue de la qualité au sein d’un centre de méthodologie et de gestion d’essais cliniques (CMG-EC) de l’Agence nationale de recherches sur le sida et les hépatites virales (ANRS)

Author: Bouyssou, C., primary, Fagard, C., additional, Reboud, P., additional, Bouteloup, V., additional, Roussillon, C., additional, Couturier, F., additional, Boilet, V., additional, Pérusat, S., additional, Schwimmer, C., additional, and Chêne, G., additional
Published: 2009
Full Text: View/download PDF

37. Méta-analyse sur données individuelles de l’exactitude diagnostique de l’élastométrie impulsionnelle (Fibroscan®) dans le diagnostic d’une fibrose hépatique significative chez les patients présentant une hépatite chronique à virus C (TE IPD Study)

Author: Asselineau, J., primary, Bouteloup, V., additional, de Lédinghen, V., additional, Thiébaut, R., additional, and Perez, P., additional
Published: 2009
Full Text: View/download PDF

38. 397 INDIVIDUAL PATIENT DATA META-ANALYSIS OF TRANSIENT ELASTOGRAPHY DIAGNOSTIC ACCURACY IN LIVER FIBROSIS ASSESSMENT OF CHRONIC HEPATITIS C PATIENTS (TE IPD STUDY)

Author: Pambrun, E., primary, Bouteloup, V., additional, de Lédinghen, V., additional, Asselineau, J., additional, Fraquelli, M., additional, Brunetto, M., additional, Forns, X., additional, Saito, H., additional, Nahon, P., additional, Pirisi, M., additional, Thiébaut, R., additional, and Perez, P., additional
Published: 2009
Full Text: View/download PDF

39. COL2-01 Thème : Infections à VIH (2) – Évolution des lipodystrophies et des anomalies glucido-lipidiques au-delà de 7 ans au sein de la cohorte ANRS CO8 APROCO-COPILOTE

Author: Collin, F., primary, Le Moing, V., additional, Capeau, J., additional, Bouteloup, V., additional, Salmon-Ceron, D., additional, Andreelli, F., additional, and Cassuto, J.P., additional
Published: 2008
Full Text: View/download PDF

40. Méta-analyse des performances diagnostiques de l’élastométrie impulsionnelle (Fibroscan®) dans l’évaluation de la fibrose hépatique chez les patients atteints d’une hépatite chronique C

Author: Bouteloup, V., primary, Thiébaut, R., additional, De Ledinghen, V., additional, and Perez, P., additional
Published: 2008
Full Text: View/download PDF

41. All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaboration.

Author: Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, van Sighem A, Kirk O, Obel N, Panos G, Ghosn J, Dabis F, Mary-Krause M, Leport C, Perez-Hoyos S, Sobrino-Vegas P, Stephan C, Castagna A, Antinori A, and d'Arminio Monforte A
Published: 2012

42. Higher HIV-1 DNA associated with lower gains in CD4 cell count among patients with advanced therapeutic failure receiving optimized treatment (ANRS 123--ETOILE)

Author: Avettand-Fenoel V, Bouteloup V, Mélard A, Fagard C, Chaix M, Leclercq P, Chêne G, Viard J, Rouzioux C, and ETOILE Study
Published: 2010
Full Text: View/download PDF

43. SUBCORTICAL WHITE MATTER HYPERINTENSITIES MAY BE ASSOCIATED WITH TISSUE LESIONS OF LIMITED SEVERITY IN ELDERLY PATIENTS WITH MILD COGNITIVE IMPAIRMENT OR SUBJECTIVE MEMORY COMPLAINT

Author: Aghetti, A., Bouteloup, V., Mangin, J. -F, jessica lebenberg, Chene, G., Dufouil, C., and Jouvent, E.

44. Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?

Author: Monge, S., Mocroft, A., Sabin, A., Touloumi, G., Sighem, A., Abgrall, S., Dray-Spira, R., Spire, B., Castagna, A., Mussini, C., Zangerle, R., Hessamfar, M., Anderson, J., Hamouda, O., Ehren, K., Obel, N., Kirk, O., Antinori, A., Girardi, E., Saracino, A., Calmy, A., Wit, S., Wittkop, L., Bucher, C., Montoliu, A., Raben, D., Prins, M., Meyer, L., Chene, G., Burns, F., Amo, J., Judd, Ali, Zangerle, Robert, Touloumi, Giota, Warszawski, Josiane, Meyer, Laurence, Dabis, François, Krause, Murielle, Ghosn, Jade, Leport, Catherine, Wittkop, Linda, Reiss, Peter, Wit, Ferdinand, Prins, Maria, Bucher, Heiner, Gibb, Diana, Fätkenheuer, Gerd, Amo, Julia, Obel, Niels, Thorne, Claire, Mocroft, Amanda, Kirk, Ole, Stephan, Christoph, Pérez-Hoyos, Santiago, Bartmeyer, Barbara, Chkhartishvili, Nikoloz, Noguera-Julian, Antoni, Antinori, Andrea, Monforte, Antonella, Brockmeyer, Norbert, Prieto, Luis, Conejo, Pablo, Soriano-Arandes, Antoni, Battegay, Manuel, Kouyos, Roger, Mussini, Cristina, Tookey, Pat, Casabona, Jordi, Miró, Josem, Castagna, Antonella, Konopnick, Deborah, Goetghebuer, Tessa, Sönnerborg, Anders, Torti, Carlo, Sabin, Caroline, Teira, Ramon, Garrido, Myriam, Haerry, David, Wit, Stéphane, Miró, M., Costagliola, Dominique, d'Arminio-Monforte, Antonella, Raben, Dorthe, Chêne, Geneviève, Barger, Diana, Schwimmer, Christine, Termote, Monique, Campbell, Maria, Frederiksen, Casper M, Friis-Møller, Nina, Kjaer, Jesper, Brandt, Rikke, Berenguer, Juan, Bohlius, Julia, Bouteloup, Vincent, Cozzi-Lepri, Alessandro, Davies, Mary-Anne, Dorrucci, Maria, Dunn, David, Egger, Matthias, Furrer, Hansjakob, Guiguet, Marguerite, Grabar, Sophie, Lambotte, Olivier, Leroy, Valériane, Lodi, Sara, Matheron, Sophie, Miró, Jose, Monge, Susana, Nakagawa, Fumiyo, Paredes, Roger, Phillips, Andrew, Puoti, Massimo, Rohner, Eliane, Schomaker, Michael, Smit, Colette, Sterne, Jonathan, Thiebaut, Rodolphe, Valk, Marc, Migrant Health Working Group for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in, Eurocoord, Castagna, Antonella, AII - Infectious diseases, APH - Global Health, Infectious diseases, APH - Aging & Later Life, Global Health, Monge, S, Mocroft, A, Sabin, A, Touloumi, G, Sighem, A, Abgrall, S, Dray-Spira, R, Spire, B, Castagna, A, Mussini, C, Zangerle, R, Hessamfar, M, Anderson, J, Hamouda, O, Ehren, K, Obel, N, Kirk, O, Antinori, A, Girardi, E, Saracino, A, Calmy, A, Wit, S, Wittkop, L, Bucher, C, Montoliu, A, Raben, D, Prins, M, Meyer, L, Chene, G, Burns, F, Amo, J, Judd, A, Warszawski, J, Dabis, F, Krause, M, Ghosn, J, Leport, C, Reiss, P, Wit, F, Bucher, H, Gibb, D, Fatkenheuer, G, Thorne, C, Stephan, C, Perez-Hoyos, S, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Monforte, A, Brockmeyer, N, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Tookey, P, Casabona, J, Miro, J, Konopnick, D, Goetghebuer, T, Sonnerborg, A, Torti, C, Sabin, C, Teira, R, Garrido, M, Haerry, D, Miro, M, Costagliola, D, d'Arminio-Monforte, A, Barger, D, Schwimmer, C, Termote, M, Campbell, M, Frederiksen, C, Friis-Moller, N, Kjaer, J, Brandt, R, Berenguer, J, Bohlius, J, Bouteloup, V, Cozzi-Lepri, A, Davies, M, Dorrucci, M, Dunn, D, Egger, M, Furrer, H, Guiguet, M, Grabar, S, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Rohner, E, Schomaker, M, Smit, C, Sterne, J, Thiebaut, R, and Valk, M
Subjects: Male, 0301 basic medicine, Latin Americans, HIV Infections, migrants, Anti-Retroviral Agents/therapeutic use, Cohort Studies, 0302 clinical medicine, Antiretroviral Therapy, Highly Active, Epidemiology, Pharmacology (medical), 030212 general & internal medicine, Immunovirological response, Young adult, ddc:616, Transients and Migrants, Health Policy, virus diseases, Middle Aged, Viral Load, 3. Good health, Europe, combination antiretroviral therapy, HIV, immunovirological response, sex, Infectious Diseases, Treatment Outcome, Anti-Retroviral Agents, RNA, Viral, Female, Sex, Viral load, Cohort study, Adult, Cart, Combination antiretroviral therapy, medicine.medical_specialty, Adolescent, HIV Infections/drug therapy, Young Adult, 03 medical and health sciences, Population Groups, medicine, Humans, RNA, Viral/blood, Aged, business.industry, Migrant, 030112 virology, Confidence interval, CD4 Lymphocyte Count, migrant, Institutional repository, Immunology, business, Demography
Abstract: Objectives: The aim of the study was to evaluate differences in immunovirological response to combination antiretroviral therapy (cART) in migrant and native men and women within a European collaboration of HIV cohorts Collaboration of Observational HIV Epidemiological Research in Europ (COHERE) in EuroCoord, 2004-2013. Methods: Migrants were defined as those with geographical origin (GO) different from the reporting country and were grouped as originating from Western Europe and Western Countries (WEWC), Eastern Europe (EE), North Africa and the Middle East (NAME), sub-Saharan Africa (SSA), Latin America (LA), Caribbean (CRB) and Asia/Oceania (ASIA/OCE). Native (NAT) individuals were defined as those originating from the reporting country. CD4 cell counts were modelled using piecewise linear mixed-effects models with two slopes, whereas models to estimate subdistribution hazard ratios (sHRs) were used for time to virological response (VR) (i.e. time from cART initiation to the first of two successive HIV RNA measurements < 400 HIV-1 RNA copies/ml). Results: Of 32 817 individuals, 25 799 (78.6%) were men. The percentage of migrants was higher in women (48.9%) than in men (21.2%) and migrants from SSA accounted for the largest migrant group (29.9% in men and 63.3% in women). Migrant men and women from SSA started at lower CD4 cell counts than NAT individuals, which remained lower over time. VR was â¥ 85% at 12 months for all groups except CRB women (77.7%). Compared with NAT men and women, lower VR was experienced by NAME [sHR 0.91; 95% confidence interval (CI) 0.86-0.97] and SSA (sHR 0.88; 95% CI 0.82-0.95) men and CRB (sHR 0.77; 85% CI 0.67-0.89) women, respectively. Conclusions: Immunovirological response to cART in Western Europe varies by GO and sex of patients. ART benefits are not equal for all, underlining the point that efforts need to prioritize those most in need.
Published: 2018

45. Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM)

Author: Valérie Boilet, Catherine Fagard, Cécile Rabian, Sybilla Peron, Caroline Roussillon, Françoise Couturier, Isabelle Cohen-Codar, Pierre-Marie Girard, Monique Termote, Eric Bellissant, Olivier Bouchaud, Karine Amat, Babacar Sylla, Aïda Benalycherif, O. Patey, Jean-Marie Poirier, Anne-Marie Taburet, Yazdan Yazdanpanah, Isabelle Poizot, Laetitia Moinot, Elisabeth Rouveix, Patrick Mercié, Eve Todesco, Amel Besseghir, Stéphane De Wit, Isabelle Pellegrin, Bruno Spire, Geneviève Chêne, Adélaïde Perrier, Laurence Morand-Joubert, Sandrine Couffin-Cadiergues, Roland Landman, Jean-Luc Meynard, S. Kolta, Vincent Bouteloup, Dupuis, Christine, Services des Maladies Infectieuses et Tropicales [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de médecine et d'épidémiologie appliquée [AP-HP Hôpital Bichat-Claude Bernard] (IMEA), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Service des maladies infectieuses et tropicales, Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], Service d’information Médicale [CHU de Bordeaux] (Pôle de Santé Publique), CHU Bordeaux [Bordeaux], ANRS 140 DREAM Study Group : Girard PM, Meynard JL, Chêne G, Kolta S, Landman R, Mercié P, Moinot L, Morand-Joubert L, Cohen-Codar I, Couffin-Cadiergues S, Poirier JM, Poizot I, Rabian C, Spire B, Taburet AM, Yazdanpanah Y, Bellissant E, Pellegrin I, Peron S, De Wit S, Patey O, Rouveix E, Yazdanpanah Y, Amat K, Benalycherif A, Sylla B, Boilet V, Bouteloup V, Couturier F, Perrier A, Roussillon C, Termote M., Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service des maladies infectieuses et tropicales [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Institut de médecine et d'épidémiologie appliquée [AP-HP Hôpital Bichat-Claude Bernard], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], and Hôpital Avicenne-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris 13 (UP13)
Subjects: Adult, Male, 0301 basic medicine, Microbiology (medical), medicine.medical_specialty, Efavirenz, 030106 microbiology, Lopinavir/ritonavir, HIV Infections, Emtricitabine, Lopinavir, Hospitals, University, 03 medical and health sciences, chemistry.chemical_compound, immune system diseases, Internal medicine, medicine, Clinical endpoint, Humans, Pharmacology (medical), Pharmacology, Ritonavir, business.industry, virus diseases, Middle Aged, Viral Load, 3. Good health, Regimen, Infectious Diseases, Anti-Retroviral Agents, chemistry, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, HIV-1, RNA, Viral, Reverse Transcriptase Inhibitors, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, France, business, Viral load, medicine.drug
Abstract: Background: Sparing of antiretroviral drug classes could reduce the toxicity and cost of maintenance treatment for HIV infection. Objectives: To evaluate the non-inferiority of efficacy and the safety of lopinavir/ritonavir (r) monotherapy versus a single-tablet regimen of efavirenz, emtricitabine and tenofovir (EFV/FTC/TDF) over 2 years. Methods: Adults on stable ART with plasma HIV-1 RNA viral load
Published: 2018
Full Text: View/download PDF

46. CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: A multinational, multicohort European study

Author: Wittkop, Linda, Arsandaux, Julie, Trevino, Ana, van der Loeff, Maarten Schim, Anderson, Jane, van Sighem, Ard, Böni, Jürg, Brun-Vezinet, Françoise, Soriano, Vicente, Boufassa, Faroudy, Brockmeyer, Norbert, Calmy, Alexandra, Dabis, François, Jarrin, Inma, Dorrucci, Maria, Duque, Vitor, Fätkenheuer, Gerd, Zangerle, Robert, Ferrer, Elena, Porter, Kholoud, Judd, Ali, Sipsas, Nikolaos V., Lambotte, Olivier, Shepherd, Leah, Leport, Catherine, Morrison, Charles, Mussini, Cristina, Obel, Niels, Ruelle, Jean, Schwarze-Zander, Carolyne, Sonnerborg, Anders, Teira, Ramon, Torti, Carlo, Valadas, Emilia, Colin, Celine, Friis-Møller, Nina, Costagliola, Dominique, Thiebaut, Rodolphe, Chene, Geneviève, Matheron, Sophie, Touloumi, Giota, Warszawski, Josiane, Meyer, Laurence, Krause, Murielle Mary, Ghosn, Jade, Reiss, Peter, Wit, Ferdinand, Prins, Maria, Bucher, Heiner, Gibb, Diana, Del Amo, Julia, Thorne, Claire, Mocroft, Amanda, Kirk, Ole, Stephan, Christoph, Pérez-Hoyos, Santiago, Hamouda, Osamah, Bartmeyer, Barbara, Chkhartishvili, Nikoloz, Noguera-Julian, Antoni, Antinori, Andrea, Monforte, Antonella d'Arminio, Prieto, Luis, Conejo, Pablo Rojo, Soriano-Arandes, Antoni, Battegay, Manuel, Kouyos, Roger, Tookey, Pat, Casabona, Jordi, Mirò, Jose M., Castagna, Antonella, Konopnick, Deborah, Goetghebuer, Tessa, Sönnerborg, Anders, Sabin, Caroline, Garrido, Myriam, Haerry, David, Berenguer, Juan, Bohlius, Julia, Bouteloup, Vincent, Cozzi-Lepri, Alessandro, Davies, Mary-Anne, Amo, Julia del, Dunn, David, Egger, Matthias, Furrer, Hansjakob, Guiguet, Marguerite, Grabar, Sophie, Leroy, Valériane, Lodi, Sara, Monge, Susana, Nakagawa, Fumiyo, Paredes, Roger, Phillips, Andrew, Puoti, Massimo, Schomaker, Michael, Smit, Colette, Sterne, Jonathan, van der Valk, Marc, Wyss, Natasha, Epidémiologie et Biostatistique, Institut National de la Santé et de la Recherche Médicale (INSERM), Team MORPH3EUS (INSERM U1219 - UB - ISPED), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Infectious Diseases, Hospital Carlos III, Center for Infection and Immunity Amsterdam - CINIMA [Amsterdam, The Netherlands], Homerton University Hospital, Stichting HIV Monitoring [Amsterdam], Universiteit van Amsterdam (UvA), Universität Zürich [Zürich] = University of Zurich (UZH), Université Paris Diderot - Paris 7 (UPD7), Service de Virologie [CHU Bichat], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Ruhr-Universität Bochum [Bochum], Geneva University Hospital (HUG), CHU de Bordeaux Pellegrin [Bordeaux], Instituto de Salud Carlos III [Madrid] (ISC), CIBER de Epidemiología y Salud Pública (CIBERESP), Istituto Superiore di Sanità (ISS), Hospitais da Universidade de Coimbra (H.U.C.), University of Coimbra [Portugal] (UC), University Hospital of Cologne [Cologne], Innsbruck Medical University = Medizinische Universität Innsbruck (IMU), Hospitalet de Llobregat, University College of London [London] (UCL), National and Kapodistrian University of Athens (NKUA), Service de Médecine Interne et Immunologie clinique [AP-HP Hôpital Bicêtre], Hôpital Bicêtre, Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), FHI 360, Università degli Studi di Modena e Reggio Emilia = University of Modena and Reggio Emilia (UNIMORE), Rigshospitalet [Copenhagen], Copenhagen University Hospital, Université Catholique de Louvain = Catholic University of Louvain (UCL), University Hospital Bonn, Department of Infectious Diseases, Institution of Medicine, Karolinska University Hospital and Karolinska Institutet, Sierrallana Hospital, Università degli Studi 'Magna Graecia' di Catanzaro = University of Catanzaro (UMG), Universidade de Lisboa = University of Lisbon (ULISBOA), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Bordeaux [Bordeaux], AP-HP - Hôpital Bichat - Claude Bernard [Paris], Infectious diseases, Wittkop, L, Arsandaux, J, Trevino, A, van der Loeff, M, Anderson, J, van Sighem, A, Böni, J, Brun-Vezinet, F, Soriano, V, Boufassa, F, Brockmeyer, N, Calmy, A, Dabis, F, Jarrin, I, Dorrucci, M, Duque, V, Fätkenheuer, G, Zangerle, R, Ferrer, E, Porter, K, Judd, A, Sipsas, N, Lambotte, O, Shepherd, L, Leport, C, Morrison, C, Mussini, C, Obel, N, Ruelle, J, Schwarze-Zander, C, Sonnerborg, A, Teira, R, Torti, C, Valadas, E, Colin, C, Friis-Møller, N, Costagliola, D, Thiebaut, R, Chene, G, Matheron, S, Touloumi, G, Warszawski, J, Meyer, L, Krause, M, Ghosn, J, Reiss, P, Wit, F, Prins, M, Bucher, H, Gibb, D, Del Amo, J, Thorne, C, Mocroft, A, Kirk, O, Stephan, C, Pérez-Hoyos, S, Hamouda, O, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Antinori, A, Monforte, A, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Tookey, P, Casabona, J, Mirò, J, Castagna, A, Konopnick, D, Goetghebuer, T, Sönnerborg, A, Sabin, C, Garrido, M, Haerry, D, Berenguer, J, Bohlius, J, Bouteloup, V, Cozzi-Lepri, A, Davies, M, Amo, J, Dunn, D, Egger, M, Furrer, H, Guiguet, M, Grabar, S, Leroy, V, Lodi, S, Monge, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Schomaker, M, Smit, C, Sterne, J, van der Valk, M, Wyss, N, Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Istituto Superiore di Sanita [Rome], Gestionnaire, Hal Sorbonne Université, Wittkop, Linda, Arsandaux, Julie, Trevino, Ana, Van Der Loeff V Schim, Maarten, Anderson, Jane, Van Sighem, Ard, Jurg, Boni, Brun-Vezinet, Francoise, Soriano, Vicente, Boufassa, Faroudy, Brockmeyer, Norbert, Calmy, Alexandra, Dabis, Francoi, Jarrin, Inma, Dorrucci, Maria, Duque, Vitor, Fãtkenheuer, Gerd, Zangerle, Robert, Ferrer, Elena, Porter, Kholoud, Judd, Ali, Sipsas, Nikolaos V, Lambotte, Olivier, Shepherd, Leah, Leport, Catherine, Morrison, Charle, Mussini, Cristina, Obel, Niel, Ruelle, Jean, Schwarze-Zander, Carolyne, Sonnerborg, Ander, Teira, Ramon, Torti, Carlo, Valadas, Emilia, Colin, Celine, Friis-Moller, Nina, Costagliola, Dominique, Thiebaut, Rodolphe, Chene, Geneviève, Matheron, Sophie, on behalf of the COHERE in EuroCoord and ACHIeV2e Study, Group, and Castagna, Antonella
Subjects: 0301 basic medicine, CD4-Positive T-Lymphocytes, Male, Internationality, [SDV]Life Sciences [q-bio], Human immunodeficiency virus (HIV), HIV Infections, medicine.disease_cause, Gastroenterology, Anti-HIV Agents/administration & dosage/adverse effects/therapeutic use, Viral/blood, Cohort Studies, 0302 clinical medicine, CD4 HIV, Pharmacology (medical), 030212 general & internal medicine, Cd4 cell count, ddc:616, Confounding, virus diseases, Middle Aged, Viral Load, 3. Good health, [SDV] Life Sciences [q-bio], Europe, HIV-2/drug effects, Infectious Diseases, HIV-1/drug effects, RNA, Viral, Female, Viral load, Cohort study, Microbiology (medical), Cart, Adult, medicine.medical_specialty, Anti-HIV Agents, 030106 microbiology, 03 medical and health sciences, Internal medicine, medicine, Humans, Pharmacology, business.industry, CD4-Positive T-Lymphocytes/immunology/virology, CD4 Lymphocyte Count, Institutional repository, HIV Infections/blood/drug therapy/immunology/virology, HIV-2, HIV-1, RNA, Panton–Valentine leukocidin, business
Abstract: Background: CD4 cell recovery following first-line combination ART (cART) is poorer in HIV-2+ than in HIV-1+ patients. Only large comparisons may allow adjustments for demographic and pretreatment plasma viral load (pVL). Methods: ART-naive HIV+ adults from two European multicohort collaborations, COHERE (HIV-1 alone) and ACHIeV2e (HIV-2 alone), were included, if they started first-line cART (without NNRTIs or fusion inhibitors) between 1997 and 2011. Patients without at least one CD4 cell count before start of cART, without a pretreatment pVL and with missing a priori-defined covariables were excluded. Evolution of CD4 cell count was studied using adjusted linear mixed models. Results: We included 185 HIV-2+ and 30321 HIV-1+ patients with median age of 46 years (IQR 36-52) and 37 years (IQR 31-44), respectively. Median observed pretreatment CD4 cell counts/mm(3) were 203 (95% CI 100-290) in HIV-2+ patients and 223 (95% CI 100-353) in HIV-1+ patients. Mean observed CD4 cell count changes from start of cART to 12months were + 105 (95% CI 77-134) in HIV-2+ patients and + 202 (95% CI 199-205) in HIV-1+ patients, an observed difference of 97 cells/mm(3) in 1 year. In adjusted analysis, the mean CD4 cell increase was overall 25 CD4 cells/mm(3)/year lower (95% CI 5-44; P=0.0127) in HIV-2+ patients compared with HIV-1+ patients. Conclusions: A poorer CD4 cell increase during first-line cART was observed in HIV-2+ patients, even after adjusting for pretreatment pVL and other potential confounders. Our results underline the need to identify more potent therapeutic regimens or strategies against HIV-2
Published: 2017
Full Text: View/download PDF

47. Statistical harmonization of versions of measures across studies using external data: Self-rated health and self-rated memory.

Author: Wu Y, Hayes-Larson E, Zhou Y, Bouteloup V, Zimmerman SC, Pederson AM, Planche V, Seamans MJ, Westreich D, Glymour MM, Gibbons LE, Dufouil C, and Mayeda ER
Subjects: Humans, Male, Female, Aged, Middle Aged, France, Memory, Surveys and Questionnaires standards, Aged, 80 and over, Diagnostic Self Evaluation, Health Status, Self Report
Abstract: Purpose: Harmonizing variables for constructs measured differently across studies is essential for comparing, combining, and generalizing results. We developed and fielded a brief survey to harmonize Likert and continuous versions of measures for two constructs, self-rated health and self-rated memory, for use in studies of French older adults., Methods: We recruited 300 participants from a French memory clinic in 2023 to answer both the Likert and continuous versions of self-rated health and self-rated memory questions. For each construct, we predicted responses to the Likert version with multinomial and ordinal logistic models, varying specifications of continuous version responses (linear or spline) and covariate sets (question order, age, sex/gender, and interactions between the continuous version and covariates). We also implemented a percentiles-based crosswalk sensitivity analysis. We compared Cohen's weighted kappa values to identify the best statistical harmonization approach., Results: In the final models [multinomial models with continuous version spline, question order (self-rated memory model only), age, sex/gender, and interactions between the continuous version and covariates], weighted kappa values were 0.61 for self-rated health and 0.60 for self-rated memory, reflecting moderate agreement., Conclusions: Primary data collection feasibly facilitates statistical harmonization of variables for constructs measured differently across studies., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2025 Elsevier Inc. All rights reserved.)
Published: 2025
Full Text: View/download PDF

48. Grey-Matter Structure Markers of Alzheimer's Disease, Alzheimer's Conversion, Functioning and Cognition: A Meta-Analysis Across 11 Cohorts.

Author: Couvy-Duchesne B, Frouin V, Bouteloup V, Koussis N, Sidorenko J, Jiang J, Wink AM, Lorenzini L, Barkhof F, Trollor JN, Mangin JF, Sachdev PS, Brodaty H, Lupton MK, Breakspear M, Colliot O, Visscher PM, and Wray NR
Subjects: Humans, Cohort Studies, Magnetic Resonance Imaging, Disease Progression, Aged, Female, Male, Cognitive Dysfunction pathology, Cognitive Dysfunction diagnostic imaging, Cognitive Dysfunction physiopathology, Alzheimer Disease pathology, Alzheimer Disease diagnostic imaging, Gray Matter diagnostic imaging, Gray Matter pathology
Abstract: Alzheimer's disease (AD) brain markers are needed to select people with early-stage AD for clinical trials and as quantitative endpoint measures in trials. Using 10 clinical cohorts (N = 9140) and the community volunteer UK Biobank (N = 37,664) we performed region of interest (ROI) and vertex-wise analyses of grey-matter structure (thickness, surface area and volume). We identified 94 trait-ROI significant associations, and 307 distinct cluster of vertex-associations, which partly overlap the ROI associations. For AD versus controls, smaller hippocampus, amygdala and of the medial temporal lobe (fusiform and parahippocampal gyri) was confirmed and the vertex-wise results provided unprecedented localisation of some of the associated region. We replicated AD associated differences in several subcortical (putamen, accumbens) and cortical regions (inferior parietal, postcentral, middle temporal, transverse temporal, inferior temporal, paracentral, superior frontal). These grey-matter regions and their relative effect sizes can help refine our understanding of the brain regions that may drive or precede the widespread brain atrophy observed in AD. An AD grey-matter score evaluated in independent cohorts was significantly associated with cognition, MCI status, AD conversion (progression from cognitively normal or MCI to AD), genetic risk, and tau concentration in individuals with none or mild cognitive impairments (AUC in 0.54-0.70, p-value < 5e-4). In addition, some of the grey-matter regions associated with cognitive impairment, progression to AD ('conversion'), and cognition/functional scores were also associated with AD, which sheds light on the grey-matter markers of disease stages, and their relationship with cognitive or functional impairment. Our multi-cohort approach provides robust and fine-grained maps the grey-matter structures associated with AD, symptoms, and progression, and calls for even larger initiatives to unveil the full complexity of grey-matter structure in AD., (© 2025 The Author(s). Human Brain Mapping published by Wiley Periodicals LLC.)
Published: 2025
Full Text: View/download PDF

49. Genetic risk factors underlying white matter hyperintensities and cortical atrophy.

Author: Patel Y, Shin J, Sliz E, Tang A, Mishra A, Xia R, Hofer E, Rajula HSR, Wang R, Beyer F, Horn K, Riedl M, Yu J, Völzke H, Bülow R, Völker U, Frenzel S, Wittfeld K, Van der Auwera S, Mosley TH, Bouteloup V, Lambert JC, Chêne G, Dufouil C, Tzourio C, Mangin JF, Gottesman RF, Fornage M, Schmidt R, Yang Q, Witte V, Scholz M, Loeffler M, Roshchupkin GV, Ikram MA, Grabe HJ, Seshadri S, Debette S, Paus T, and Pausova Z
Subjects: Humans, Male, Female, Aged, Risk Factors, Middle Aged, Genetic Predisposition to Disease, Dementia genetics, Dementia pathology, Magnetic Resonance Imaging, Cohort Studies, Polymorphism, Single Nucleotide, Aged, 80 and over, White Matter pathology, White Matter diagnostic imaging, Atrophy genetics, Cerebral Cortex pathology, Cerebral Cortex diagnostic imaging, Genome-Wide Association Study
Abstract: White matter hyperintensities index structural abnormalities in the cerebral white matter, including axonal damage. The latter may promote atrophy of the cerebral cortex, a key feature of dementia. Here, we report a study of 51,065 individuals from 10 cohorts demonstrating that higher white matter hyperintensity volume associates with lower cortical thickness. The meta-GWAS of white matter hyperintensities-associated cortical 'atrophy' identifies 20 genome-wide significant loci, and enrichment in genes specific to vascular cell types, astrocytes, and oligodendrocytes. White matter hyperintensities-associated cortical 'atrophy' showed positive genetic correlations with vascular-risk traits and plasma biomarkers of neurodegeneration, and negative genetic correlations with cognitive functioning. 15 of the 20 loci regulated the expression of 54 genes in the cerebral cortex that, together with their co-expressed genes, were enriched in biological processes of axonal cytoskeleton and intracellular transport. The white matter hyperintensities-cortical thickness associations were most pronounced in cortical regions with higher expression of genes specific to excitatory neurons with long-range axons traversing through the white matter. The meta-GWAS-based polygenic risk score predicts vascular and all-cause dementia in an independent sample of 500,348 individuals. Thus, the genetics of white matter hyperintensities-related cortical atrophy involves vascular and neuronal processes and increases dementia risk., (© 2024. The Author(s).)
Published: 2024
Full Text: View/download PDF

50. Development and assessment of algorithms for predicting brain amyloid positivity in a population without dementia.

Author: Le Scouarnec L, Bouteloup V, van der Veere PJ, van der Flier WM, Teunissen CE, Verberk IMW, Planche V, Chêne G, and Dufouil C
Subjects: Humans, Male, Female, Aged, Biomarkers blood, Middle Aged, Cohort Studies, tau Proteins cerebrospinal fluid, tau Proteins blood, Aged, 80 and over, Peptide Fragments cerebrospinal fluid, Peptide Fragments blood, Alzheimer Disease blood, Alzheimer Disease diagnostic imaging, Amyloid beta-Peptides cerebrospinal fluid, Brain diagnostic imaging, Brain metabolism, Brain pathology, Algorithms, Positron-Emission Tomography, Magnetic Resonance Imaging methods
Abstract: Background: The accumulation of amyloid-β (Aβ) peptide in the brain is a hallmark of Alzheimer's disease (AD), occurring years before symptom onset. Current methods for quantifying in vivo amyloid load involve invasive or costly procedures, limiting accessibility. Early detection of amyloid positivity in non-demented individuals is crucial for aiding early AD diagnosis and for initiating anti-amyloid immunotherapies at early stages. This study aimed to develop and validate predictive models to identify brain amyloid positivity in non-demented patients, using routinely collected clinical data., Methods: Predictive models for amyloid positivity were developed using data from 853 non-demented participants in the MEMENTO cohort. Amyloid levels were measured potentially repeatedly during study course through Positron Emision Tomography or CerebroSpinal Fluid analysis. The probability of amyloid positivity was modelled using mixed-effects logistic regression. Predictors included demographic information, cognitive assessments, visual brain MRI evaluations of hippocampal atrophy and lobar microbleeds, AD-related blood biomarkers (Aβ42/40 and P-tau181), and ApoE4 status. Models were subjected to internal cross-validation and external validation using data from the Amsterdam Dementia Cohort. Performance also was evaluated in a subsample that met the main criteria of the Appropriate Use Recommendations (AUR) for lecanemab., Results: The most effective model incorporated demographic data, cognitive assessments, ApoE status, and AD-related blood biomarkers, achieving AUCs of 0.82 [95%CI 0.81-0.82] in MEMENTO sample and 0.90 [95%CI 0.86-0.94] in the external validation sample. This model significantly outperformed a reference model based solely on demographic and cognitive data, with an AUC difference in MEMENTO of 0.10 [95%CI 0.10-0.11]. A similar model without ApoE genotype achieved comparable discriminatory performance. MRI markers did not improve model performance. Performances in AUR of lecanemab subsample were comparable., Conclusion: A predictive model integrating demographic, cognitive, and blood biomarker data offers a promising method to help identify amyloid status in non-demented patients. ApoE genotype and brain MRI data were not necessary for strong discriminatory ability, suggesting that ApoE genotyping may be deferred when assessing the risk-benefit ratio of immunotherapies in amyloid-positive patients who desire treatment. The integration of this model into clinical practice could reduce the need for lumbar puncture or PET examinations to confirm amyloid status., (© 2024. The Author(s).)
Published: 2024
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

116 results on '"Bouteloup V"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources